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ABSTRACT 
 
BACKGROUND: Despite significant advances in HIV research, treatment, and prevention, 
Georgia is experiencing a raging epidemic. The Atlanta metropolitan area contains almost two-
thirds of the state’s diagnosed cases of HIV. It is also home to the federally-funded Emory 
University Center for AIDS Research (Emory CFAR), which invests heavily into the careers of 
early stage investigators who are ready to enter HIV/AIDS research field. 
OBJECTIVE: The main goal of this project was to analyze the impact of Emory CFAR 
Developmental Core services on institutional efforts to recruit early stage investigators (ESIs) 
into the field of HIV research and develop their careers, increase AIDS-designated grant funding, 
and promote public knowledge about the HIV epidemic. Specifically, it looked at the Emory 
CFAR’s investment into the careers of ESIs through several Developmental Core grant 
mechanisms, as well as the impact of this investment from three perspectives: global, 
organizational, and personal. 
METHOD: Global impact was evaluated by first indexing all ESI-authored publications that 
resulted from research supported by Emory CFAR Developmental Core funding. Then, journal 
impact factors were calculated and analyzed to determine if these publications appear in 
respected journals. Organizational impact was assessed by looking at the total CFAR investment 
into ESIs via various Developmental Core mechanisms, determining the total amount of new 
extramural funding to the University that resulted from these investments, and then calculating 
the return on investment (ROI). To evaluate personal impact, a short survey was distributed to all 
the Developmental Core awardees that are still at Emory University.  
RESULTS: The analysis of publications showed that Developmental Core awardees do publish 
in peer-reviewed journals, both open access and traditional, with respectful impact factors. ROI 
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analysis showed that the activities of the Emory CFAR Developmental Core impact the 
university’s fiscal portfolio. ESIs reported receiving new grants resulting from their CFAR 
Developmental Core award. Depending on the award mechanism, ROI ranged from about 100% 
to over 6000%. Even though an 84% response rate was achieved, there were not enough data to 
determine the personal impact-specifically, if receipt of a Developmental Core award impacted 
the age of ESIs when they received their first R01 grant. However, the survey did uncover 
additional benefits of CFAR Developmental Core services for ESIs. 
CONCLUSIONS: Overall, the activities of the Emory CFAR Developmental Core were found to 
have three separate impacts: global, organizational, and personal. Findings also support previous 
studies that addressed the need for similar faculty development programs. This analysis is the 
first of its kind. While methods would need to be modified to fit local CFAR mechanisms, this 
project developed a framework that can be used by other CFARs to evaluate the impact of their 
Developmental Core services. Results also can be used by Core leadership to make decisions 
about services that should be offered in the future. CFAR leadership can present results to the 
University when requesting funding. Likewise, this analysis can be used by the NIH CFAR to 
demonstrate the effectiveness of the program. 
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It was a great mystery to all of us.” (Ho in “The Age of AIDS”, (Simone, 2006)) 
 “By the time the first cases of AIDS in the United States were diagnosed, 250,000 Americans 
were infected.” (Curran in “The Age of AIDS”, (Simone, 2006)) 
 “The epidemic of HIV in America is forgotten, but not gone.” (del Rio in “Why the South is the 
epicenter of the AIDS crisis in America, (PBS NewsHour, 2016)) 
Chapter I 
INTRODUCTION 
 
This work will study the impact of the Emory Center for AIDS Research (CFAR) 
Developmental Core on efforts to recruit early stage investigators into the field of HIV research, 
develop their careers, increase AIDS-designated grant funding to Emory University, and promote 
public knowledge about the HIV epidemic. The CFAR at Emory University is sponsored both by 
university funds through institutional commitments and by taxpayers’ dollars through the 
National Institutes of Health. Demonstrating that funds from both sources are used effectively 
and efficiently would support the need for continuation and possible expansion of the program 
both on national and local levels.  
This project will look at the impact of Emory CFAR by examining its contributions in 
three areas: 
1. How have Emory CFAR Developmental Core awardees increased knowledge and 
success around HIV in public health?
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2. How much in external funds have Emory CFAR Developmental Core awardees increased 
the Emory University fiscal portfolio as it pertains to AIDS-designated NIH funding? 
More specifically, what is the rate of return on the dollars awarded via developmental 
grant mechanisms, which include Ramp Up awards, CFAR-series awards, and 
Administrative supplements?  
3. How have Emory CFAR Developmental Core services and funding improved the success 
of individual HIV investigators new to the field? In particular, since NIH reports the 
increasing age of first-time grantees, how do Developmental Core awardees’ age 
compare to the NIH’s data on the age of investigators at the time of receipt of a first R01-
equivalent grant? Also, how successful are the Core awardees in establishing contacts 
and collaborations that can potentially lead to future independent NIH funding? 
For the purposes of this study the following definition of “early stage investigator” will 
be used: 
Early stage investigator-a researcher who has not previously competed successfully as 
Project Director/Principal Investigator (PD/PI) for a substantial NIH independent research 
award. Specifically, a PD/PI is identified as an early stage investigator if he/she 
has not previously competed successfully for an NIH-supported research project other than the 
certain early stage or small research grants or for the indicated training, infrastructure, and career 
awards (National Institutes of Health, 2016b). 
“The Emory CFAR has been extremely successful in strategically expanding a University-wide, 
multidisciplinary community of scientists whose NIH-funded research has led to globally 
recognized interventions that prevent new HIV transmissions and enhance the wellbeing of 
people living with and at risk for HIV.” (del Rio, Curran, Hunter, 2016, p. 337). Part of forming 
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and expanding that University-wide community is not only connecting existing researchers and 
providing support for their activities, but also recruiting new investigators into HIV/AIDS 
research by providing resources they need in order to establish successful careers. Those 
activities are managed through the Emory CFAR Developmental Core, which provides numerous 
services and resources to faculty members interested in HIV research. Through those efforts, 
early stage investigators are able to advance their careers in the field. Ultimately, this support can 
contribute to scientific developments in HIV treatment and prevention in order to improve the 
public health of not only local residents, but of people living with HIV/AIDS everywhere in the 
world. This work will focus on evaluating activities of the CFAR Developmental Core to 
determine if these investments impact certain areas of development of early stage investigators. 
The federally funded Centers for AIDS Research (CFAR) program, administered through 
the NIH, provides administrative and shared research support to synergistically enhance and 
coordinate high-quality HIV research projects. CFARs accomplish this through core facilities 
that provide expertise, resources, and services that cannot otherwise readily be obtained through 
traditional funding mechanisms. 
The CFAR program emphasizes the importance of interdisciplinary collaboration, 
especially between basic science and clinical investigators, in order to facilitate translational 
research in which findings from the laboratory are brought to the clinic and vice versa. Likewise, 
the program places an emphasis upon the inclusion of minorities and inclusion of prevention and 
behavioral change research (National Institute of Allergy and Infectious Diseases, 2018a). CFAR 
is funded by multiple institutes within the NIH. The mission of the CFAR program is to support 
a multidisciplinary environment that promotes basic, clinical, epidemiologic, behavioral, and 
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translational research in the prevention, detection, and treatment of HIV. CFARs accomplish this 
mission by: 
x Providing scientific leadership and institutional infrastructure dedicated to HIV research; 
x Stimulating scientific collaboration in interdisciplinary and translational research; 
x Promoting development of sustainable multidisciplinary HIV/AIDS research programs at 
each CFAR institution; 
x Strengthening capacity for HIV research in developing countries; 
x Fostering scientific communication; 
x Sponsoring training and education; 
x Promoting knowledge of CFAR-supported research findings and the importance of HIV 
research through community outreach; 
x Promoting and supporting innovative NIH HIV/AIDS research initiatives; 
x Establishing collaborative research between CFARs and supporting HIV research 
networks; 
x Facilitating technology transfer and development through the promotion of scientific 
interactions between CFARs and industry; 
x Supporting research on prevention and treatment of HIV in hard-to-reach domestic 
populations, especially among urban, low-income rural, and minorities (National Institute 
of Allergy and Infectious Disease, 2015). 
Currently, there are 19 CFARs located throughout the United States (National Institute of 
Allergy and Infectious Diseases, 2018b). 
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FIGURE 1: CENTERS FOR AIDS RESEARCH, DEVELOPMENTAL CFARS SITES. SOURCE: 
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, 2018B 
 All CFARs are selected on a competitive basis. Institutions or organizations with an 
HIV/AIDS funded research base (FRB) -i.e. the annual total amount paid to an organization 
using NIH “AIDS dollars” funding - of $10M annually are eligible to apply. Based on the actual 
amount of total HIV/AIDS FRB during the fiscal year (October 1-September 30) preceding the 
calendar year of application, applications may be submitted for the following amounts: 
Tier 1: Minimum FRB of $10M, but less than $40M, organization may apply for $1.5M total 
costs in the first year; 
Tier 2: Minimum FRB of $40M, but less than $80M, organization may apply for $2.25M total 
costs in the first year; 
 Tier 3: Minimum FRB of $80M, organization may apply for $3M total costs in the first year; 
In order to apply for a certain tier, institution must maintain the same FRB during the year of 
submission. They also must maintain that minimum in order to qualify for the same tier in 
subsequent years after year 1 (Department of Health and Human Services, 2017). 
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 During the 2016 competitive renewal cycle, Emory University qualified to apply and was 
funded as a tier 2 CFAR with base funding of 2.25 M. Sustained tier 2 eligibility was especially 
exciting, because a university’s FRB may change quickly due to many factors, like grants 
ending, investigators leaving, etc. 
Atlanta, located in the epicenter of the epidemic, is well resourced. Emory University has 
a record of outstanding results in the fight to stop the disease. Emory researchers have been 
instrumental in discovering and developing effective therapies for the treatment of HIV, reducing 
transmission rates, and improving patients’ quality of life. The impact of the University cannot 
be overstated. More than 90% of patients in the U.S. (and many around the world) who are on 
medication for HIV take antiretroviral drugs developed at Emory (Loftus, 2010). Additionally, 
the Emory CFAR, which started as an AIDS Interest Group in 1995, has shaped and 
strengthened the HIV research landscape by providing otherwise unavailable equipment, 
services, materials, and expertise to HIV investigators (del Rio, Curran, Hunter, 2016). It is 
precisely this multidisciplinary approach that must continue to bring HIV rates down, not only in 
Georgia, but worldwide.  Investigators belonging to the Emory CFAR network work together to 
address the epidemic locally by focusing on areas around Atlanta as well as concentrating on the 
Southern States. They also work in many countries, including South Africa, Kenya, Georgia, and 
many others. Additionally, many investigators are involved in research that utilizes modern 
technology, such as mobile apps and games to drive up HIV awareness, and the rates of testing 
and prevention. Localized efforts could benefit the entire country and beyond as successful 
strategies of getting people tested, diagnosed, and into treatment are identified. 
The wide variety of barriers that exist today in the fight to combat the global HIV 
pandemic require researchers from multiple backgrounds, disciplines, and community groups to 
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come together to successfully combat this disease. In particular, it is critical to develop interest 
about HIV research among early stage investigators, and to nurture and grow that interest by 
offering opportunities and resources. 
In today’s funding climate, it is difficult for early stage investigators to obtain 
independent funding. The Emory CFAR Developmental Core seeks to provide critical support to 
promising junior faculty as they transition from an unfunded mentee to a NIH-funded 
independent AIDS investigator, and then to an HIV research mentor in their own right (del Rio, 
et al., 2016).  
“The overarching goal of the Developmental Core is to expand the breadth and depth of 
NIH-funded HIV/AIDS research at Emory University and Morehouse School of Medicine 
through strategic recruitments; the funding, mentoring, and development of HIV/AIDS 
investigators; and the synergistic development of individual and institutional partnerships”  
(Emory University, 2016a).  
The Emory CFAR Developmental Core provides support to early stage investigators 
through a Comprehensive Platform of Assistance and Training in HIV Research (PATH) 
initiative. This initiative provides a broad, integrated program of funding and mentoring support. 
The four components of PATH are:  
1. Research funding 
2. Mentoring assistance 
3. Proposal support 
4. Professional development  
These components form an integrated platform of services across the “idea to 
independence and beyond” continuum (Center for AIDS Research at Emory University, 2016a). 
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Another one of the Core’s most significant activities is the small grants program. 
Currently, the Developmental Core offers the following funding opportunities (Emory 
University, 2016a): 
CFAR-Series Awards 
 
x CFAR-03 Mentored Research Award is designed to help move CFAR early stage 
investigators toward NIH independent investigator status in HIV/AIDS research by 
funding mentored research projects that will strengthen the competitiveness of 
subsequent NIH applications. Typically, these awards provide up to $40,000 in direct 
costs for up to two years. 
x CFAR-CFAR (CFAR-C) Mentored Research Award is designed to enable cross-CFAR 
collaborations that will foster inter-institutional research synergy and help move CFAR 
early stage investigators toward independent investigator status in NIH-funded 
HIV/AIDS research. The budget is also up to $40,000 in direct costs for up to two years 
from Emory CFAR funds, with additional contributions by the collaborating CFAR. 
x CFAR-K (CFAR-K) Mentored Research Award is designed to help CFAR early stage 
investigators who currently hold NIH K awards move more rapidly toward independent 
investigator status in NIH-funded HIV/AIDS research by providing research funding for 
projects not fully covered by the NIH K award. These projects also offer up to $40,000 in 
direct costs for up to two years. 
Emory CFAR purposely bases their awards program on NIH R03 awards so that early 
stage investigators are exposed to the “NIH way” as early as possible. The reasons for selecting 
the R03 mechanism on which to model the CFAR-Series awards include: 
x R03 NIH awards can be requested for pilot or feasibility studies; 
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x They do not require preliminary data; 
x They may be requested to develop methodology or new research technology; 
x They are small, self-contained research projects with budgets for direct costs of $50,000 
per year; 
x NIH has a standardized application and review process (National Institutes of Health, 
2016c)  
This development award mechanism helps early stage investigators not only learn how to 
prepare a competitive application, but also become familiar with standard NIH forms and the 
application and review process. They also learn how to work with pre- and post-award teams 
available through the Emory Research Administration shared service centers. The ultimate goal 
of this type of award is to generate enough data in order to submit a successful application for 
funding to the NIH or to develop a concept that, with some additional resources, will drive such 
an application. 
Ramp Up Awards 
 
x CFAR Opportunity Awards are intended to remove obstacles to HIV research 
productivity among CFAR investigators by providing small but crucial resources that 
cannot easily or immediately be obtained through other funding mechanisms. Funds can 
be requested for multiple uses, including the following: overcoming obstacles 
encountered during a current NIH-funded research project; obtaining data needed for a 
scored NIH grant application that is being revised for a resubmission; and/or supporting a 
new application that is expected to be submitted within the next 12 months. Funding is 
limited to $2,000 in direct costs. 
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x CFAR Collaborative Travel Awards are designed to enable collaborations that will 
immediately or ultimately lead to new NIH funded projects in HIV/AIDS. Funds of up to 
$2,000 in direct costs are available in order to make it possible for CFAR early stage 
investigators to meet face to face with potential research collaborators from other 
institutions in order to develop a solid NIH grant application. 
x CFAR Poster Printing Awards provide training in the design of scientific posters that will 
attract attention, be easy for other researchers to scan, efficiently summarize research, 
and stimulate interest in the poster presenter’s research. These awards also provide poster 
tutorial recipients with funding toward the printing of posters that will assist early career 
and new HIV investigators in disseminating the results of their research 
Administrative Supplements 
 
x NIH CFAR Administrative Supplements provide early stage investigators with the 
opportunity to apply for administrative supplements to the CFAR base grant. These 
supplements are federally funded and can be used for equipment or special projects for 
which funds are not available through the regular Emory CFAR Administrative or 
Developmental Cores.  
x CFAR ADELANTE Program is a national grants program currently in its second cycle. 
The goals of the ADELANTE Program are to decrease HIV-related health disparities in 
the Hispanic/Latino community and to promote the mentored development of new 
investigators to focus on HIV in Hispanic/Latino populations. The funding is for two 
years with an annual budget of up to $75,000 in direct costs.  
Evident from this list of available funding opportunities, Emory CFAR invests heavily in 
the development of faculty interested in HIV research. This investment comes not only from the 
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NIH (taxpayer) dollars, but also from other Emory University institutional sources and 
organizations, including Children's Healthcare of Atlanta, the Nell Hodgson Woodruff School of 
Nursing, the Winship Cancer Institute, the Georgia Clinical & Translational Science Alliance, 
and the Morehouse School of Medicine (Emory University, 2016a).  
In addition to pilot award funding, the Emory CFAR Developmental Core provides the 
following services: 
x Proposal support activities that build skills in the foundation of work of conceptualizing, 
developing, writing, submitting, reviewing, and responding to peer-review application 
critiques; all with the ultimate goal of increasing the strength of fundable NIH 
applications in HIV research. 
x Mentoring assistance activities that address the field from multiple perspectives including 
mentoring administration, relationship formation, implementation, and training for 
investigators who wish to make the mentee to mentor transition. 
x Professional development activities that help CFAR investigators cultivate new or 
enhanced expertise in research methods, science writing, NIH-style research proposal 
reviewing, and science communication (del Rio, et al., 2016).  
Even though all the CFAR Developmental Core activities have been in place for a long 
time, they have not been formally evaluated. Prior awardees’ subsequent performance in 
securing additional NIH funding suggests a high rate of success in terms of a monetary return on 
investment at an estimated 2,000%. Notably though, various additional factors must be 
considered to calculate a true percentage of the Core’s return on investment. This analysis of the 
CFAR Developmental Core should factor in more than simple dollar-to-dollar investment, as 
evaluating strictly financial returns in terms of downstream NIH funding after Core service 
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utilization would provide an incomplete picture. There are many more types of professional and 
personal outcomes possible from dollars invested. A formal evaluation of various Developmental 
Core activities would demonstrate which of those activities are most successful, and which may 
need improvement.  
Such evaluation would be beneficial not only for the CFAR program itself, but for the 
larger research community, the University, the federal government, and the general public, given 
that taxpayer money is largely being used to fund federal AIDS research programs. Through this 
analysis, CFARs and similar centers that offer developmental services to early stage 
investigators would gain a better understanding of which services are most beneficial and cost-
efficient. The University, which co-funds many of the centers with internal funds, would be able 
to clearly see the impact of its funding use. Finally, with an ever-increasing demand for 
transparency when it comes to use of taxpayer money, funding agencies would be able to 
demonstrate effective and efficient use of grant funds.  
Additionally, in 2015, the NIH announced that it will no longer support setting a fixed 
10% of its budgets to fund research on HIV as it had in prior years (Kaiser Family Foundation, 
2015). Kaiser (2015) writes that that mandated budget level made it difficult for some of the 
institutes to ensure high-quality research, as the fixed funding regulation forced NIH to fund 
projects that were on a low-priority list. As a result of the 2015 NIH decision, some funding will 
be repurposed to fund other high-priority areas.  
Adding to the concerns about funding is the fact that the new administration, elected in 
2016, has shifted priorities from public health and research to border security and other areas. 
President Trump has repeatedly proposed cutting health research funds both for domestic and 
international programs. However, so far, Congress pushed back on those proposals (Beaubien, 
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2018; Pear, 2017;The AIDS Institute, 2018). Unfortunately, some cuts are happening anyway, as 
the current administration has repurposed funding remaining from the previous fiscal year in the 
Ryan White program, which provides support services for people living with HIV but do not 
have sufficient health care coverage or financial resources, to care for separated migrant children 
(Shugerman, 2018). This is concerning, since using AIDS resources to alleviate another 
unrelated crisis has the potential to make the HIV/AIDS epidemic worse. Concerns about the 
future funding of these programs makes the ability to demonstrate effectiveness and efficiency of 
federally funded research programs that much more critical. In the short term, programs must 
show that they are effective in combating the HIV/AIDS epidemic. In the long term, they must 
show that investing in this research and developing early stage investigators is beneficial to the 
country as a whole by improving public health in general and the quality of life of those living 
with HIV. 
Demonstrating success of the CFAR’s developmental grants program could present an 
argument for maintaining or even increasing the budget levels dedicated to AIDS research.  
With the possibility that HIV/AIDS research funding levels will be reduced, CFARs and 
HIV investigators will become increasingly accountable to the NIH for each dollar spent. In 
order for Emory CFAR and the NIH CFAR to justify their existence, clear evidence of successful 
results must be available. With this data on hand, a potential increase in NIH funding for specific 
areas of research and programs, as well as increased commitments from Universities and the 
public, could be possible.  
The main goal of this project is to demonstrate the impact of the Emory CFAR 
Developmental Core on the success of HIV research programs, not only within Emory 
University and the Atlanta Metro Area, but throughout the nation. The Emory CFAR is 
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sponsored by Emory University funds and taxpayers’ dollars, as made available and 
administered through the NIH. Demonstrating that funds from both sources are used effectively 
and efficiently would warrant the continuation and possible expansion of the program. Moreover, 
success of the CFAR Program could mean advances to curb the HIV epidemic, which would 
eventually benefit society as a whole through improved public health. Working locally, Emory 
CFAR researchers are making an impact globally. Demonstrated success of even one CFAR 
could spur the development of additional public policies that would accelerate efforts in the 
battle against HIV and other deadly diseases.  
Three areas of impact of Emory CFAR Developmental Core will need to be evaluated: 
1. How have Emory CFAR Developmental Core awardees increased knowledge and 
success around HIV in public health? Global impact of Core awardees will be evaluated 
by looking at publications that resulted from the support provided by the Developmental 
Core. More specifically, this project will look at the journal impact factors (JIF) of 
journals where awardees published their work and citation factors for each of the articles 
published. 
2. How much in external funds have Emory CFAR Developmental Core awardees increased 
Emory University’s fiscal portfolio as it pertains to NIH funding? This section will 
determine the return on investment (ROI) for each of the different funding mechanisms 
offered by the Developmental Core (Ramp up awards, CFAR-Series, and Administrative 
supplements).  
3. How have Emory CFAR Developmental Core services improved the success of 
individual early stage investigators? This section will examine what services awardees 
view as the most beneficial at certain stages of their careers. This section will also 
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examine if services provided by the Developmental core assist early stage investigators in 
obtaining their first independent funding at an earlier age. 
The following chapters will look closely at the potential impact of grant and university 
funded activities and their effects on developing early stage investigators’ careers, increasing 
public knowledge about HIV research findings, increasing Emory University’s AIDS-designated 
fiscal portfolio, and promoting collaborations in order to build on the successful and meaningful 
fight against HIV.  
The literature review will look at the current funding climate and the importance of 
public financing of biomedical research, will illustrate effects of that funding on faculty success, 
and will provide a brief history of NIH grant programs. It also will talk about the impact of 
competitive grant funding on faculty productivity (particularly measured by publications), as 
well as provide some examples of successful faculty development programs.  
The methodology section of this work will describe in detail the research questions it 
aims to address and methods for evaluating activities of the Emory CFAR Developmental Core. 
Various approaches will be taken to answer each of the three questions, from data-gathering to 
conducting a brief survey among Developmental Core awardees. 
The results will be then presented in the analysis and findings section, providing 
information as to whether the activities are effective and what, if any, adjustments need to be 
made. Given that Emory CFAR submitted a successful competitive renewal application to the 
NIH in 2016, feedback will be useful no matter the outcome. Successful activities can be 
enhanced and improved during this funding cycle, and those not seen as beneficial can be 
redesigned in order to strengthen the competitive renewal proposal that will be due in 2021. The 
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timeline works because Emory CFAR will have time to make any adjustments and/or 
enhancements and analyze the outcomes of those changes before competing for funding again. 
Research findings will further be discussed in the conclusions section and 
recommendations will be presented to the Emory CFAR on what, if any, improvements or 
adjustments to Developmental Core activities are needed or whether additional evaluations 
would be beneficial. 
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Chapter II 
LITERATURE REVIEW 
 
This chapter will look at the literature available currently as it pertains to grant funding, 
challenges that early stage investigators face when trying to get established as independent 
investigators, impact of funding on faculty productivity, and some of the successful faculty 
development programs implemented at other organizations, among other aspects. It is the goal of 
this review to provide a good illustration of the need for investing in early stage investigators in 
order to magnify their impact on the future of public health. 
Brief History of HIV/AIDS Epidemic 
 
The AIDS epidemic that continues to this day was the reason for the development and 
implementation of the CFAR program. To better understand the significance of the epidemic and 
the need for resources to fight it, looking at the history of AIDS in the United States is beneficial. 
 On June 5, 1981, the U.S. Centers for Disease Control and Prevention published a 
Morbidity and Mortality Weekly Report (MMWR) that described cases of a rare lung infection, 
Pneumocystis carinii pneumonia, in five young, previously healthy gay men. The ages of these 
men ranged from 29 to 36, and all of them were treated with medications available at the time. 
However, at the time of the publication of the MMWR, two of the five patients had died (Centers 
for Disease Control and Prevention, 1981). Pneumocystis pneumonia in the United States is 
almost exclusively limited to immunosuppressed patients (Walzer, Perl, Krogstad, Rawson, & 
Schultz, 1974). It was unusual to see this disease in five previously healthy individuals with no 
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apparent immunodeficiency. The fact that all infected individuals were homosexuals suggested 
that there was some association between the lifestyle and acquisition of the disease, perhaps 
through sexual contact (Centers for Disease Control and Prevention, 1981).  
 This report would become the first mention of what later would become known as the 
AIDS epidemic. Throughout the year, more similar cases of men, whose immune systems were 
not working properly, were reported. In addition to opportunistic infections (infections that occur 
more frequently and are more severe in individuals with weakened immune systems) (Centers 
for Disease Control and Prevention, 2016b), Kaposi sarcoma was reported. Typically, this type 
of cancer occurred in elderly persons or immunosuppressed renal transplant recipients, and was 
rarely life-threatening. By the end of 1981, 159 cases of Kaposi sarcoma and other opportunistic 
infections had been reported in the United States (Curran, 2011).  By year’s end, there were 270 
total cases of severe immune deficiency among gay men, and 121 of those individuals had died 
(AIDS.gov, 2016). It became clear that a new, highly concentrated epidemic of life threatening 
illness was occurring in the US, and that it was one of immunosuppression (Curran, 2011). 
Several studies were conducted among gay men that found many patients with AIDS had sexual 
contact with another person with AIDS within 5 years before the symptoms appeared (Centers 
for Disease Control and Prevention, 1982a). This finding strongly suggested that the new 
syndrome was caused by a sexually transmissible infectious agent (Curran, 2011).  
In 1982, an elderly man with severe hemophilia A was reported to have died from 
Pneumocystis carinii pneumonia, and two more cases of this disease were reported in young men 
with severe hemophilia. All of these cases were accompanied by severe immunosuppression, and 
none of the patients engaged in homosexual contact or needle sharing (Centers for Disease 
Control and Prevention, 1982b). Then, AIDS cases were also reported in infants (Centers for 
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Disease Control and Prevention, 1982c; Oleske, et al., 1983; Ruvenstein, et al., 1983), female sex 
partners of men with or at high risk of AIDS (Centers for Disease Control and Prevention, 1983; 
Harris, et al., 1983), and infants and adults who had received blood transfusions (Centers for 
Disease Control and Prevention, 1982d; Curran, et al., 1984). These cases provided evidence that 
AIDS was caused by an infectious agent that could be transmitted by blood and from mother to 
child, as well as through homosexual and heterosexual contact (Curran, 2011). What was initially 
called a “gay plague” was shown to be putting other people at risk of the disease (Curran, 2011). 
It was not until 1983 that the actual virus was discovered. 
Multiple science teams around the world worked on finding the cause of AIDS. On April 
23, 1984, Margaret Heckler, the Secretary of Health and Human Services, announced that Dr. 
Gallo of the National Cancer Institute (NCI) of the NIH had isolated the virus which caused 
AIDS, and that there would be soon a commercially available test that would be able to detect 
the virus with almost 100% certainty (Rainey, 2006). However, this discovery was not without a 
controversy. The reality of the human immunodeficiency virus (HIV) discovery is that two 
scientists of the Pasteur Institute in France, Dr. Luc Montagnier and Dr. Francoise Barre-
Sinoussi, successfully isolated the virus and sent the samples to Dr. Gallo.  In December of 1983 
Dr. Gallo submitted a paper for publication proposing the theory that a retrovirus was the cause 
of AIDS (Rainey, 2006).  Later, a test was developed to detect HIV antibodies. The U.S. 
government denied the French scientists a patent and awarded it to Dr. Gallo instead. The 
Pasteur Institute challenged the patent in court. Gallo and Montagnier agreed out of court to 
share equal credit for their discovery (Rainey, 2006). In 1987 this dispute was finally decided on 
at the government level, which was unusual. Prime Minister Chirac and President Reagan 
announced that the initial contest ended in a draw with both parties being presented with equal 
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rights to the patent for testing of HIV (Rawling, 1994). Dr. Luc Montagnier, and Dr. Francoise 
Barre-Sinoussi were awarded the Nobel Prize in Physiology in 2008 for their discovery of the 
human immunodeficiency virus, HIV (Nobel Prize, 2008). 
But this case is not about a U.S. scientist misleading the public and claiming credit for a 
scientific discovery. This story highlights just how important it is for researchers to have 
sufficient resources and support in order to make discoveries and publish their findings. Science 
is not stagnant, and work continues all the time, with new discoveries happening frequently. It is 
those scientists that have the best support (financial, mentoring, or other) that are often able to be 
the first to publish (Hagen, 2016).  
Now that the cause of AIDS was identified, scientists could start working on finding 
ways to at least manage the newly identified virus and its impact. The significance of the impact 
of this new disease is demonstrated by Harden and Fauci (2012), who write that “between 1950s 
and 1981, physicians, whose practice focused on infectious disease, almost always saw their 
patients get well. Penicillin and broad spectrum antibiotics, coupled with vaccines against polio 
and other childhood diseases, freed most patients and physicians in the industrialized world from 
the fear of death by diseases caused by bacteria, viruses, and other types of microbes” (Harden & 
Fauci, 2012). The new virus would demonstrate to the physicians and researchers just how 
vulnerable human life still was.  
The HIV epidemic continues to this day. According to a Joint United Nations Programme 
in HIV/AIDS (UNAIDS) fact sheet, there were 36.9 million people living with HIV in the world 
in 2015 (UNAIDS, 2018). Sub-Saharan Africa remains the most severely affected region, with 
nearly 1 in every 25 adults (4.1%) are currently living with HIV and accounting for nearly two-
21
thirds of the people living with HIV worldwide (World Health Organization, 2018). The map 
below depicts the distribution of HIV cases throughout the world: 
 
FIGURE 2:PREVALENCE OF HIV ADULTS AGED 15 TO 49, 2017. BY WHI REGION SOURCE: 
WORLD HEALTH ORGANIZATION, 2018 
But it is not necessary to venture far to see, firsthand, just how big the HIV epidemic still 
is. At the beginning of the 21st century, Georgia found itself in the middle of the raging 
HIV/AIDS epidemic, despite advances in prevention and treatment options available. Georgia 
was ranked fifth highest in the nation for the total number of adults and adolescents living with 
HIV infection in 2016. The total number of persons living with HIV infection in Georgia was 
56,789 as of the end of 2016. Seventy-nine percent of those diagnosed with HIV infection in 
Georgia during 2016 were male, 71% were Blacks, and 83% of males 13 years and older were 
men who have sex with men. A large portion of diagnosed persons (20%) were tested late, which 
resulted in missed opportunities for prevention and treatment of HIV infection. Georgia ranked 
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1st in the rate of HIV diagnosis among adults and adolescents, and 3rd in the rate of persons living 
with HIV, surpassed only by New York and Texas (Georgia Department of Public Health, 2016). 
Localizing the problem even further, a look at Metro Atlanta is even more alarming. The 
Atlanta metropolitan area contains almost two thirds (61%) of the state’s diagnosed cases of HIV 
(Georgia Department of Public Health, 2016). These statistics raise a question among HIV 
researchers about the reasons for increased HIV infection diagnosis at a time when accurate tests, 
effective treatment options, and education materials have been developed and are available. 
Multiple reasons have been cited. Dr. Wendy Armstrong, site Director for the Emory CFAR 
Clinical Research Core, operating out of the Ponce Clinic performance site, states that access to 
care for the African American HIV-positive community is one of the main reasons the epidemic 
continues in great numbers among that demographic group: “It is such a prevalent disease in our 
population for a group of patients who don’t have easy access to care” (PBS NewsHour, 2016). 
Other major contributors to the continuing epidemic include stigma against certain lifestyles 
(homosexuality, drug use, transgenderism, and being poor or underprivileged) and the disease 
itself, and funding shortfalls due to Georgia’s decision not to expand Medicaid under the 
Affordable Care Act (PBS NewsHour, 2016).  
In 1985, Slaff and Brubaker pointed out that, despite significant research efforts globally, 
effective AIDS treatments have not been identified. As of that time, science has not been able to 
increase the average life expectancy of AIDS patients beyond 18 months following the diagnosis. 
They go on to state that antiviral agents and immune boosters have been ineffective and that the 
general consensus in the medical and scientific communities is that effective therapy or a cure 
would not be possible for many years to come (Slaff & Brubaker, 1985). Today, thanks to the 
efforts of researchers around the world, HIV-positive people can enjoy a nearly normal life span 
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and most likely will never progress to AIDS thanks to the available antiretroviral therapies 
(AIDS.gov, 2015). This is possible today because governments around the world invested in 
their scientists and in the efforts to study HIV and AIDS. In the United States, the NIH “has led 
the global research effort against HIV/AIDS over the past 34 years, enabling the development of 
rapid HIV tests and the identification of a new class of HIV-fighting drugs that could be 
combined in life-saving ways in the clinic” (U.S. Department of Health and Human Services, 
2015). 
In particular, two public policies in the United States played a significant role in the fight 
against HIV not only inside the country, but also around the world.  
1. In 1988, NIH established the Office of AIDS Research (OAR) to coordinate 
AIDS research and to serve as a focal point for AIDS policy and budget development 
(U.S. Department of Health and Human Services, 2016). Since 1990 AIDS has received 
10% of the NIH’s overall budget, when Congress and NIH informally agreed that it 
should grow in step with NIH’s overall budget (Kaiser, 2015). In FY18, the total OAR 
budget was $58,348,000, which is lower than in previous fiscal years (U.S. Department 
of Health and Human Services, 2018).  
2. On July 30, 2008, H.R. 5501, the Tom Lantos and Henry J. Hyde United States 
Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 
2008 was signed into law, authorizing up to $48 billion over the next 5 years to combat 
global HIV/AIDS, tuberculosis, and malaria. Today, this U.S. Government initiative to 
help save the lives of those suffering from HIV/AIDS around the world is known as the 
U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). The special focus of the 
program is on improving the health of women, newborns and children. The Global Health 
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Initiative’s goal is to save the greatest number of lives by increasing and building upon 
what works and, then, supporting countries as they work to improve the health of their 
own people (The United States President's Emergency Plan for AIDS Relief, 2016). 
These policies were especially important, since the very beginning of the AIDS epidemic 
was practically ignored by the Reagan administration. Dr. James Curran states: “There was an 
open neglect, if you will, and the failure of the president for many years to even mention the term 
AIDS. One of the most difficult things for us at the CDC was feeling like the communities that 
were at greatest increased risk didn't trust us because we worked for an administration which 
wouldn't mention the word AIDS” (Simone, 2006). That is why additional resources not only 
meant increased financial commitment, but also demonstrated that this country is ready to fight 
the disease with all its ability. It is because of that commitment that major advances happened 
that allow people with HIV to have a nearly normal life now. HIV infection has changed from a 
virtual death sentence into a manageable chronic disease. Today, HIV-infected people in their 
20s who receive combination therapy may expect to live to age 70 or beyond (U.S. Department 
of Health and Human Services, 2015). That is why it is so important to continue those efforts. 
 Today, because of the longer life expectancy for people with HIV, it is easy to think that 
the epidemic is over, that there are effective treatments, and the problem is not significant. True, 
knowledge that people infected with HIV virus can have an almost normal life is encouraging. 
However, the magnitude of the continuing epidemic becomes especially clear when looking at 
historical data. In 1985 Slaff and Brubaker estimated that there were about 500,000 people living 
with what was then called AIDS infection (Slaff & Brubaker, 1985). The CDC (2001) reported 
that in 1981-1987 there were 50,280 people with the AIDS diagnosis in the US (Centers for 
Disease Control and Prevention, 2001). At the end of 2013, there were 1,242,000 people living 
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with HIV in the United States (Centers for Disease Control and Prevention, 2016a). Clearly, the 
epidemic continues to this day. Carlos del Rio, Emory CFAR Principal Investigator and Co-
Director, summarizes current situation well: “The epidemic of HIV in America is forgotten, but 
not gone” (PBS NewsHour, 2016). Efforts to fight HIV/AIDS must continue through 
development of new enthusiastic researchers that will work in many different areas of life, 
including basic sciences, behavioral sciences, policy studies, public finance, and many others. 
Not only will these researchers benefit people living with HIV/AIDS, reduction in the number of 
people living with HIV would lessen financial burden on the economy by reducing healthcare 
costs for a significant number of people and also by having a healthier population that can live a 
productive life. 
Biomedical Research Funding Climate 
 
Federal funding for biomedical research in the United States has fueled discoveries that 
have advanced our understanding of human disease, led to novel and effective diagnostic tools 
and therapies, and made the US research enterprise an international model. Additionally, NIH 
funding has become an essential source of support for academic medical centers, providing 
funding for faculty and staff salaries, operational expenses, and even capital improvements 
related to research (Loscalzo, 2006). In addition to being a source of new treatments and 
preventive measures, research is also seen as a route to public policy, economic development, 
and new commercial products (Dorcey, De Roulet, Thompson, Reminick, Thai, Ehite Stellato, 
Beck, George, Moses, 2010). The NIH is the largest non-commercial funder of biomedical 
research in the United States (Cech, 2005). With a budget of about $24 billion annually (U.S. 
Department of Health and Human Services, 2018), the NIH supports many research activities in 
many areas. The National Institute of Allergy and Infectious Disease’s annual budget is around 
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$1.4 billion (U.S. Department of Health and Human Services, 2018). The funding amounts have 
not always been this high. The NIH began to support biomedical research in 1938 with a total 
appropriation of $464,000 (Mandel & Vessell, 2004), an amount that has steadily increased to 
the current level. In 1995, the US House of Representatives’ budget resolution called for a cut in 
funding for the National Institutes of Health of 5% for FY 1996 and a freeze on NIH funding 
through FY 2000. However, the NIH received an increase of almost six percent for FY 1996, 
followed by 7% increases in each of the following two years, despite the economy still being 
weak (Porter, 2005). An increased pace of scientific discoveries and increasingly strong political 
support fueled the doubling of the NIH budget over the next five-year period, from FY 1999 
through FY 2003, after which the growth slowed down in FY 2004 and FY 2005 (Mandel & 
Vessell, 2004). In fact, it can be argued that after the funding boom of 1998-2003, the following 
years were stagnant for the NIH. The NIH budget for FY 2007 was $28.6 billion, which is a 
0.1% decrease from the previous year, and a 3.8% decrease after adjustments for inflation were 
made. This was the first budgeted reduction in NIH support since 1970 (Loscalzo, 2006). 
Nevertheless, the United States remains the largest funder of life sciences. In 2003, the total U.S. 
investment in research and development from all sources (industry, government, academia, 
philanthropy) totaled $284 billion, which represented 2.6% of the nation’s gross domestic 
product (Porter, 2005). In 2010, global expenditure on life sciences research was $240 billion. 
The U.S. was the largest funder with about $70 billion in commercial and $40 billion in 
governmental and non-profit funding annually. This number represented slightly more than 5% 
of the U.S. healthcare expenditure (Mcleod, Michie, Roberts, Dirnagl, Chalmers, ioannisis, Al-
Shahi Salman, Chan, Glasziou, 2014).  
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As stated above, biomedical research funding plays a significant role in support of 
university research centers by covering the bulk of their operating expenses. In 2002, total 
biomedical research expenditures at universities and colleges was $19.6 billion, up from $10.7 
billion in 1995. Federal expenditures accounted for 64%, and institutional funds accounted for 
17%. Interestingly, the percentage of the funds going to ten of most heavily funded institutions 
remained the same at 19% (Moses III, Dorsey, Matheson, & Thier, 2005). This is an interesting 
fact, since it suggests that the same universities are receiving the most NIH dollars due to certain 
factors, which may include infrastructure, expertise available, and research record. It is clear that 
the investment by the federal government in biomedical research is not a small one. The 
significant role this investment plays is not only in advancing public health, but also in providing 
ways to sustain functioning research centers within universities, necessitating development 
efforts that provide junior faculty within universities and colleges with skills and training in 
order to receive this research funding via various grant mechanisms.  
Faculty Career Development and Grant Funding 
  
Before getting into a discussion about why career development programs are important, it 
is necessary to define development. Camplin and Steger (2000, 1) define development as 
“targeted enhancement of an individual or a collective set of individuals to serve better the 
mission of the organization.” Various funding agencies that sponsor biomedical research already 
recognize the importance of investing in junior researchers and already have mechanisms in 
place that provide funding for specific training and development projects. Those mechanisms 
range from training awards for graduate students to fellowship and career development grants. 
The goal of such training awards is to develop researchers that will lead science in the future. 
Some grant mechanisms are intended to facilitate the transition from the mentored scientist to the 
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independent investigator, or to provide protected time for newly independent investigators to 
develop their research programs. Other grants go directly to research institutions to educate and 
train predoctoral students and postdoctoral or clinical fellows. These programs cover scientists, 
clinicians, and other health professionals conducting basic, translational, and clinical research 
(Mason, Faupel-Bader, Ginsburg, Seger, DiJoseph, Schnell, Wiest, 2013). Many researchers will 
argue that the main goal of such programs is to cultivate scientists that will be successful in 
getting external funding, mainly R-series grants from the NIH. 
Career development awards (K-award programs) from the NIH comprise the most 
significant mechanisms for securing research funding and may be predictive of future R01 
support for junior faculty. The NIH K programs were created with the specific mission of 
training independent scientific investigators through intensive mentoring and dedicated research 
time (Rangel & Lawrence, 2004). The importance of developing early stage investigators is 
obvious, since NIH has fifteen different career development programs listed on its web site. 
Those programs range from awards designed to support new investigators who still need 
mentoring to programs designed to support those researchers who want to develop specific 
skillsets or who may be ready to transition into an independent investigator (National Institutes 
of Health, 2018a). NIH programs that target developing investigators are particularly important 
because previous NIH funding is the strongest predictor of future NIH support, and recipients of 
career development awards have access to preliminary data and a track record of funding to 
facilitate the successful transition to winning their first R01 grant (Rangel & Lawrence, 2004). 
Current Challenges 
 
While there is an emphasis on developing early stage investigators and a push to support 
and mentor the new generation of scientists, a disturbing change has been happening within the 
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field of sponsored research. Who is being funded for what type of research has changed steadily 
over the last years. Investigators now receive their first independent research grant, an R01 or 
other equivalent R-series award, at a median age of 42 years for those with PhD degrees, and 44 
years for those with MDs (Cech, 2005). Cech (2005, 1390) quotes Zerhouni, who wrote: “In 
today’s world, Marshall Nirenberg would get his Nobel Prize before he got his first NIH grant”. 
Newer information provided by Daniels (2015) in his article adds that the average age at which 
an investigator with a medical degree receives their first R01 or equivalent grant has increased 
from less than 38 years in 1980 to more than 45 year in 2013. At the same time, the number of 
principal investigators for such grants who are 36 years old or younger has declined from 18 % 
in 1983 to 3% in 2010. More than twice as many R01s are awarded to researchers who are over 
65 years old as are to investigators younger than 36 years old. Moreover, this trend is visible in 
all NIH grants, as the percent of all grant funding awarded to scientists under the age of 36 has 
decreased from 5.6% to 3%  from 1980 to 2012 (Daniels, 2015). 
Cech (2005) lists several reasons for the increase in age when investigators receive their 
first R01 grant. They include the fact that new faculty wait longer to apply for NIH funding, and 
the fact that almost half of first-time applications are ranked as noncompetitive, so they are not 
discussed at the study sections and are returned to the applicants for revisions and possible 
resubmission. Rejection reasons cited by study sections include applications being overly 
ambitious, the need for more preliminary results confirming projects’ feasibility, and the desire 
for significant assurance that projects will work (Cech, 2005). This seems to place early stage 
investigators in a difficult predicament since, without their own funding, they are unable to start 
their own laboratories, pursue their own research, and advance their own careers in academic 
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science. As a result, many young researchers choose to leave their research careers for careers in 
industry, other countries, or outside of science altogether (Daniels, 2015).  
Daniels (2015) also proposes three reasons for decline in research funding to young 
scientists. They are similar to the reasons cited by Cech (2005), and include longer training 
periods that introduce a delay in obtaining research grants, disadvantage of young scientists due 
to aspects of the grant process that tend to favor systematically more experienced scientists over 
new entrants, and imbalances in the total costs of federally funded research borne by sponsoring 
institutions, such as universities and research laboratories, relative to the NIH. While the first 
reason is obvious, the second reason cites such factors as the complexity of the grant application 
process, lack of preliminary funding and available resources, and even personal preferences of 
the reviewers. The third reason references the fact that the university share of support for all 
university-based research has risen from 8.7% in 1962 to 19.4% in 2012. This increase may 
jeopardize universities’ ability to support robust scientific research (Daniels, 2015).  
Similar trends were observed with research funding even in the 1960s and 1970s. A study 
by RAND Corporation found that even at those times, more experienced researchers were more 
likely to receive research project funding and career development funding than those who were 
in the “new investigator” career stage. Also, higher-quality candidates from institutions that were 
considered more research intensive were more likely to be approved for funding or awarded 
higher priority scores (Carter, Winkler, & Biddle, 1987). This agrees with the statements above, 
that grants are more likely to be awarded to more experienced researchers, for projects that have 
a high probability to succeed. Thus, early stage investigators may find themselves in a vicious 
circle of trying to obtain funding while having their application denied even a chance for review 
due to lack of that very funding.  
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One may ask why it is important to allow investigators to obtain funding at a younger 
age. Jacob and Lefgren provide a couple of reasons. First, graduate training represents a large 
financial investment by taxpayers, universities, and students. In 2009, authors state “the average 
cost of tuition, fees, and living expenses associated with graduate study of the biological sciences 
in a high quality program was approximately $51,000. Therefore, social return of such 
investments should be maximized by ensuring a smooth transition from a graduate program into 
independent research” (Jacob & Lefgren, 2011, 864). The second reason for the need to ensure 
that researchers are funded at a younger age is derived from the study by Stephan and Levin, 
who found that the research productivity of life scientists is greatest prior to the age of forty 
(Stephen & Levin, 1989, Jacob & Lefgren, 2011).  
Gender Differences 
 
One other dimension of grant funding is worth looking at. It is possible that gender may 
play a role on the success rates of applications and funding levels. Multiple studies on this 
subject were conducted for both basic science researchers and clinicians. Anderson Eloy, Svider, 
Kovalerchik, et al. looked at grant funding of otolaryngologists. They found that the mean NIH 
award to men was $362,946, and was statistically different than the mean award to women of 
$287,188. Male researchers were found to have statistically higher total NIH funding per 
individual than female researchers. They also found that, by academic rank, male investigators 
had higher mean NIH awards and mean total NIH funding per individual than female researchers 
at all ranks, except associate professor. However, statistical significance was only seen on 
comparisons of assistant professors (Anderson Eloy, et al., 2013). The authors discovered that, 
overall, women had fewer submissions of grant applications, and suggest that any disparities in 
grant funding are likely due to underrepresentation of female researches at senior academic 
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ranks. However, this study did find that lower-ranked female faculty had statistically lower 
awards and funding levels than their male colleagues. At the same time, the authors note that 
higher funding levels may be due to the fact that male investigators simply applied for higher 
amounts (Anderson Eloy, Svider, Kovalerchik, Baredes, Kalyiussef, Chandrasekhart, 2013).  
Another study that looked at gender differences in research grant applications and 
funding outcomes found significant gender difference in the mean number of submissions per 
applicant, success rate, number of years, and amount requested. In all of those variables, values 
were higher for male researchers than for female researchers. However, similarly to the study 
described earlier, after controlling for academic rank, success rates were not significantly 
different. Also, similarly to the study by Anderson Eloy et al, this study showed that significant 
differences in the amounts awarded to males compared to amounts awarded to females exist only 
among lower academic ranks (in this case, instructor and associate professor). Also, female 
investigators submitted fewer applications per person during the 3-year study period and were 
less likely than their male counterparts to submit more than one grant. Women also requested 
lower amounts of funding, which agrees with the study described previously. Grants submitted 
by women also received fewer years of funding. The study did find similar results to the one by 
Anderson Eloy et al., which concluded that significant differences between sexes in dollars 
awarded exist at the ranks of instructor and associate professor. Among higher academic ranks, 
however, women attained parity with their male colleagues in both the amount of funding and 
number of years requested (Waisbren, Bowels, Hasan, Emans, Goldberg, Could, Levine, 
Lieberman, Loeken, Longtine, Nadelson, Farkas Perenaude, Quinn, Randolph, Solet, Ullrich, 
Walensky, Weitzman, Christou, 2008). 
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NIH also conducted a study on sex differences in application, success, and funding rates 
in the agency’s extramural program. The results were similar to the studies described above and 
showed that success and funding rates for men and women were not statistically different in most 
programs. The disparities were often related to overall lower percentage of women applicants 
compared to men, and not due to decreased funding rates of successful applications from women. 
There was, however, a statistically significant difference in both application and funding rates for 
subsequent grants. Looking at the R01 mechanism, women and men had success rates (meaning 
number of applications funded) that were not statistically different, but women had a lower 
funding rate (meaning their awards were smaller than those of male researchers) that was 
statistically significant. Also, experienced male applicants had higher funding rates than 
experienced females. Men were also more successful submitting renewal applications compared 
to women, when measured by success rates or funding rates. Interestingly, this study presents 
results different from the studies described above. In analysis of the R01 program, the only 
subgroup in which men outperformed women with statistical significance was experienced 
investigators applying for renewal awards (Pohlhaus Reineke, Jiang, Wagner, Schaffer, & Pinn, 
2011).  
Multiple reasons are thought to contribute to the disparities among sexes in successfully 
obtaining grant funding. They include lack of mentorship opportunities, family considerations 
(Anderson Eloy, et al., 2013), and greater commitment to education (being more involved in 
teaching and clinical practice) being observed more among women researchers than in men 
(Anderson Eloy, et al., 2013; Waisbren, et al., 2008). Additionally, Waisbren et al. (2008) 
suggest that women may become co-investigators instead of principal investigators due to 
reasons described above. Finally, Pohlhaus et al. (2011) acknowledges that the reasons for lower 
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funding rates among female investigators are unknown, but could include unconscious bias in 
review or selection due to male investigators’ more developed social networks.  
Of particular importance is the fact that lower ranking female faculty do show lower 
levels of funding and success. Success in obtaining grant funding is not only important to 
advance scientific knowledge, but also is critical to the career development of faculty (Waisbren, 
et al., 2008). Inadequate mentorship was cited as one of the reasons for observed lower success 
and funding rates of women researchers among other things. These reasons are in line with what 
Emory CFAR is trying to address through the work of its Developmental Core.  
Impact of Training Programs 
 
While it seems logical and expected that training programs that invest in early stage 
investigators would contribute to increasing their chances of success when submitting grant 
applications, a study evaluating career development awards programs at the National Cancer 
Institute (NCI) offered some interesting results. New NCI K mechanisms have been consolidated 
or created to target specific scientific disciplines, career paths, or populations shown to be 
underrepresented in biomedical research. In 2013, the NCI Center for Cancer Training supported 
ten K grant mechanisms that varied by discipline, program focus, and applicant eligibility 
(Mason, et al., 2013). Mason and colleagues studied these mechanisms in order to determine 
whether being funded through a K mechanism contributed to receiving one’s first R01 grant 
faster, and whether having a K award led to more subsequent NIH grant funding and an 
increased number of publications. The results of the study showed that more K awardees in the 
comparison cohort were awarded grants from the NIH Institutes and Centers than non-awardees. 
The awarded grants included not only R01 grants, but also P01, U01 and other research project 
grants.  
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The study also looked at peer-reviewed publications as a relevant indicator of subsequent 
research activity. Findings indicated that a significantly larger portion of awardees had 
subsequent research publications than non-awardees. Additionally, the study found that among 
those who published, the average and median number of publications per awardee were 
significantly higher than for non-awardees for some K-type awards (K01, K07, and K23 
mechanisms). K awardees also had significantly improved odds of conducting subsequent funded 
research or contributing to research in clinical trials. However, there was one area where having 
K award did not show a significant advantage. The mean time to receive an R01 grant for 
awardees and non-awardees was within 1 year of each other, so there was no significant 
difference in time to receive R01 funding for K awardees and non-awardees. The only significant 
difference in the full cohort was found in the K01 mechanism, as the K01 applicants’ median 
time to R01 was shorter than the comparison cohort median for all K mechanisms combined. 
Finally, the study found that the median age of K applicants for awardees and non-awardees was 
similar (between 36 and 37 years). Since the time to first R01 was similar, (at about 3.5-4 years), 
the study concluded that the age at which both K awardees and non-awardees received their first 
R01 grant was 40 to 41 years old, which is consistent with other studies and publications. 
Overall, the study concluded that K awardees were more likely to apply for and receive 
subsequent research funding from the NIH and to derive additional benefits in pursuing research 
careers and participating in the scientific enterprise (Mason, et al., 2013). 
While the K mechanism seems to positively impact the likelihood of future funding and 
publication rates, not all career development or training programs have that distinct of an impact. 
An F32 postdoctoral fellowship program was found by Jacob and Lefgren to have only a slightly 
positive effect on the number of publications. That impact was statistically insignificant. 
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However, they found that receiving an F32 fellowship has a statistically significant impact in 
several career productivity “thresholds”, which include 5 or more publications in years 1-5 and 
6-10 following an awarded application, 5 or more first author publications over the same time 
periods, more than 200 citations in the 10 years after an awarded application, and more than 
$200,000 in NIH funding within 10 years of the F32 application being awarded. Therefore, the 
study concluded that receipt of an NIH postdoctoral fellowship (F award) significantly increases 
the probability that a new PhD will successfully make the transition to a research career and 
yield a high number of publications from an individual during the 10 year period after receiving 
the grant (Jacob & Lefgren, 2011).  
Another study by Camblin and Steger (2000) presents reasons for an increased need of 
faculty development initiatives, which include addressing the issues of vitality and renewal, 
strengthening relationships among colleagues, supporting stated institutional missions, and 
dealing with both the faculty member’s and institution’s “capacity to survive”. These reasons 
may be translated into the world of research faculty, where the “need for vitality and renewal” 
and the “capacity to survive” refer to the requirement of obtaining external funding in order to 
maintain one’s faculty appointment and to continue his or her research. Additionally, they could 
mean the need to develop new skills in order to “branch out” into new, less crowded, research 
fields. Again, the ultimate goal is to obtain external funding. As discussed above, relationships 
with colleagues are also important for efforts to secure research grants, as some authors argue 
that networking and relationships may play a role when the decisions about whether to review a 
particular application or to fund a specific proposal are made.  
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Successful Examples 
 
A study conducted at the University of Cincinnati focused on a new faculty development 
initiative. While the University offered many faculty development initiatives, inclusive of 
workshops, travel awards, and others, there was a need for a more advanced program. An 
agreement was reached between the administration and faculty, in which the university agreed to 
provide funds dedicated to professional development. As a result of this agreement, series of 
awards and workshops were established, which included individual grants of up to $5,000, 
collaborative grants of up to $100,000, departmental grants of up to $100,000, a Faculty Summer 
Institute Workshop, a Technology Workshop, and formation of an endowment in the amount of 
$200,000 per year for future faculty development activities. All projects had to be completed 
within twelve months of funding. When the survey about the experience with the program was 
sent out, nearly half of respondents came from two colleges within the University, the college of 
Medicine (23%) and the College of Arts and Sciences (23%). Of those who received funding, 
47% indicated that they had also indirectly benefited from an award made to someone else. This 
percentage is triple the rate of the contact made with the faculty who were unsuccessful in 
obtaining developmental funds. Again, the biggest portion of responses from funded faculty 
came from Arts and Sciences (Camblin & Steger, 2000). While this study does not focus on 
obtaining further research funding, it does confirm that both universities and faculty find value in 
career development programs. From establishing contacts and collaborations, to adjusting the 
way faculty teach or conduct research, to learning how to navigate the grant application process, 
and to receiving independent external funding, investing in faculty is important and in demand.  
A study by Jones, Mack, Patterson, and Cohn (2011) focused on the return on investment 
from research funding by the Thoracic Surgery Foundation for Research and Education 
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(TSFRE). The study found that over 70% of respondents to the survey still collaborate with their 
mentor and that 70% have residents or students in their own research laboratories. The study also 
found that TSFRE funding helps to support the next generation of extramurally-funded thoracic 
surgeons-scientists. Forty four percent of co-sponsored NIH/TSFRE K-awardees had an R01 
grant at the time of the study, and received these R01s on average about 5 years after the first 
year of their K award. Additionally, even without a K award, the rate of junior faculty obtaining 
R01 awards after receiving TSFRE award is nearly 40% (Jones, et al., 2011). This particular 
study is important to this work because it demonstrates that developmental awards from sources 
other than the NIH have a significant impact on the researchers’ ability to secure NIH R01 
awards.  
Return on investment (financial and through publications) 
 
Now that the importance of career development programs and investment in the development 
of faculty and researchers has been made clear, a question of feasibility and efficiency arises. 
Developmental programs require resources, often significant, in order to continue existing. 
Programs that award grants need constant flow of funds in order to fund proposals. Continued 
investment in such programs requires good return. The question of return on investment on such 
programs is becoming more and more important. From universities to the NIH, information on 
effectiveness of developmental programs is desired.  
Evaluating return on investment of NIH grants is difficult. The typical approach of 
calculating dollars earned does not always work, because investing in biomedical research comes 
back as additional knowledge, expertise, collaborations, publications, medicines, and other 
aspects in addition to subsequent grant funding. Cech (2005, 1390) explains the reason for such 
challenges: “There is reason for optimism that … the huge investments in molecular biology and 
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genomics research made 10 or 30 years ago will provide an increasingly robust flow of new and 
effective medicines. Yet this gap of 10 to 30 years between discovery research and 
pharmaceuticals being prescribed by physicians also gives reason to pause. In the investment 
world, “past performance is no guarantee of future results.” Similarly for biomedicine, just 
because the funding policies in place decades ago are bearing fruit today, there is no guarantee 
that today’s funding policies will provide the same level of future returns of research discovery.” 
Traditionally, the contribution of scientific research to knowledge has been measured by the 
number and impact of scientific papers in peer reviewed literature (Grant, Cottrell, Cluzeau, & 
Fawcett, 2000). A study by Svider, Hussain, Folbe, Couldwell, Liu, and Anderson Eloy (2014) 
looked at the relationship between NIH funding and scholarly impact as it applies to neurological 
surgery. This study found that the h index (a bibliometric measure) was higher for those faculty 
that were successful in obtaining NIH funding. This association between NIH funding and 
scholarly impact is preserved even after controlling for academic rank (Svider, et al., 2014).  
A look at one more study by Pagel and Hudetz (2015) shows a similar approach to evaluating 
return on investment of grant funding by using the h-index together with publication, duration of 
activity, publication rate, citation, citation rates, and NIH funding for each recipient. The study 
found that recipients of Foundation grants (non-federal awards from research foundations) had 
high rates of publications, and those publications are often cited. Additionally, recipients of these 
grants received NIH funding in the amount of $448.44 million. Those who acquired NIH grants 
had greater scholarly output (publications) than those who did not receive NIH funding. In turn, 
recipients with more publications were also more likely to receive more NIH grants (Pagel & 
Hudetz, 2015). This last finding is interesting and returns to the first assumption of this work, 
which speculates that increased investment in researchers leads to increased NIH funding in the 
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future. Pagel and Hudetz (2015) demonstrated that a smaller investment may lead to an increased 
number of high-impact publications, which, in turn, may lead to the increased NIH funding.  
Significance of Journal Impact Factor 
 
It is necessary to explore the concept of publication impact. Raff, Johnson, and Walter 
(2008, 36) write: “Published papers are the currency of science…” That currency is often 
measured by the impact factor of journals in which the articles appear. In the same letter, Raff et 
al. (2008) states that in the current research climate, it is often more important where you publish 
than what you publish, and a high level of importance is given to papers published in high-
impact journals such as Science (Raff, et al., 2008). Alberts, Brooks, and Kelner (2008) add that 
an inappropriately high value is placed in publishing in certain journals. Notkins (2008) explains 
that high-profile journals are generally identified by and are synonymous with high impact factor 
scores. A common practice in biomedical research has been judging the importance and quality 
of a publication by the impact factor of the journal in which the article appeared. Those impact 
factors are often used in making decisions about hiring a researcher, tenure, and receiving 
promotions and grants (Notkins, 2008). It is true that journal impact factor, as a measure of 
performance, faces a significant amount of criticism. At the same time, those people that criticize 
it acknowledge that it has become a performance standard now dominating research practices 
(Sheckman, 2013). Additionally, it is not uncommon for laboratory leaders (principal 
investigators) to make not only hiring decisions, but to decide how to allocate resources, time, 
mentorship, etc, based on the impact factor of a journal in which his/her mentee investigator is 
planning to publish (Rushforth & De Rijcke, 2015). Even Eugene Garfield, the inventor of the 
journal impact factor measurement, acknowledges that use of the term “impact factor” has 
gradually evolved, especially in Europe, to include both journal and author impact. Granting and 
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other agencies are tempted to use the journal impact factor in their decisions. “Presumably, the 
journal’s impact and the mere acceptance of the paper for publication is an implied indicator of 
prestige and subsequent citation” (Garfield, 1999, 980).  
Despite widespread criticism, it is obvious that using journal impact factor as a measure 
of performance in the biomedical research field has become part of “the culture” of that field 
(Rushforth & De Rijcke, 2015). Garfield (1999) adds that while journal impact factor is not 
perfect, there is nothing better that has the advantage of being in existence. He adds that 
experience shows that the best journals are those in which it is the most difficult to have an 
article accepted. He concludes that the use of the journal impact factor as a measurement is 
widespread because it fits well with the opinion about the best journals in each field (Garfield, 
1999). 
Several key publications will guide the analyses that will take place in the future chapters 
of this project. Since publishing in high-profile journals seems to be a large part of the 
biomedical research culture, a close examination of the Developmental Core awardees’ 
publications will be performed in order to determine where they fall in the perceived importance 
in the field of HIV research. As Garfield (1999), Raff et al. (2008) and others note, impact 
factors often may play a key role in decisions related to the early stage investigator’s career 
moves and even his or her ability to obtain grant funding. While journal impact factor is not a 
perfect tool to measure researchers’ impact (Garfield, 1999), it is still often used to do that, so 
ensuring that Developmental Core awardees are publishing in journals that are perceived as 
influential in the field would be one way to contribute to their successful careers. 
Rangel and Lawrence (2004) wrote that previous NIH funding may be a predictor of 
future R01 support for junior faculty (Rangel & Lawrence, 2004). Based on this publication, we 
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should see at least some success among recipients of the Developmental grants when it comes to 
obtaining R01 grants.  
Another key focus of this project’s analysis will be the average age of Developmental 
Core awardees at the time they obtain their first independent NIH award. Cech (2005) and 
Daniels (2015) demonstrate current challenges new investigators face due to various factors 
resulting in delays with obtaining initial independent NIH awards and the average age of first-
time awardees increasing over time, which may result in significant losses to society, both 
financial and related to productivity, as described by Jacob and Lefgren (2011) and Stephen and 
Levin (1989). This study will also refer to Cech (2005) when determining return on investment, 
both financial and through journal publications. 
This project will attempt to determine whether the activities of the CFAR Developmental 
Core yield results similar to the study by Mason at al. (2013), which shows that recipients of 
some career training awards from the NIH were more successful in obtaining future NIH 
funding, and being able to secure independent funding at a younger age.  
As previously mentioned, the extent of the current HIV/AIDS epidemic is large, not only 
on global level, but also close to home. With advances in therapies and treatments available, it is 
easy to forget about the epidemic taking place in our own backyard. HIV/AIDS can be 
considered a manageable chronic disease, which may make it seem less severe. However, 
enormous numbers of people are still infected every year, and thousands go without treatment. 
That is true especially for some groups. We still do not have a vaccine, and we still do not have a 
cure for this disease. At the same time, it is due to efforts of countless researchers that effective 
therapies exist now. That is why it is critical to continue to support research efforts and to 
continue recruiting, training, and developing new researchers who will carry these efforts into 
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the future. Many factors come into play when talking about developing new HIV/AIDS 
investigators.  
As can be seen from the above discussion, early stage investigators interested in 
establishing independent careers face significant challenges in a competitive funding climate, 
from access to good mentoring programs, to publishing in quality journals, to obtaining 
independent funding, requiring continuous support. With grants being awarded to more 
established researchers, early stage investigators face additional hurdles that they must overcome 
on their way to successfully securing independent funding. Additionally, female investigators in 
lower academic ranks may face added challenges, which lead to lower rates of independent 
funding. However, it is also clear that certain programs may increase success and provide 
support necessary for those researchers in order to get a head start in the fields in which they are 
interested.  
NIH has several programs, such as post-doctoral fellowships and training awards that 
seem to contribute, at least on some level, to the success with publications and obtaining funding. 
Also, universities are recognizing more and more the need to support new investigators not only 
to receive more grant dollars, but also to establish and retain leadership in certain research areas. 
Successful programs were piloted in several universities, and Emory University has several 
programs as well. 
 Based on this literature review, it is the goal of this project to determine if the CFAR 
Developmental Core successfully and effectively promotes growth of independent HIV/AIDS 
investigators and helps them develop skills necessary in order to consistently publish in quality 
journals and obtain independent NIH funding. Additionally, this project will, for the first time, 
gather and analyze a wide scope of data that will assess whether CFAR as a program provides 
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significant benefits not only to researchers and universities, but also to the American public 
through slowing the spread of HIV/AIDS and curtailing the epidemic.  
The following chapters will focus on the efforts of the Emory CFAR Developmental 
Core to recruit, develop, and retain junior faculty in the critical area of HIV/AIDS research.
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Chapter III 
METHODOLOGY 
 
As described in Chapter I, the main goal of this work was to examine the impact of the 
Developmental Core of the CFAR at Emory University in three ways: globally on the HIV/AIDS 
knowledge base; locally on Emory University; and individually on early career HIV 
investigators.  
The CFAR at Emory is sponsored both by university funds and by the taxpayers’ dollars 
through the NIH. Demonstrating that funds from both sources are used effectively and efficiently 
would warrant the continuation and possible expansion of the program both on national and local 
levels. Moreover, success of the program could mean success in the fight against HIV, which 
would benefit society by enabling better public health. Working locally, Emory CFAR 
investigators are making an impact globally. Demonstrated success of even one of the 19 
national CFARs could lead to adjustment and development of additional public policies that 
would boost efforts in the fight against HIV and other deadly diseases.  
Three research questions relevant to the public administration impact of the Emory CFAR 
Developmental Core were evaluated: 
1. Global Impact — how have Emory CFAR Developmental Core awardees contributed to 
the global HIV knowledge base? 
2. Organizational Impact — what impact have Emory CFAR Developmental Core awardees 
had on Emory University’s fiscal portfolio as it pertains to the NIH funded research 
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base? More specifically, what is the rate of return on the dollars awarded via the CFAR-
series pilot grant mechanism, Administrative Supplement mechanism, and Ramp Up 
award mechanism? 
3. Personal Impact — how have Emory CFAR Developmental Core services personally 
impacted the professional development and funding success of early stage and new HIV 
investigators? 
The main approach to answering these questions was through data-gathering from various 
sources within CFAR’s programmatic records, including the Emory CFAR’s application for 
competitive renewal, individual awardees’ progress reports submitted to the Emory CFAR, 
annual Emory CFAR progress reports submitted to the NIH, and a survey distributed to all of the 
Developmental Core awardees. Additionally, an internal Emory University database, OnBase, 
was utilized to gather data on AIDS-designated external grants awarded to Emory University as a 
direct result of CFAR Developmental Core-supported research. 
The following sections describe the methodology used to answer each of these questions.  
Research question 1: Global Impact — how have Emory CFAR Developmental Core 
awardees contributed to the global HIV knowledge base? 
In answering research question 1, the following hypotheses were established: 
H10: Emory CFAR Developmental Core awardees had no impact on the global HIV 
knowledge base. 
H11: Emory CFAR Developmental Core awardees had an impact on the global HIV 
knowledge base. 
The timeframe for this section of the project is 1998-2016. These years cover the time from 
when the Emory CFAR was established through the year in which the latest competitive funding 
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application was submitted to the NIH. During this time, Developmental Core services have not 
significantly changed.  
This evaluation looked at whether recipients of Developmental Core awards were able to 
contribute to the global knowledge base on HIV/AIDS. Contribution to the global knowledge 
base is made, in part, through publications in scientific research journals. In order for 
publications to be viewed as significant, they must appear in respected top-tier, peer-reviewed 
journals. Publishing in such journals is especially important to early stage investigators, as it 
gives their findings more credibility and recognition early in their careers. This question is 
particularly timely because numerous online scientific journals have been recently established 
and in the media. These online journals and databases are not always peer-reviewed. Therefore, 
even multiple publications in such journals would not contribute greatly to the global knowledge 
base and would not generate the same amount of recognition for investigators in the field of 
HIV. Being recognized as an expert at the very beginning of one’s research career is critical for 
the early career and new investigators, as it may contribute to establishing their name in the field 
and obtaining independent NIH funding. 
While there was not a perfect way to evaluate each publication, journal impact factors (JIF) 
and citation factors were used to judge the impact of each publication on the global HIV 
knowledge base. The output of the Developmental Core was represented by journal publications 
that stemmed from research supported by the CFAR Developmental Core small grants program. 
This information was self-reported by Developmental Core awardees through mandatory, annual 
progress reports submitted to the Core. Publication data for 2012-2016 were available, and 
publication data for 1998-2011 were collected by reviewing progress reports submitted to the 
Core. The quality of each publication was measured by two parameters: citation factor and JIF. 
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Citation factor is defined as the cumulative number of times that an individual publication was 
cited by one or more other published journal articles. This factor allowed for evaluation of the 
contribution of a particular publication to the scientific knowledge base. The contribution is 
considered greater for publications that have been cited more times. This information was 
gathered through the Emory University library, using the Thomson Reuters Web of Science 
databases.  
JIF is a statistical measure used to compare journals in a given field. The list of impact 
factors is published every year and is available through the Emory University library. Impact 
factor is an important measure of contribution to the global knowledge base, as research 
published in journals with higher impact factors is considered to be more significant. Since 
publications are very field-specific, the journals that are recognized as being the most respected 
were used as a benchmark for this work and will include Science, AIDS, The Journal of 
American Medical Association (JAMA), and AIDS and Behavior. These publications cover not 
only work produced by basic scientists, but also clinician scientists and behavioral scientists who 
work in the area of HIV.  
For the JIF evaluation, impact factors for each of the benchmark journals was recorded for 
each year in which there were publications that resulted from Developmental Core-supported 
research. Impact factors change annually for each journal, so this information for each reported 
publication needed to be collected. Then, the impact factors of all journals for each particular 
year were averaged, recorded, and compared to the benchmark impact factors.  
To see a clear visual representation of the quality of publications, JIFs were plotted on a chart 
with the year of publications on the X axis, and the impact factor on the Y axis. While the 
relationship between publication year of the journal and journal impact factors cannot be 
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established, such plotting made it easy to see if recipients of Developmental Core awards publish 
in journals that are comparable to benchmark journals, or if they publish in less reputable 
journals. There are many other factors that may affect the quality of each publication, such as 
availability of mentoring, research resources, personal circumstances, etc. However, the 
activities and practices of the Developmental Core have not changed significantly over the years. 
Therefore, data-gathering for this particular question only served to signal whether the Core 
needed to devote additional resources to guide awardees to publish in more scientifically 
significant journals. This element of the project could reveal if investigators may need to be 
educated about the importance of targeting their manuscript submissions to well-respected, peer-
reviewed journals instead of publishing in journals that are not peer-reviewed. In other words, 
teaching investigators to prioritize quality publications over the sheer quantity of published 
work. 
An additional dimension of the contribution to the HIV knowledge base is the citation factor. 
Since there is not a single most respected publication that can be used as a benchmark, citation 
factors for all publications were recorded in Table A1 (Appendix A). This information is 
available through the Web of Science database. The higher the number of times a particular 
article was cited, the more significant the contribution to the global knowledge of HIV. 
To summarize, this part of the study sought to answer “Yes” or “No” to two questions: 
1. Are recipients of Developmental Core awards publishing in respected peer-reviewed 
HIV/AIDS journals? 
2. Do other researchers cite Emory CFAR awardees’ publications in their work? 
If the answer was “Yes” to one or both of these questions, the conclusion will be that the 
Developmental Core awardees do indeed contribute to global HIV knowledge base.  
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Research question 2: Organizational Impact — what impact have Emory CFAR 
Developmental Core awardees had on Emory University’s fiscal portfolio as it pertains to the 
NIH funded research base? More specifically, what is the rate of return on the dollars awarded 
via the CFAR-series pilot grant mechanism, Administrative Supplement mechanism, and Ramp 
Up award mechanism? 
External research funding often comprises a large portion of universities’ budgets. In 
particular, grant and contract funding from federal agencies, such as the NIH and the Centers for 
Disease Control and Prevention, as well as funding from large pharmaceutical companies are 
important to not only advance biomedical research, but also to provide employment to many 
different professions (scientific, clinical, teaching, and administrative) through provision of 
funds that cover salaries, fringe benefits, and other expenses. Therefore, external grant funding 
likely plays a significant role in most research universities’ financial well-being. The CFAR 
Developmental Core aims to contribute accordingly, through development of early stage 
investigators by means of pilot grant funding. This initial funding allows investigators to 
generate crucial data in order to secure independent NIH funding. This project examined the 
impact of the Developmental Core grant mechanisms on Emory University’s fiscal portfolio by 
looking at the rate of return on CFAR dollars invested. A positive return on investment would 
indicate that the program is working as intended. The higher the rate of return indicates stronger 
program outcomes. 
The return on investment (ROI) is a calculation that determines the amount of additional 
profits produced as a result of a certain investment. ROI is usually expressed as a percentage. 
The formula used for calculating ROI is:  
ܴܱܫ ൌ ୋୟ୧୬୤୰୭୫୍୬୴ୣୱ୲୫ୣ୬୲ିେ୭ୱ୲୭୤୍୬୴ୣୱ୲୫ୣ୬୲
େ୭ୱ୲୭୤୧୬୴ୣୱ୲୫ୣ୬୲
ܺͳͲͲ    
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Emory CFAR Developmental Core has three developmental grant mechanisms in which 
it awards funds to early stage and new HIV investigators:  
x CFAR-series awards (CFAR-03, CFAR-C, CFAR-K); 
x Ramp Up awards (Opportunity Awards, Collaborative Travel Awards, and Poster 
Awards); 
x Administrative Supplements awarded by the NIH and managed through the 
Developmental Core  
Calculating separate ROIs on each of these activities is useful to Emory University when 
evaluating the effectiveness of its investments of institutional resources and to the NIH when 
evaluating the effectiveness and efficiency of its Developmental Cores. A clear picture of which 
award mechanism is the most effective in generating financial return would allow both the NIH 
CFAR Program and the Emory CFAR to make more informed decisions and adjustments to the 
program to ensure that only the most beneficial funding mechanisms are utilized. Therefore, a 
separate ROI for each type of award was determined.  
Based on the discussion above, the following hypotheses were tested in this section of the 
project: 
H20: There is no relationship between Emory CFAR Developmental Core awardees 
receiving funds via a Developmental Core mechanism and the Emory fiscal portfolio 
as it pertains to NIH funding.  
H21: There is a positive relationship between Emory CFAR Developmental Core 
awardees receiving funds via a Developmental Core mechanism and the Emory fiscal 
portfolio as it pertains to NIH funding.  
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H30: There is no difference in the return on investment (ROI) among the three Emory 
CFAR Developmental Core award mechanisms. 
H31: The ROI of the CFAR-series pilot grant mechanism is different from the ROI of the 
Administrative Supplement mechanism. 
H32:  The ROI of the Administrative Supplement mechanism is different from the ROI of 
the Ramp Up award mechanism. 
H33:  The ROI of CFAR-series pilot grant mechanism is different from the ROI of the 
Ramp Up award mechanism. 
For the purposes of testing these hypotheses, the following terms were be used: 
Emory University fiscal portfolio - the total amount of funding in dollars received from 
the NIH as a result of a competitive application process by all investigators at Emory University. 
It is important to establish a distinction between the full Emory University fiscal portfolio and 
the level of contribution of Developmental Core awardees. This project will look at the return on 
investment (expressed as a percentage) on the CFAR dollar only and a total contribution 
(expressed in total NIH dollars) of CFAR Developmental Core awardees relative to the total 
Emory University fiscal portfolio. 
Investment - total CFAR Developmental Core dollars invested in the development of 
early stage and new HIV investigators through various funding mechanisms as described below. 
This information is tracked and is available for the entire project period of 1998-2016. 
Return on Investment - calculated ratio of total NIH dollars received by Emory 
University through grant funding to total CFAR dollars invested in early stage and new HIV 
investigators through various Developmental Core funding mechanisms. 
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Total NIH dollars - sum of all grant dollars received by Emory University that resulted 
from an initial Developmental Core investment. This information is partially available. All 
external grants obtained as a result of the Core-supported research are reported to the Core using 
unique NIH grant numbers. The NIH RePORTER system that provides grant data will be used to 
confirm total funding amounts for grants that have ended. The Emory University grants database, 
OnBase, which stores all notices of awards to all investigators will be used to confirm full 
funding amounts for grants that are active. Only external grants that were awarded to Emory 
University will be used in the calculation of total NIH dollars received. 
Impact of Developmental Core awardees - additional NIH dollars received by Emory 
University via the competitive grant application process by investigators who received pilot 
funding from the CFAR Developmental Core.  
The return on investment was calculated based on the total CFAR dollars (both federal 
and university) invested through CFAR’s three funding mechanisms and total NIH dollars 
received by the University as grant funding. 
The difficulty in calculating ROI on CFAR funded projects comes from the fact that 
funding for all pilot awards comes from both NIH and institutional sources. Some developmental 
awards are funded by NIH dollars, while others are funded by institutional dollars. Federally 
funded projects provide money not only for direct costs, but also for indirect costs, which at 
Emory University could range from 26% to 78.5% depending on the project activity scope and 
the location where the activity is conducted (Emory University, 2016b). Direct costs are defined 
by the NIH as costs that can be identified specifically with a particular sponsored project, an 
instructional activity, or any other institutional activity, or that can be directly assigned to such 
activities relatively easily with a high degree of accuracy. Indirect costs, (also referred to as 
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facilities and administration (F&A, FAC or IDC) are defined as necessary costs incurred by a 
recipient for a common or joint purpose benefitting more than one cost objective, and not readily 
assignable to the cost objectives specifically benefitted, without effort disproportionate to the 
results achieved (National Institutes of Health, 2016a).  
Projects funded with institutional funds generally do not include F&A. Therefore, a pilot 
project that has $40,000 in direct costs and is funded with NIH dollars that carries 56% F&A will 
have a total budget of $62,400, while a similar project funded with institutional dollars will have 
a total budget of $40,000. Generally, F&A on projects funded with institutional dollars is “cost-
shared,” or covered by internal institutional resources.  
Such variance between these types of total budgets presents a challenge when calculating 
ROI, so it is important to define the base on which ROI is calculated. Due to complexities arising 
from trying to account for cost-shared expenses, and to better reflect CFAR investment and 
returns on that investment, the ROI in this project was calculated on total CFAR dollars. This 
approach makes cost-sharing contributions irrelevant. In other words, if calculating ROI on two 
projects with $40,000 direct costs, but funded from different sources, the total amount of CFAR 
dollars invested will be $62,400 + $40,000 = $102,400. 
This approach was used for the ROI calculation for all types of awards issued by the 
Developmental Core. The gain from investment equaled the total amount of external NIH 
funding received by investigators as a result of the Developmental Core-supported research. This 
information is collected by the Emory CFAR regularly and is available for public use. Unique 
NIH grant numbers are also available, which can be used in the NIH RePORTER system to 
confirm grant data and total amounts for grants that ended. However, this dataset has one 
limitation. The total grant amounts are available through their most current active year. This 
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meant that ROI may be skewed because grants still have several years to be funded, which are 
not calculated into the gain. A permission from Finance Grants and Contracts was requested and 
granted to obtain the full amount of funding by looking up notices of awards in the University-
wide database. This approach resolved most of the inaccuracies in calculating ROI.  
 It was the focus of this study to only look at the ROI as it pertains to NIH dollars. 
Therefore, this work only looked at the return on investment generated by grants awarded by the 
NIH, since that is the only funding source of value to the NIH - the CFAR Program’s funding 
agency - when considering the success of the CFAR Developmental Core. It is important, 
however, to remember that true ROI is almost certainly much higher if this project expanded the 
analysis to include all grants resulting from CFAR Developmental Core awards. Many 
Developmental Core awardees go on to receive funding from other agencies and sponsors, such 
as the Centers for Disease Control and Prevention (CDC), pharmaceutical companies, and 
private foundations. Since the goal of this work was to determine the impact of Developmental 
Core awardees on Emory’s fiscal portfolio, grants obtained by investigators external to Emory 
University were not included in the ROI calculation. 
Therefore, the final formula to be used in this work was: 
ܴܱܫ ൌ ୘୭୲ୟ୪୒୍ୌୈ୭୪୪ୟ୰ୱ୅୵ୟ୰ୢୣୢି୘୭୲ୟ୪େ୊୅ୖୈୣ୴ୣ୪୭୮୫ୣ୬୲ୟ୪େ୭୰ୣୈ୭୪୪ୟ୰ୱ୍୬୴ୣୱ୲ୣୢ
୘୭୲ୟ୪େ୊୅ୖୈ୭୪୪ୟ୰ୱ୍୬୴ୣୱ୲ୣୢ
ܺͳͲͲ  
In addition to calculating a cumulative ROI on all developmental awards, ROI was also 
calculated for each type of award mechanism (pilot grants, opportunity awards, and 
supplements). This separate calculation allowed clear delineation of what funding mechanism 
yields the highest ROI and, therefore, is most successful. 
While the approach to this research question was relatively straightforward, the main 
limitation to addressing this question was incomplete reporting of grants obtained as a direct 
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result of Developmental Core funding. However, the survey described in the next research 
question was designed to solicit responses that helped to reduce or eliminate this limitation. 
Research Questions 3: Personal Impact — how have Emory CFAR Developmental Core 
services personally impacted the professional development and funding success of early stage 
and new HIV investigators? 
One of the main goals of the Emory CFAR Developmental Core is to ensure the success 
of investigators who are new to the HIV research field. Success in fields like HIV research 
extends beyond individual investigators. It has the potential to improve the reputation of the 
academic institution and to impact public health locally and globally. Public administrators, 
including grant managers and program officers at funding agencies, must be interested in the 
success of new investigators due to their potential impact on the entire population of the country. 
In academic research, the main measure of success is the ability to secure independent grant 
funding. However, it is also important to look at other personal and professional measures of 
success. The main indicator studied in this section of the project was the early stage 
investigator’s age when he or she first received an R01-equivalent grant, specifically if the first 
independent funding directly resulted from CFAR Developmental Core-supported research. 
Obtaining independent grant funding at a younger age would indicate possible individual success 
that resulted from the work of the Developmental Core. This data was collected through a 
survey. Additionally, awardees were asked to assess the importance of other related 
Developmental Core services that they received. The following hypotheses were tested for this 
section of the project: 
H40: There is no relationship between Emory CFAR Developmental Core Services and 
an investigator’s age at time of receipt of his or her first ever NIH R01-equivalent. 
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H41: There is a relationship between Emory CFAR Developmental Core Services and an 
investigator’s age at time of receipt of his or her first ever NIH R01-equivalent. 
NIH reports suggest that the current median age at which PhDs get their first NIH grant is 
42, and 44 for MDs. A younger age at receipt of first independent NIH grant may signal that the 
investigator utilized more successful strategies that could be expanded to other investigators and 
applied to similar programs. Specifically, it may indicate that the CFAR Developmental Core 
mechanisms and services used by these successful investigators are working as designed, helping 
early stage and new investigators get established earlier in the field of HIV research through 
securing independent funding. Information on age at time of receipt of a first NIH grant was 
obtained via a survey distributed to all Developmental Core awardees that are still at Emory 
University. 
Developmental Core awardees were contacted through a brief email request to answer 
several questions. Only those investigators who are internal to Emory University were contacted. 
Emory CFAR keeps detailed records of all awardees, so the entire population is available to be 
contacted, which eliminates the need to select a representative sample. The choice to contact 
only Emory internal investigators was made in order to stay consistent with the approach in 
calculating ROI. This is also consistent with the main goal of this project which is to demonstrate 
benefit not only to individual investigators and potential program impact on public health, but to 
Emory University as an academic institution that providing significant funding support to the 
CFAR program.  
Given the fact that the latest trends in NIH funding show that the average age at which 
investigators are awarded their first independent NIH grant is increasing, a lower average age at 
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the time of securing first NIH independent grant would show success of the Developmental Core 
programs in the development of early stage and new investigators.  
All identified awardees were contacted via email. This email contained an invitation and 
a link to participate in a brief web-based survey. The survey was built and administered via 
Qualtrics, a survey tool available to Valdosta State University students. The main goal of the 
survey was to gather demographic information and compare the results to the trends described in 
the literature review. An inquiry about collaboration resulting from the CFAR developmental 
award was included in order to gauge the impact of such funding on the potential for obtaining 
future grants. Questions to assess the awardees’ opinions on various other Developmental Core 
services were added. These questions addressed which available Developmental Core services 
early stage investigators in various stages of their careers viewed as most beneficial. A sample of 
the survey is included in Appendix E. Names of the respondents were collected in order to 
facilitate future contact in case clarification or follow up inquiry was needed. Two reminders 
were sent out to those who had not responded at 1 and 2 weeks after the original invitation was 
sent via email. Knowing names of those who had not responded eliminated frustration among 
those who did respond, as they did not receive survey reminders. 
A t-test was planned to be utilized to compare the mean of ages of Developmental Core 
early stage investigators and the mean of ages of first time R01-equivalent recipients reported by 
the NIH. Currently, NIH data on age is available through 2013. That timeline fits with this 
analysis, because Emory CFAR excludes from the analysis awards that ended two years ago or 
less and those awards that are still active. R01-equivalent grants may have not been obtained 
every year from 1998-2013. Therefore, years with no grants received were excluded from the 
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analysis. That result could indicate that the work of the Emory CFAR Developmental Core has 
affected new investigators’ success in the field of HIV research.  
Additionally, this project looked at established contacts and collaborations, as those could 
potentially lead to successful applications and receipt of NIH funding in the future. The ultimate 
goal of the Developmental Core is to provide necessary support to new investigators to be able to 
secure independent funding. While a particular investigator may have been unsuccessful in 
obtaining an independent R01 or equivalent grant after completing their pilot award, some may 
view newly established contacts and collaborations as an alternative but equally significant gain. 
If a majority of respondents reported that they have established promising contacts and possible 
collaborative opportunities, this could signal potential for successful grant applications in the 
future, thus impacting the personal success of individual investigators. This information was 
obtained via the same survey that went out to Emory faculty who had received CFAR 
Developmental Core awards. 
Finally, this project looked at which services Developmental Core awardees perceive as 
the most important and beneficial. Those questions addressed whether any services need to be 
eliminated, improved, or expanded. A low response rate was an anticipated limitation of this 
study, however a high response rate for this survey was achieved because CFAR awardees have 
stayed in close contact with the Developmental Core personnel long after they have completed 
their awards and established themselves as independent investigators.  
 There could be additional factors that affect awardees’ abilities to obtain grants. For 
instance, there is no information available on what portion of NIH-reported first time R01 
equivalent awardees had access to similar programs to the CFAR Developmental Core. It was 
not within the scope of this work to account for all possible factors impacting (or promoting) the 
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success of investigators. Instead, it was the goal of this project to determine if a more 
comprehensive study is needed to confirm the validity and efficacy of Developmental Core 
methods.  
A look at these three research questions separately presented a solid picture of how 
effective the CFAR Developmental Core is in its efforts to improve public health in the local 
areas and beyond through providing support to early stage and new HIV investigators. Studying 
the three research questions described above demonstrates how the Developmental Core 
performed over the last 17 years. A review of the chart displaying the rankings of publications 
and journals that have published Developmental Core-supported research allows core leadership 
to see whether more emphasis needs to be placed on advising awardees to submit their work to 
higher ranking journals. Also, it could demonstrate that the Core may need to expand its 
mentoring services. Additionally, if the chart shows consistently high impact and citation factors 
compared with the leading AIDS publications, this would signal that Emory CFAR 
Developmental Core awardees are contributing to the knowledge base in HIV research.  
The ROI shows which of the three Developmental Award mechanisms is the most 
successful. The mechanisms that yield the highest ROI in terms of bringing NIH dollars to 
Emory University were deemed the most successful. Core leadership may be able to make 
decisions to award more of a certain type of grant, while limiting or completely eliminating 
another, which would result in a more efficient use of federal and institutional funds.  
 The t-test shows whether Emory CFAR Developmental Core awardees are receiving 
independent funding at a younger age. If they are, this could mean that the practices of the 
Developmental Core truly impact new investigators’ careers by providing necessary funding for 
pilot studies and much needed mentoring and professional development. Receiving NIH funding 
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at a younger age indicates that investigators become established in the field of HIV research 
earlier and have more productive years left to conduct research and, hopefully, advance the fight 
against HIV at a faster pace. A majority of Developmental Core recipients reporting that 
collaborations developed as a result of Developmental Core support would indicate that his or 
her potential to continue to develop in the field, moving on to publications and independent grant 
applications. 
Finally, the menu of Developmental Core services was evaluated for applicability and 
importance. The results could help determine if any adjustments to the services provided by the 
Developmental Core are needed. Depending on the results, several actions could take place. A 
greater emphasis could be placed on mentoring. A look at the various Developmental Core 
award mechanisms and their calculated ROI could demonstrate which (pilot award, opportunity 
award, or supplement) is the most successful in expanding Emory University’s fiscal portfolio. 
Decisions could be made to reallocate funds and manpower to focus more on awarding and 
administering the most successful mechanisms. Results of the survey could trigger a shift to 
place focus on developing and strengthening certain Developmental Core services, while 
maintaining, limiting, or even eliminating others.  
Since the effect of the Core’s activities is so multi-dimensional, answering the three 
research questions would generate a good set of information about success of the Core overall. 
This information will be important during future progress reports, as well as competitive 
applications for continuing funding to the NIH. Additionally, positive results demonstrated by 
this small project could be presented to the main NIH CFAR in order to confirm that the program 
is functioning as it was designed.  
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On the National CFAR level, results could be used by other CFARs to develop similar 
programs, if this study finds Emory practices successful. The NIH program team mentioned 
inconsistencies in practices from one CFAR to another, making an overall evaluation 
challenging. Streamlining some of the processes and services could allow for a set of cross-
CFAR evaluation criteria to be developed. Additionally, other CFARs may elect to adopt 
services and award mechanisms being used by the Emory CFAR if this project demonstrates that 
they generate good ROI.  
Additionally, NIH has a number of similarly-structured, grant-giving programs that could 
use the framework of this study to evaluate their own developmental activities. On a smaller 
scale, positive results of this study could provide CFAR leverage when requesting institutional 
support from Emory University. Therefore, this project could potentially have an impact at the 
university level, as well as contribute to shaping of national policy when it comes to funding of 
HIV research.   
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Chapter IV 
RESULTS 
 
This chapter will present, interpret, and synthesize data obtained over the course of this 
project. The main goal of the data collection was to assess the impact of the Emory CFAR 
Developmental Core investments (both monetary and non-monetary) in HIV/AIDS research on 
three levels - global, organizational, and personal:  
1. Global Impact — how have Emory CFAR Developmental Core awardees contributed 
to the global HIV knowledge base? 
2. Organizational Impact — what impact have Emory CFAR Developmental Core 
awardees had on Emory University’s fiscal portfolio as it pertains to the NIH funded 
research base? More specifically, what is the rate of return on the dollars awarded via 
the CFAR-series pilot grant mechanism, Administrative Supplement mechanism, and 
Ramp Up award mechanism? 
3. Personal Impact — how have Emory CFAR Developmental Core services personally 
impacted the professional development and funding success of early stage and new HIV 
investigators? 
As stated in Chapter 3, global impact was assessed by analyzing the journal impact factor 
and the citation factor of publications that resulted, at least in part, from Emory CFAR 
Developmental Core services and activities; organizational impact was measured by the CFAR 
Developmental Core funding mechanisms’ return on investment of total CFAR dollars - both 
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federal and institutional (Emory University); and personal impact was gauged by a 
Developmental Core award recipient’s age at the time of obtaining his or her first R01-equivalent 
award. Developmental Core service usage by the awardees was examined in order to determine 
which, if any, services are being utilized. Examining service usage also presented a clearer 
picture about what services awardees see as most beneficial depending on the stage of their 
careers. 
Publication data were obtained from progress reports that the Emory CFAR annually 
submits to NIH and the Thomson Reuters Web of Science database. Return on investment data 
were collected from the Emory CFAR’s self-compiled annual progress reports submitted to the 
NIH, as well as NIH RePORTER and eRA Commons federal funding databases. Using eRA 
Commons, federal notices of awards to Emory University investigators that resulted, at least 
partially, from CFAR developmental awards were downloaded and award amounts were 
confirmed in order to accurately calculate returns. Finally, data on investigators’ age and service 
usage were obtained via a short survey. The entire population of developmental awardees was 
available to receive questionnaires, and the survey yielded a response rate of over 80%. Such an 
approach allowed data collection and analysis that produced a multi-dimensional picture of the 
impact of investments made by the Emory CFAR Developmental Core.  
This project also assessed the value add of the CFAR Developmental Core funding 
opportunities and services. Return on investment was calculated for each of the three 
developmental award mechanisms. The results were compared to determine the effectiveness of 
each mechanism. Non-funding services provided by the Core also were examined in order to 
determine what investigators view as valuable. 
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The following sections of the chapter will describe results of those analyses. First, the 
global impact will be presented by cataloging all the publications that resulted from CFAR 
developmental awards and analyzing the publications’ journal impact factor (JIF) and citation 
counts. The second section will take a deep look at return on investment generated by CFAR 
developmental awards. In other words, it will include a detailed analysis of the return on every 
dollar the Emory CFAR has invested in early stage HIV investigators via various developmental 
award mechanisms. Finally, results of the investigator survey will be summarized and analyzed 
to determine if there is a correlation between activities of the CFAR Developmental Core and the 
age of Core-supported investigators when they received their first R01-equivalent award. 
ANALYSES AND FINDINGS 
 
Research Question 1: Global Impact 
 
In order to answer the first research question, “How have Emory CFAR Developmental Core 
awardees contributed to the global HIV knowledge base?” a significant amount of publication 
data had to be collected, cataloged, and analyzed. Data were used to test the following 
hypotheses: 
H10: Emory CFAR Developmental Core awardees had no impact on the global HIV 
knowledge base. 
H11: Emory CFAR Developmental Core awardees had an impact on the global HIV 
knowledge base. 
The criteria to determine if an awardee’s publication contributes to the global HIV knowledge 
base included: 
1. Awardees are publishing articles in scientific journals; 
2. Published articles appear in journals that were: 
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a) Peer-reviewed or included publications by invitation only; 
b) Had journal impact factors (JIF) of more than “0”1;  
c) Were available to a wide audience either by print or via online versions; 
3. Published articles have citation counts of more than “0,” meaning that the articles were 
cited in other publications at least one time. 
For the purposes of this project, satisfying conditions 1 and either 2 or 3 suggests that the 
publication is contributing to the global HIV/AIDS knowledge base. 
Data collection 
 
  Since CFAR Developmental Core awardees’ contribution to the global HIV knowledge 
base is measured in journal impact factor and citation counts, information on publications that 
resulted from research supported by the Core first needed to be gathered, organized by 
publication year, and analyzed for impact. A publication list was compiled from Emory CFAR 
annual progress reports to NIH and CFAR competitive renewal applications. Additionally, 
investigators who had received CFAR developmental awards were asked in the fall of 2017 to 
send publication updates to the CFAR. These self-reported publications were added to the 
evaluation in order to capture the most updated picture of the CFAR Developmental Core’s 
impact on the global HIV knowledge base. Journal impact factor data were only available 
through 2016; therefore, publications from 2017 were not included in the analysis. Similarly, 
these publications were not evaluated for their citation count, because they are too new to have 
been cited. 
After the CFAR Developmental Core-supported publications were cataloged, the next step 
was to address the impact of the scientific journals in which these publications appeared. In order 
                                                 
1 Per World of Science database, there were nine journals with JIF of “0” in 2016 
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to do that, a journal impact factor (JIF) for each scientific journal was recorded using the 
Thomson Reuters Web of Science database. The JIF is a measure of a journal’s relative 
importance in the field as compared to other journals. It is calculated by dividing the number of 
current year citations to the source items published in that journal during the previous two years 
(Clarivate, 2018). A separate JIF for each journal was retrieved from the database for every year 
in which a relevant publications appeared.  
Unfortunately, JIFs were not available for six journals for the years in which 
Developmental Core related articles appeared. Additionally, there were no publications in 2001 
and 2002. No specific reasons were identified for not having publications in these two years; it 
was simply by chance. Publications without an available journal impact factor and the years of 
missing data (2001 and 2002) are accounted for in the analysis below.  
Next, a benchmark JIF was needed in order to see where journals with CFAR 
developmental awardee publications fell. Four areas of publications were considered when 
setting the benchmarks: overall biomedical science, clinical, AIDS overall research, and AIDS 
and behavioral sciences. Covering these four areas was necessary because CFAR investigators 
have varying research backgrounds and areas of expertise. They also often collaborate with 
colleagues with training and research portfolios in different topical areas. Additionally, by 
covering these four publication areas, it ensures that the potential audience for developmental 
awardees’ publications represents a diverse pool.  
After a review of publications by senior HIV researchers at Emory University and 
discussions with CFAR Developmental Core leadership, four journals were selected as 
benchmarks for impact: Science, AIDS, The Journal of American Medical Association (JAMA), 
and AIDS and Behavior. Science and JAMA are recognized by biomedical research community 
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as top journals for basic science and clinical science, respectively. AIDS and AIDS and Behavior 
are field-specific journals, recognized as having high impact on HIV/AIDS research.  
These four benchmarks represent a cross-section of high impact journals in which early 
stage HIV investigators would strive to have their work published - with Science being the 
ultimate goal. Publications in journals like Science and JAMA would be of interest to the entire 
biomedical research community, even researchers who are not in the HIV field. Theoretically, 
such exposure could trigger not only new HIV research collaborations, but also cross-field 
collaboration (i.e. cancer, cardiovascular, etc.) that could lead to groundbreaking research with a 
more global impact on the well-being of all people.  
It is important to note that the majority of CFAR Developmental Core support is directed to 
early stage investigators and to those who are new to HIV/AIDS research. Therefore, it is not 
expected that their publications would appear in these aforementioned benchmarks journals since 
they are viewed by the most seasoned researchers as the ultimate place to publish. Compounding 
this limitation is the fact that HIV is a somewhat narrow research field. It is more reasonable to 
expect that early stage investigators would first publish in field-specific journals. 
Once the four benchmark journals were selected, a JIF for each journal for each year of the 
Emory CFAR (1998-2016) was collected and recorded to be used later in the analysis (Appendix 
A, Table A1). 
Lastly, after obtaining journal impact factor data, each developmental awardee publication 
was analyzed through the Web of Science database to calculate its citation count (i.e. the number 
of times that particular publication was cited in other works). It is important to note that h-index 
an author-level metric that measures both the productivity and citation impact of a particular 
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researcher does exist. However, it was not an appropriate measure for this project, as it takes into 
account all scholar’s publications, not just a specific group.  
Findings 
 
The results of the data collection were impressive. Through 2016, 128 articles were 
published by CFAR Developmental Core awardees. The awardees’ articles appeared in 66 
separate sources — one was a magazine (Migration World Magazine), 62 were peer-reviewed 
journals, and three were journals that only accept articles by invitation (Current Infectious 
Disease Reports, Current Opinion in HIV and AIDS, and Immunological Reviews). Several of 
these journals were open access, meaning that readers do not need to pay to access the articles 
published in them. See Table A2 in Appendix A for a full list of CFAR Developmental Core 
award-relevant publications.  
The JIFs for journals in which these articles were published were then recorded separately 
by publication and by year. The lowest JIF recorded was 0.59 (Patient Education and 
Counseling, 1998), and the highest was 31.027 (Science, 2012). The average JIF for all 
publications was 4.498. These results are provided in Table A1 (Appendix A).  Since JIFs were 
not available for six journals for the years in which Developmental Core related articles 
appeared, these journals were not factored in to the average journal impact factor. Publications 
without an available JIF are highlighted in yellow in Table A1 (Appendix A).  
Just as with the CFAR-publishing journals, average JIFs were also calculated for the four 
benchmark journals using data from 1998-2016 (Figure 3).  The average benchmark JIFs are as 
follows: 
x Science-29.49 
x JAMA-25.61 
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x AIDS-5.98
x AIDS and Behavior-2.61 
In order to visually represent how the CFAR-publishing journals compare to the 
benchmark journals, the JIFs for the four benchmark journals were first plotted in a chart. The 
publication year was used as the x-axis and the journal impact factor as the y-axis in the chart to 
clearly show the benchmarks that were used to determine impact of other publications. After 
plotting the benchmarks, the impact factors of journals that contain publications by 
developmental awardees were averaged for each year and plotted as a separate line. (Figure 3).  
 
FIGURE 3. IMPACT FACTORS OF JOURNALS CONTAINING EMORY CFAR DEVELOPMENTAL 
CORE PUBLICATIONS, 1998-2016 
Since Emory CFAR Developmental awardees did not report any publications in 2001 and 
2002, there was no impact to the global HIV knowledge base via publication for those years.  
The average JIFs for CFAR-funded journals for 2001 and 2001 were set at “0” for plotting 
purposes, as seen in the fifth line in Figure 3 above.  
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Finally, citation counts for each developmental awardee publication were calculated and 
recorded. A full list of Developmental Core-supported publications with the citation factor (i.e. 
number of citations) is provided in Table A2 (Appendix A).  
Analysis 
  Aside from 2001 and 2002, developmental awardees published their research in 
numerous scientific journals in every year since 1998 - the year the Emory CFAR was 
established (Table A2, Appendix A). As stated earlier, most of these publications appeared in 
peer-reviewed journals (n = 62). Additionally, a few publications appeared in journals that only 
accept invited papers. Both data points indicate a certain level of respect and credibility for the 
work produced by Emory CFAR investigators. In recent years, CFAR-supported publications 
have increasingly appeared in open access journals. Open access journals also are peer-reviewed, 
ensuring the credibility of the published research. However, unlike the traditional scholarly 
journals, open access publications are available to everyone without the requirement of a paid 
subscription. This allows a much broader audience to have access to high-quality, peer-reviewed 
articles. These results demonstrate that Emory CFAR early stage investigators are utilizing 
multiple venues for publications, which should help them reach the widest audience possible. 
Journal Impact Factor Analysis 
 
As mentioned above, the journal impact factor (JIF) reflects a journal’s ability to attract 
high-quality publications (Garfield, 1996). This journal-based data point is applicable to 
Developmental Core awardees’ publications; the implication is that if an awardee had an article 
published in a journal with a high JIF, it indicates that the publication was deemed as “the best” 
among other articles. It is true that this approach is subjective. However, it satisfies the demands 
of the CFAR Developmental Core leadership team and offers a uniform measure to evaluate 
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awardees’ contribution to the global HIV knowledge. It is important to note that the use of JIFs 
as a performance metric has come under scrutiny in the past. Even so, the research community 
still relies on this measure when considering faculty promotion, tenure, and even funding 
allocation. 
As seen in Figure 3, the average JIF for awardees’ publications remained relatively stable 
from 1998 to 2016 (excluding 2001 and 2002 in which no CFAR-supported publications were 
reported). There appears to be a peak in 2012, resulting from one publication in Science. 
Publications in Science are atypical for early stage investigators, so this particular result can be 
viewed as an outlier. Consistent JIF data suggest that, even with recent technological 
developments and easy-access publishing venues, awardees are consistently publishing in 
journals that are respected in the field of HIV research. It also suggests that awardees are 
consistently contributing to the global HIV knowledge base. 
  Figure 3 also shows Science and JAMA journal impact factors are consistently higher 
than AIDS and Behavior and AIDS, as well as the average JIF for awardees’ publications. That is 
explained by the fact that first two journals cover a wide variety of research and medical sectors. 
AIDS and Behavior and AIDS are very specific to the HIV research field, making their overall 
reach narrower and impact lower due to the large number of competing scientific and clinical 
publications. The same can be said for the vast majority of journals that are publishing HIV-
specific work from the CFAR developmental awardees. Therefore, it is logical that the line for 
the average JIF for Developmental Core-publishing journals fell closer to the lines for the two 
field-specific journals (AIDS and AIDS and Behavior). 
  Looking closer at the average five JIF scores, it is easy to see that Emory CFAR 
Developmental Core-supported publications (4.498) compare well with the benchmark 
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publications. The Developmental Core average falls between the values for AIDS and Behavior 
(2.61) and AIDS (5.98), suggesting that CFAR early stage investigators publish in journals that 
are respected in the field of HIV research. While these field-specific journals are not read by as 
wide of an audience as Science (29.49) and JAMA (25.61), the global HIV research community is 
expected to have access to these publications and thus, the CFAR developmental awardees’ 
findings. 
It is important to reiterate that the purpose of this section is not to assess the size of 
developmental awardees’ publications impact on the HIV global knowledge base, but whether 
the publications had an impact at all. The main concern with respect to global impact is that, with 
technology developing rapidly, online journals are available that are not necessarily reputable 
and often publish articles “for a fee.” It would be easy for quantity to overshadow the quality of 
publications. The main goal of the journal impact factor analysis was to see if awardees are 
publishing in respected journals that utilize a peer-review process and are viewed as having some 
impact in the field. 
Citation count analysis 
 
Since publications supported by the Emory CFAR Developmental Core are the focus of 
this project, citation count analysis was performed only for those publications that met these 
criteria. In total, the 128 articles resulting from activities of the Emory CFAR Developmental 
Core were cited a total of 3,395 times. Out of the 128 articles published by developmental 
awardees, only 7% (n = 9) of publications did not have any associated citations. Six of those nine 
publications were published in the last year of data collection (2016), feasibly making them too 
new to be cited. The highest citation count calculated for the developmental awardee 
publications was 303, the average was 26.52, the median was 16, and standard deviation was 
 74 
 
36.94. (Table A2, Appendix A). The citation count findings are important for the evaluation of 
awardees’ contribution to the global HIV/AIDS knowledge base because it shows that their work 
is being referred to by other publications. That implies a certain level of expertise that the 
Development Core awardees are thought to have in this research field. Awardees’ work 
continues to contribute to global HIV/AIDS knowledge through being cited in other publications 
by other researchers. 
Determination 
 
The research question for this component of the project addressed whether Emory CFAR 
developmental core awardees contributed to the global HIV knowledge base on satisfying 
following conditions: 
1. Awardees are publishing articles in scientific journals; 
2. Published articles appear in journals that were: 
a) Peer-reviewed or included publications by invitation only; 
b) Had journal impact factors (JIF) of more than “0”;  
c) Were available to a wide audience either by print or via online versions; 
3. Published articles have citation counts of more than “0”.  
  A review of all of the publications that resulted from Developmental Core funding from 
the beginning of Emory CFAR until 2016 showed that most publications satisfy these conditions. 
Only 7% of publications (n = 9) did not have any citations, and there were only two years in 
which awardees did not report any publications. Since the goal of this component of the project 
was to determine whether there was a contribution to the global HIV knowledge base - not to 
evaluate that impact or determine significance of each individual publication, it is possible to 
 75 
 
argue that CFAR Developmental Core awardees do contribute to the global HIV knowledge 
base. 
The results detailed above indicate the Emory CFAR Developmental Core contributed to 
common knowledge. Over the first 18 years of the Emory CFAR, investigators supported by the 
Developmental Core funding mechanisms have actively published dozens of articles in 
reputable, peer-reviewed journals. Additionally, many have taken advantage of the availability of 
open source journals that make research more accessible to the general public by lifting any 
financial barriers. Results show that developmental awardees utilize multiple sources to 
disseminate their study findings (traditional journals, open source journals, magazines, online 
journals, and international publications), contributing to a broad HIV knowledge base. 
Additionally, these contributions are strengthened by the fact that several CFAR-supported 
publications appeared in journals that publish work only by invitation. This confirms that 
research conducted by early stage investigators who are supported by the CFAR Developmental 
Core is recognized in the scientific community in myriad ways. 
Based on the results described above, the null hypothesis is rejected and alternative 
hypothesis is accepted: 
Research Question 2: Organizational Impact 
 
To answer the second research question, “Organizational Impact — what impact have 
Emory CFAR Developmental Core awardees had on Emory University’s fiscal portfolio as it 
pertains to  the NIH funded research base? More specifically, what is the rate of return on the 
dollars awarded via the CFAR-series pilot grant mechanism, Administrative Supplement 
mechanism, and Ramp Up award mechanism?” data on CFAR developmental awards and the 
outcomes from those funded projects were analyzed. The following hypotheses were tested: 
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H20: There is no relationship between Emory CFAR Developmental Core awardees 
receiving funds via a Developmental Core mechanism and the Emory fiscal portfolio 
as it pertains to NIH funding.  
H21: There is a positive relationship between Emory CFAR Developmental Core 
awardees receiving funds via a Developmental Core mechanism and the Emory fiscal 
portfolio as it pertains to NIH funding.  
H30: There is no difference in the return on investment (ROI) among the three Emory 
CFAR Developmental Core award mechanisms. 
H31: The ROI of the CFAR-series pilot grant mechanism is different from the ROI of the 
Administrative Supplement mechanism. 
H32:  The ROI of the Administrative Supplement mechanism is different from the ROI of 
the Ramp Up award mechanism. 
H33:  The ROI of CFAR-series pilot grant mechanism is different from the ROI of the 
Ramp Up award mechanism. 
 The Emory CFAR supports three types of developmental funding awards: Ramp Up 
awards, CFAR-series pilot grants, and Administrative Supplements. Each award type has a 
different purpose, and they all also differ in funding amounts. Ramp Up awards are quick small-
scale grants (typically up to $2,000), designed to fill a critical, time-sensitive need. CFAR-series 
pilot grants are medium-scale awards ($40,000-$60,000), designed to allow an early stage 
investigator to perform preliminary research that will enable them to collect pilot data to bolster 
future applications for independent federal funding. These awards provide up to two years of 
non-renewable funding. Administrative Supplements are large-scale awards (usually at least 
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$100,000) to cover special interest projects that are designated, funded, and initiated by NIH. For 
additional detail on the award types offered through the CFAR, please see Appendix C.  
Overall, the goal of all the awards offered by the CFAR Developmental Core is to enable 
early stage investigators to successfully compete for independent NIH funding, preferably R01-
equivalent grants, by providing necessary funding, resources, mentoring support, and training.  
 Emory University has several similar pilot grant mechanisms administered by other 
programs and centers. In the case of the CFAR, Emory University provides additional 
institutional funding to share the costs of the CFAR developmental awards program with the 
Emory CFAR’s primary funding agency, the National Institutes of Health. In other words, non-
federal university funds supplement the CFAR program. Even though these institutional funds 
are tracked separately, they are considered part of the Developmental Core’s total funds. Awards 
may be funded in one of three ways: only NIH federal funds, only Emory institutional funds, or 
co-funded from both federal and institutional sources. Therefore, it is important to consider the 
total CFAR investment in all analyses. 
Data collection 
 
 Data on each CFAR Developmental Core award mechanism and the outcomes were 
collected from annual progress reports that CFAR submitted to NIH. Before data analysis began, 
it became clear that there is a reporting inconsistency that may skew results reported to the NIH. 
When reporting outcomes that resulted in part due to a CFAR developmental grant, some 
awardees reported anticipated or remaining funding amounts as of the date when they wrote the 
progress report. Others reported the total awarded amount. The rest reported just the funding 
amount for the current grant year. This discrepancy could have resulted in an inaccurate 
calculation of the ROI that was reported to the NIH. To rectify reporting inconsistencies, original 
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NIH notices of award were pulled from the NIH Commons database, and amounts from those 
original documents were recorded in the outcomes tables (Tables B3, B4, and B5 in Appendix 
B).  
Before diving into analysis, it is appropriate to reiterate that total CFAR investment refers to 
total CFAR dollars. It includes both NIH federal and Emory institutional funds. Therefore, the 
calculation for the return on investment (ROI) for each category will be as follows: 
ܴܱܫ ൌ
ୋୟ୧୬୤୰୭୫୍୬୴ୣୱ୲୫ୣ୬୲ሺ୘୭୲ୟ୪୬ୣ୵୒୍ୌ୥୰ୟ୬୲ୱୟ୵ୟ୰ୢୣୢ୲୭୉୫୭୰୷ሻିେ୭ୱ୲୭୤୍୬୴ୣୱ୲୫ୣ୬୲ሺ୘୭୲ୟ୪୉୫୭୰୷େ୊୅ୖ୊୳୬ୢୱሻ
େ୭ୱ୲୭୤୧୬୴ୣୱ୲୫ୣ୬୲ሺ୘୭୲ୟ୪୉୫୭୰୷େ୊୅ୖ୤୳୬ୢୱሻ
ܺͳͲͲ  
Since two key terms (NIH R01 grant and ROI) are visibly similar and may not be easily 
distinguishable by a reader, an underline will be used to clearly mark ROI (return on 
investment). 
Findings 
 
Ramp Up Awards 
 
 Over the first 18 years that the Emory CFAR has been in existence, 62 Ramp Up awards 
were issued for a total of $132,870. One of these Ramp Up award was issued to cover data 
collection for an existing NIH-funded R34 grant, so no project outcome was expected. Even so, 
this Ramp Up award was factored into the ROI calculation in order to properly reflect the entire 
CFAR investment. An additional three of the 62 Ramp Up awards were issued as supplemental 
funding to existing CFAR-series pilot awards to provide additional funding to fill a critical need 
(i.e. data collection, equipment and/or supply purchase). These three awards were not included in 
the ROI calculation for Ramp Up awards. Instead, they were included in the ROI calculation for 
CFAR-series pilot awards. 
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 Data indicated that 11 Ramp Up awards were converted into NIH-funded extramural 
awards — two of which were new R01 grants and one was an R01 supplement. An additional 
two Ramp Up awards contributed to the successful application for a single NIH award.  As 
previously stated, the total CFAR investment (both NIH and Emory) in the Ramp Up awards 
mechanism totaled $132,870. The total amount of new extramural grants awarded to Emory 
University as a result of these Ramp Up awards was $8,731,680. All data are presented in Table 
B3 (Appendix B). The ROI calculation was as follows: 
ܴܱܫ ൌ ଼ǡ଻ଷଵǡ଺଼଴ିଵଷଶǡ଼଻଴
ଵଷଶǡ଼଻଴
x100=6,472% 
 The results of the Ramp Up award calculation shows that the ROI was 6,472%. That 
means that for each dollar invested by the Emory CFAR into Ramp Up awards, Emory 
University received $6,472 in new funding from NIH. This is impressive information, especially 
given that Ramp Up awards are very small in terms of funding power. Please note that the 
calculation used the total CFAR investment of $132,870 in order to determine the correct ROI. 
While only $35,027 was invested in Ramp Up awards that actually were converted into 
extramural grants, using this figure would be inaccurate since it excludes a large portion of the 
total funds invested into this funding mechanism. Therefore, an ROI value that excludes the total 
CFAR investment would be artificially inflated. Additionally, NIH requests that ROI is 
calculated on total money invested, not just the portion converted into new grants. 
CFAR-series Awards 
 
A total of 58 CFAR-series pilot awards were issued to early stage investigators. As stated 
above, three Ramp Up grants were awarded to supplement existing CFAR-series grants. The 
amount of these Ramp Up awards is included in the calculation of total Emory CFAR investment 
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because they were issued as additional money to existing CFAR-series awards. It would be 
inaccurate to calculate them into the Ramp Up award ROI, as they were not expected to be 
converted into extramural grants. Instead, their purpose was to remove an obstacle encountered 
by an investigator during the course of a CFAR-series award. The data collection showed total 
Emory CFAR investment into CFAR-series awards was $2,672,668. Awardees reported that 
their CFAR-series awards helped, at least in part, to successfully apply for a total of 30 new NIH 
grants issued to Emory University.  
While several types of extramural NIH awards were reported as being received by the 
CFAR-series award recipients, R01-equivalent grants are reported separately to the NIH and are 
of particular interest. The moment when an investigator obtains an R01-equivalent is usually 
considered the start of the scientist’s career as an independent investigator and researcher. 
Therefore, while all grants received by developmental awardees are valuable, R01-equivalent 
grants - particularly an investigator’s first ever R01-equivalent grant - are the ultimate goal of 
CFAR Developmental Core funding mechanisms. Thirty new NIH awards were obtained by 
Core awardees based on, at least partially, the support provided by the CFAR Developmental 
Core. 
Out of 30 new NIH grants received by Emory University, there were 43% (n=13) R01-
equivalent grants that resulted from CFAR-series pilot funding. Nine of those 30 R01-equivalent 
grants were the recipient’s first ever independent NIH award. Another 13% (n=4) were the 
developmental awardee’s first ever NIH R01-equivalent awards, but not his or her first NIH 
independent funding (Figure 4). In other words, these investigators reported that they have had 
independent NIH awards that were funded by mechanisms other than R01 (such as 
Developmental Research Grant Award (R21), Research Scientist Development Award (K02)). 
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FIGURE 4 NEW NIH AWARDS OBTAINED, AT LEAST PARTIALLY, DUE TO 
SERVICES OF EMORY CFAR DEVELOPMENTAL CORE 
Total Emory CFAR investment (both NIH and Emory) into the CFAR-series pilot award 
program was $2,672,668. The total external dollars awarded to Emory University as a result of 
CFAR-series pilot projects equaled $36,254,300. Details for the CFAR-series pilot awards issued 
and NIH grants received as a result of that pilot funding are in Table B4 (Appendix B).  The ROI 
calculation was as follows: 
ܴܱܫ ൌ ଷ଺ǡହଶସǡଷ଴଴ିଶǡ଺଻ଶǡ଺଺଼
ଶǡ଺଻ଶǡ଺଺଼
ݔͳͲͲ ൌ1,266% 
As can be seen from the above numbers, CFAR-series pilot awards bring an impressive 
amount of NIH dollars to the university, resulting in an ROI or 1,266%.  Not all CFAR-series 
grants were converted into new NIH awards. Even so, those that were converted succeeded in 
bringing large extramural federal grants relative to a relatively small CFAR investment of 
between $40,000 and $60,000. Furthermore, the resulting NIH grants were awarded by different 
institutes, suggesting a wide scope of HIV research was supported by the Emory CFAR 
Developmental Core through the pilot funding award mechanism.  
57%
30%
13%
43%
Other NIH Awards (Non-R01)
First Ever R01 AND First Ever NIH Independent Funding (13 (
First Ever  R01, but not First Ever IndependentNIH Funding
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Administrative Supplements 
 
The Emory CFAR has been successful in obtaining several types of federal supplements 
to the main CFAR grant from NIH. NIH awards these Administrative Supplements to the Emory 
CFAR in order to fund promising special interest research projects that have the potential to 
generate additional external funding. This component of the project looks at such NIH 
Administrative Supplements that are administered through the CFAR Developmental Core.  
 There were a total of seven NIH Administrative Supplements awarded to Emory CFAR 
investigators, resulting in a total CFAR investment (NIH and Emory) of $1,220,148. Only one of 
the seven Administrative Supplements was converted into an independent R01-equivalent award. 
However, that single award brought a total funding amount of $2,393,299 to Emory University. 
It is also worth noting that this award was the first ever R01-equivalent received by this 
particular investigator. Therefore, the total ROI for Administrative Supplements was 96%, as 
calculated below: 
ܴܱܫ ൌ ଶǡଷଽଷǡଶଽଽିଵǡଶଶ଴ǡଵସ଼
ଵǡଶଶ଴ǡଵସ଼
ݔͳͲͲ ൌ96% 
 Likewise, details of the Administrative Supplemental awards obtained by Emory 
investigators and NIH grants obtained as a result of this funding are in Table B5 (Appendix B).  
Determination 
 This component of the project assessed the efficiency of the three funding award 
mechanisms provided through the Emory CFAR Developmental Core. In particular, it compared 
the three mechanisms to discover if one was more successful than others in generating NIH 
funding for Emory University. Such analysis was necessary in order to determine the best use of 
CFAR resources. As described above, each mechanism varies in the amount of dollars invested. 
Ramp Up awards are small-scale and targeted grants, designed to fulfill a critical need or to 
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eliminate a specific barrier. On the other hand, CFAR-series pilot grants and Administrative 
Supplements are designed to provide initial seed funding for a particular idea or project that has 
potential to generate additional federal funding. Administrative Supplements were analyzed 
separately, as NIH funds them and requests reporting on them separately. 
 Based on the fact that each developmental award mechanism was able to generate 
revenue and had a positive ROI, H20  can be rejected. Therefore, we can accept this alternative 
hypothesis: 
H21: There is a positive relationship between Emory CFAR Developmental Core 
awardees receiving funds via a Developmental Core mechanism and the Emory fiscal 
portfolio as it pertains to NIH funding.  
Clearly, each CFAR Developmental Core-supported award mechanism contributes to 
increasing of Emory University fiscal portfolio on some level.  
When it comes to ROI, the results indicate that each mechanism has a different impact in 
terms of dollar-for-dollar return on investment. Ramp Up awards showed the highest ROI 
(6,472%), followed by CFAR-series pilot grants (1,266%), and closing with the Administrative 
Supplements (96%). These results allow us to reject the null hypothesis H30, and accept the 
following alternative hypotheses: 
H31: The ROI of the CFAR-series pilot grant mechanism is different from the ROI of the 
Administrative Supplement mechanism. 
H32:  The ROI of the Administrative Supplement mechanism is different from the ROI of 
the Ramp Up award mechanism. 
H33:  The ROI of CFAR-series pilot grant mechanism is different from the ROI of the 
Ramp Up award mechanism. 
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 It is important to understand that, while all ROI calculations are different, the goal of this 
component of the project is not to determine which ROI is better. Rather, NIH simply requests 
CFARs to gather accurate ROI data and calculate precise ROI values every year as a barometer 
of the CFAR’s overall success rate.  
The variation in ROI between developmental award mechanisms also has internal value 
for the CFAR. Seeing that the ROI values differ for each type of developmental award should 
allow CFAR leadership to make decisions on how to best allocate precious limited financial and 
staff resources. Of particular interest are the ROI values of Ramp Up and CFAR-series pilot 
awards. At first glance, it may seem that Ramp Up awards are much more successful based on 
the ROI alone. However, other factors must be considered, such as the number of external 
awards received and the number of investigators successfully applying for NIH grants that 
resulted from this funding mechanism. While the calculated ROI is much higher for Ramp Up 
awards, the actual number of external grants awarded is much less than the number of NIH 
grants obtained as a result of the CFAR-series pilot awards. The lower ROI for CFAR-series 
awards represents more external awards, but higher CFAR investment. CFAR directors may use 
this information when deciding whether to make changes or enhancements to a particular 
developmental grant mechanism. Also, having accurate ROI numbers provides the CFAR 
directors with information that can be useful when requesting additional resources from the 
university or other potential sponsors.    
Finally, these ROI numbers are requested by the NIH at the time of CFAR progress report. 
They are then used to help secure new or maintain current funding levels for the National NIH 
CFAR Program. Showing strong ROI numbers signals that the program is successful and has an 
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impact on the careers of early stage investigators, as well as the public health community and 
general public who benefit from HIV research.  
This component of the project also illuminated other useful information for the Emory 
CFAR. Over the course of this project, it was discovered that there was variation in how CFAR-
supported investigators were reporting total funding amounts for external grants that resulted 
from their CFAR developmental awards. Some reported total awards as of that particular year, 
others reported total awards just for that year, while the rest reported total amounts awarded. 
Inconsistent reporting skews ROI calculations, potentially negatively impacting the final overall 
ROI value that NIH assigns to the Emory CFAR.  
Research Question 3: Personal Impact 
 
To answer the third research question, “Personal Impact - how have Emory CFAR 
Developmental Core services personally impacted the professional development and funding 
success of early stage and new HIV investigators?”, a short survey was sent to all recipients of 
CFAR developmental in order to test the following hypotheses: 
H40: There is no relationship between Emory CFAR Developmental Core Services and 
an  
investigator’s age at time of receipt of his or her first ever NIH R01-equivalent. 
H41: There is a relationship between Emory CFAR Developmental Core Services and an 
investigator’s age at time of receipt of his or her first ever NIH R01-equivalent. 
Please note that for the purposes of this project, individual success of an early stage 
investigator is measured as age of receipt of the first NIH R01-equivalent grant.  Ideally, the 
results would show that Emory CFAR developmental awardees are receiving their first R01-
equivalent grants at an age that is significantly lower than the average age of first time R01-
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equivalent recipients as reported by the NIH. A significant difference was agreed to be equal or 
more than five years. 
Data collection 
 
 The survey was sent to the entire population of CFAR Developmental Core awardees 
who were still at Emory University. It was intentionally designed as a short questionnaire to 
make it more attractive to busy faculty members. In total, 49 surveys were sent via email, which 
included a link to the survey. After two follow-up emails, 41 surveys were returned, two 
awardees declined to participate as they are retired and are out of the research field, and the rest 
of the surveys were not returned. The response rate equaled 84%.  
Findings 
 
Degrees 
 
All of the respondents had either an MD or a PhD degree. Thirty-nine percent of 
respondents (n = 16) indicated an MD as their degree, 56 % (n = 23) indicated that they have a 
PhD, and 5% (n = 2) had a dual MD/PhD degree. Of the 16 respondents with an MD degree, six 
had another graduate-level degree (MPH, MSc), and two of the 23 respondents with a PhD 
degree had another graduate-level degree (MPH, MHS). Of all respondents, 24% (n = 10) has 
multiple degrees (i.e. MD/PhD, MHS, MPH, MSC). 
Funding 
 
Of the 41 people who returned the survey, 61% (n = 25) indicated that they were able to 
secure external federal funding that resulted at least in part from a developmental award. Of 
those 25 respondents, only one did not receive an NIH grant; rather, that investigator was 
awarded a CDC U01, which is a large grant, often totaling over $1 million per year. Sixteen of 
these 25 respondents were successful in obtaining their first ever R01-equivalent grant and 
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indicated in the survey answers that the Developmental Core did contribute to their success at 
least on some level. Nine of these 25 respondents indicated that they were successful in obtaining 
multiple NIH awards. Awardees reported receiving four of the R01-equivalent grants in 2017. 
However, these grants would not have been included in the pilot award outcomes analysis above 
as they are too new. 
It is worth reiterating that NIH requires the Emory CFAR to report on two types of 
funding outcomes resulting from developmental awards: total NIH funding and funding obtained 
via R01-equivalent grants (typically considered to be the start of an investigator’s independent 
research career). Mirroring that NIH data request, this project looked at all NIH funding obtained 
at least partly from Emory CFAR developmental awards, as well as tracking CFAR-sponsored 
projects that resulted in R01-equivalent awards.   
Of all 41 respondents, 58% (n=21) said that their CFAR Developmental Core award 
helped in obtaining their first ever NIH award. However, only 47% (n=16) of all respondents 
reported the same when it came to obtaining their first R01-equivalent award. That lower number 
may be explained by many reasons. For example, some investigators may have decided to leave 
the field of HIV/AIDS research. The implication is that while their first NIH funding was 
supported by the Developmental Core, the subsequent R01-equivalent may have been in an area 
unrelated to the activities of the CFAR.  
Age at Time of Receipt of First R01-Equivalent Grant 
 
The research question that was the most intriguing was whether the activities of the 
Emory CFAR Developmental Core played a role in significantly lowering the age at which 
investigators received their first NIH grant. This question arose from literature that suggests that 
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there has been “graying” of NIH researchers, meaning that investigators have been receiving 
their first grants at an increasingly older age over time.  
The survey data indicated the average age at which the CFAR early stage investigators 
received their first ever NIH award was 40.94 years. The youngest investigator was 28, and the 
oldest was 58. However, the survey data cannot be compared to a national sample of NIH 
investigator age data, because a report on the first NIH non-R01 grant recipient age is not 
available. However, reports are available for investigator age at the time of receipt of their first 
ever R01-equivalent award (“Average Age and Degree of NIH R01-Equivalent First-Time” 
report provided in (Appendix D)). Therefore, it is possible to compare those numbers to the same 
category of Developmental Core awardees once the survey data are cleaned up and data on just 
the first ever R01-equivalent awards are isolated by excluding any investigators with awards that 
were not their first ever R01-equivalent grants or those with other types of grants. First ever R01-
eqivalent data were obtained via survey. Sixteen respondents indicated that they acquired their 
first ever R01-equivalent awards due to, at least in part, their developmental awards. However, 
upon closer examination, three investigators’ awards could not be located in the NIH database, 
which means that either they were not the Principal Investigators on the grants or that the grants 
were awarded by agencies other than the NIH. Another three awards were obtained in 2017, for 
which NIH age data is not available. Therefore, Emory CFAR investigator data were available 
for five years: 2007, 2009, 2010, 2011 and 2015. The average age of Emory CFAR early stage 
investigators at the time of receipt of their first R01-equivalent grant was 43. As can be seen 
from “Average Age and Degree of NIH R01-Equivalent First-Time” report provided in 
Appendix D, this result is very close to the average ages reported by the NIH. 
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 A comparison via a one-sample t-test was planned to be performed for NIH average 
versus CFAR average age by degree type- grantees with MD degree only; grantees with PhD 
degree only; and recipients with a dual MD/PhD degree. However, concerns about the resulting 
sample size arose, especially because some years (2007, 2009, and 2011) only had one data point 
each. With that concern in mind, a decision was made to perform a calculation to estimate the 
power of such test. Based on the assumption that five years would be considered “significantly 
lower” than what is reported as averages by the NIH and descriptive statistics for the sample 
below, power calculations were performed in Sigma XL program to evaluate the chance of the 
proposed t-test to be able to reject the null hypothesis.  
Age at time of Receipt of first R01-
equivalent 
  
Mean 43.6 
Standard Error 2.012185103 
Median 43 
Mode 39 
Standard Deviation 6.363087999 
Sample Variance 40.48888889 
Kurtosis 2.12590824 
Skewness 1.307796559 
Range 22 
Minimum 36 
Maximum 58 
Sum 436 
Count 10 
FIGURE 5 DESCRIPTIVE STATISTICS FOR AWARDEES REPORTING RECEIPT OF FIRST 
EVER R01-EQUIVALENT DUE TO, AT LEAST IN PART, CFAR DEVELOPMENTAL CORE 
SERVICES 
 After performing an estimated power calculation based on a set of specified parameters, 
results showed that the power of a one-sample t-test comparison of means would only be 0.596, 
which is not sufficient for the test to be successful: 
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Sample Size 
(N) Difference 
Standard 
Deviation 
Significance Level 
(Alpha) 
Power (1 - 
Beta) 
10 5 6.4 0.05 0.596090 
FIGURE 6 ESTIMATED POWER OF ONE-SAMPLE T-TEST COMPARISON OF MEANS 
FOR FIRST TIME R01-EQUIVALENT RECIPIENTS. 
Since a power value of 0.9 is typically viewed as being sufficient to reject the null 
hypothesis, it is clear that the t-test, if performed with the sample size available, would only have 
0.596 chance of being able to do that. Therefore, a t-test cannot be performed due to low power 
of available data.  
Next, a sample size necessary to satisfy the requirement of power value of 0.9 or higher 
needed to be determined. Another test was performed in Sigma XL program using the same 
assumptions. The results are below: 
Power (1 - 
Beta) Difference 
Standard 
Deviation 
Significance Level 
(Alpha) 
Sample Size 
(N) 
Actual 
Power 
0.9 5 6.4 0.05 20 0.911898709 
FIGURE 7 SAMPLE SIZE NECESSARY IN ORDER TO ACHIEVE POWER LEVEL OF 
0.9 TO TEST FOR SIGNIFICANCE OF DIFFERENCES OF THE MEANS OF FIRST 
TIME R01-EQUIVALENT RECIPIENTS. 
 
Determination 
 
 As these results show, the minimum sample size necessary to test for differences of the 
means of Emory CFAR awardees and NIH-reported age at time of receipt of first R01-equivalent 
is 20. Therefore, the sample of 10 that is available based on the survey results is insufficient to 
perform statistical analysis of the means. With that, there is not enough information to reject the 
null hypothesis: 
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H40: There is no relationship between Emory CFAR Developmental Core Services and 
an investigators’ age at time of receipt of first ever NIH R01-equivalent. 
 While this relationship cannot be confirmed, it is possible that without the help of the 
Developmental Core, the average age of Emory CFAR early stage investigators could have been 
higher than the average age at the time of first R01-equivalent award receipt reported by the 
NIH. A look at the entire NIH CFAR program and all of the users of the Developmental Cores 
across the other 19 CFARs could offer a more definitive picture by providing a sample large 
enough to perform necessary statistical analyses.  
Additional Information 
 
Recipients of CFAR developmental awards also were asked about their use of other 
Developmental Core services in the online survey. These additional questions helped to assess 
what services early stage investigators view as most valuable. Knowing this information could 
help the CFAR directors to make better informed decisions about what services the 
Developmental Core should offer in the future, as well as how to better allocate monetary and 
staff resources.  
Professional Contacts 
 
For the survey question on whether CFAR developmental awards were helpful in 
developing new professional contacts that have led or may lead to future collaborations, 83% (n 
= 36) respondents said “yes.” When asked to quantify the number of those collaborations, 
answers ranged from 1 to 30. This is encouraging, as such contacts could lead to successful 
applications for NIH funding in the future. 
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Developmental Core Services 
 
As described previously, the Emory CFAR Developmental Core offers multiple services 
to the HIV research community. They include mentorship, developmental funding awards 
(CFAR-series, Ramp Up, and Administrative Supplements), study design consultation, pre-
submission feedback, grant writing training and assistance, IRB protocol preparation assistance, 
and several other services. (See Appendix C for a complete list.)   
For the survey questions on utilization of these Developmental Core services, results 
varied for past versus future plans. This outcome was expected, and it can likely be explained by 
whether or not the respondent considers him or herself an independent researcher. 
Developmental awards are of most interest to early stage investigators who are just trying to 
begin their independent research careers. This funding-based service offered by the 
Developmental Core provides a “kick start” for recipients in terms of their ability to generate 
pilot data, allowing them to develop more competitive NIH award applications. Developmental 
awards also help their early careers by financially supporting participation in conferences - 
which in turn promote networking, new collaborations, and opportunities to present the research 
results.  
Not surprisingly, the largest service utilized in the past was CFAR-series awards. Almost 
all of the survey respondents indicated that they received this type of support. However, moving 
forward, investigators plan to use other CFAR Developmental Core services more 
proportionally. Figure 8 below shows what services the respondents planned to utilize in the 
future. The leading responses were collaboration travel awards, Ramp Up awards, study design 
consultation, pre-submission feedback, R-Club membership, and project-based training.  
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FIGURE 8. UTILIZATION OF SERVICES PROVIDED BY THE EMORY CFAR 
DEVELOPMENTAL CORE (PAST VS. FUTURE) 
The results are logical and not surprising. CFAR-series pilot grants are designed to mirror 
the NIH application and work process. During the course of a CFAR-series award, early stage 
investigators are trained to apply for grants, manage their funding within strict guidelines, 
properly report outcomes, develop collaborations, and publish results. The goal of these awards 
is to enable the awardees to apply for independent NIH funding, preferably R01-equivalent 
awards. Therefore, after CFAR-series awards are completed, services like Ramp Up awards 
(designed to fill a specific gap), pre-submission feedback, collaboration travel awards, IRB 
protocol development should be in a higher demand by past developmental awardees, as they 
prepare their initial independent NIH applications. 
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Conclusion 
 
This chapter presents results of a research project that investigated the impact of the 
investments of the Emory CFAR Developmental Core from three vantage points: global, 
organizational, and personal.  
Global impact was assessed through a thorough publication analysis. The results indicate 
that early stage investigators who have utilized Emory CFAR Developmental Core services do 
contribute to global HIV knowledge by publishing in peer-reviewed journals. Also, the 
publications resulting from the investigators’ developmental awards are being cited by other 
investigators. For the most part, the impact factors of journals containing Emory CFAR 
Developmental Core-supported publications fall near selected benchmark, suggesting the quality 
of those publications is satisfactory.  
Organizational impact was evaluated through analysis of the return on investment (ROI) 
for each of the three CFAR Developmental Core award mechanisms to assess if developmental 
awardees are contributing to Emory University’s fiscal portfolio. Overall, the CFAR 
developmental awards program is successful, but the ROI differs for each award mechanism. A 
closer look needs to be taken at Ramp Up awards, as they show an ROI of over 6,000%. A return 
of this magnitude is not expected as only a few of the small-scale Ramp Up awards were 
converted into NIH-funded grants. However, this high ROI does suggest that the program is 
successful and has the potential to bring large benefits in return for a small investment. CFAR-
series pilot grants also were found to be successful, as their ROI was high (over 1,000%). In fact, 
the quantity of CFAR-series awards converted into NIH-funded grants was higher than Ramp Up 
awards, indicating that the pilot funding offered through the CFAR-series may make a more 
lasting impact on careers of higher numbers of investigators. Administrative Supplements 
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yielded an ROI of just about 100%. This result, while still positive, is much lower than the other 
two categories. However, it is not surprising that projects with limited periods of performance 
and highly targeted topics could be less successful, given that NIH funding priorities may change 
while these Supplemental projects are being performed. 
Finally, a survey was used to measure personal impact. Survey results suggest that 
investigators’ interest in the CFAR Developmental Core services is strong. A trend appeared 
during the analysis, highlighting that interest in CFAR funding decreased and interest in other 
Core services increased after investigators obtained developmental awards. That makes sense, 
since availability of funding probably allowed them to obtain data and/or remove barriers in 
order to submit competitive NIH applications. At that point, services like pre-submission 
feedback and/or IRB preparation were more valuable.  
There was no clear evidence that Developmental Core funding helps to lower the average 
age of investigators at the time of first R01-equivalent award. However, it is possible that the age 
at receipt of first R01-equivalent award would have been even higher if early stage investigators 
did not utilize services offered by the Emory CFAR Developmental Core. 
Overall, activities of the Emory CFAR Developmental Core were found to be successful. 
This project also revealed that certain factors may influence how outcomes and ROI data are 
reported to the NIH.  While the results indicate that the Core is doing what it was designed to do, 
they also show certain adjustments in reporting processes may ensure that project outcomes are 
accurately collected and reported to NIH. Additionally, these project results provide useful 
information about what services early stage investigators are interested in at various points in 
their careers. This information will be useful to the CFAR leadership when planning which 
services to continue offer through the Developmental Core and what, if any, changes and/or 
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improvements need to be made. The following chapter will look in greater detail at the results 
and lessons learned.
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Chapter V 
CONCLUSIONS 
 
In 1981 the world was struck with an unknown disease that caused people to die. At first, 
it presented itself as Pneumocystis carinii pneumonia in five young, previously healthy gay men 
(Centers for Disease Control and Prevention, 1981). Over the next several months, more people 
of different ages and backgrounds became ill and died of this unknown disease, which was 
named Acquired Immune Deficiency Virus. It was not until 1983 that the actual Human 
Immunodeficiency Virus causing AIDS was discovered.  
The HIV epidemic continues to this day. There is still no cure or vaccine. According to 
the Joint United Nations Programme in HIV/AIDS (UNAIDS) fact sheet, there were 36.7 million 
people living with HIV in the world in 2015 (UNAIDS, 2018). This problem also hits close to 
home, as Georgia finds itself in the middle of the raging HIV/AIDS epidemic. Georgia was 
ranked fifth highest in the nation for total number of adults and adolescents living with HIV 
infection in 2013. The number of people with undiagnosed HIV infection in Georgia is estimated 
to be the second highest in the US, at 18.7%. The nine-county Atlanta metropolitan area contains 
two thirds (66%) of the state’s diagnosed cases of HIV, with Fulton and DeKalb counties 
accounting for 47% of all of the state’s diagnosed cases (Georgia Department of Public Health, 
2016). 
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In the years since the discovery of the HIV, major advances have been achieved in the 
fight against the disease. These successes were made possible by investments from governments 
and other organizations around the world, and by the dedication of scientists who tirelessly work 
to one day discover a cure for AIDS. There is still a lot to be done, so there is a constant need for 
researchers interested in the HIV/AIDS fight. Developing and retaining talented scientists is one 
of the areas on which the Emory University Center for AIDS Research (Emory CFAR) focuses. 
More specifically, it is the goal of the Emory CFAR Developmental Core to support early stage 
investigators by providing necessary resources and support as they try to establish themselves as 
independent researchers (ideally, by obtaining an NIH R01- equivalent grant). 
This project was designed to examine the services of the Emory CFAR Developmental 
Core and to study and evaluate the impact of Developmental Core award recipients on three 
levels:  
1. Global Impact — how have Emory CFAR Developmental Core awardees contributed 
to the global HIV knowledge base? (Research Question 1); 
2. Organizational Impact — what impact have Emory CFAR Developmental Core 
awardees had on Emory University’s fiscal portfolio as it pertains to the NIH funded 
research base? More specifically, what is the rate of return on the dollars awarded via 
the CFAR-series pilot grant mechanism, Administrative Supplement mechanism, and 
Ramp Up award mechanism? (Research Question 2); 
3. Personal Impact — how have Emory CFAR Developmental Core services personally 
impacted the professional development and funding success of early stage and new HIV 
investigators? (Research Question 3). 
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Research Question 1: Global Impact 
 
Question Background and Findings 
 
Traditionally, the contribution of scientific research to knowledge has been measured by 
the number and impact of scientific papers published in peer-reviewed literature (Grant, et al., 
2000). Several studies found that investigators with previous grant funding experience have 
higher scholarly output as measured by the number of publications, their impact, and citation 
factors (Svider, et al., 2014), (Pagel & Hudetz, 2015). Publication output is not only important 
for contribution to the global HIV/AIDS knowledge base, but it is often used as the currency of 
scientific research. It is often more important where a scientist publishes than what they publish 
(Raff, Johnson, & Walter, 2008). This high emphasis on publications by scientists, and especially 
by early stage investigators as they try to claim their place in the biomedical research 
community, dictated this project’s approach in evaluating the impact of CFAR Developmental 
Core awardees on the global HIV/AIDS knowledge base. Assuming that previous funding is an 
indicator of scholarly output (Svider, et al., 2014), information about all publications resulting 
from Developmental Core awards was gathered and evaluated for impact and citation factors. 
Contributions to the global HIV knowledge base were measured by awardees’ publications in 
scientific journals. More specifically, impact factors of journals containing awardees’ 
publications, and citation factors of those publication were examined. Several conditions were 
set in order to determine the answer to research question 1. 
The following hypotheses were tested: 
H10: Emory CFAR Developmental Core awardees had no impact on the global HIV 
knowledge base. 
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H11: Emory CFAR Developmental Core awardees had an impact on the global HIV 
knowledge base. 
The results showed that awardees did have an impact on the global HIV knowledge base. 
There were 128 publications, most of which were published in peer-reviewed journals. Several 
publications appeared in journals that publish works by invitation only, which suggests that those 
articles were regarded as high-quality by other experts in the field. Many of the publications 
appeared in open access journals, ensuring access by a wider interested population. Journal 
impact factor (JIF) analysis showed that Core-related awardees’ publications had JIFs that are 
more in line with selected field-specific journals, AIDS and Aids and Behavior, and remained 
stable from 1998 to 2016. The average JIF for Developmental Core publications was 4.498, 
which fell right between the average JIF for AIDS (2.61) and AIDS and Behavior (5.98). This 
information shows that awardees consistently publish in respected journals that reach not only 
the biomedical research community, but also an audience outside of the scientific field through 
open access journals which lift any financial burdens there may be when it comes to journal 
subscriptions. It is important to note that this analysis applies to the field of HIV/AIDS research. 
When comparing to impact factors of Science (29.49) and JAMA (25.61), which are widely 
considered the gold standards in research and clinical communities, JIFs of CFAR-related 
publications were much lower. This finding is not surprising, as early stage investigators are not 
expected to be highly successful publishing in those journals so early in their research careers. 
Another dimension of contributing to the global HIV/AIDS knowledge base that was 
studied was the number of citations that awardees’ publications generated, the assumption being 
that global knowledge is disseminated by investigators’ work being cited in other researchers’ 
publications. That means that works by Developmental Core awardees are respected and that 
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awardees are thought to have achieved a certain level of expertise in the field. Only 7% (n=9) of 
publications did not have any citations. Six of those nine were published in 2016, feasibly 
making them too new to be cited. Overall, the works of Developmental Core awardees were 
cited 3,395 times. The highest citation count calculated for the developmental awardee 
publications was 303, the average was 26.52, the median was 16, and the standard deviation was 
36.94.  
Based on analysis of the results, the null hypothesis can be rejected and the alternative 
hypothesis can be accepted. Developmental Core awardees did have an impact on the global HIV 
knowledge base. 
Research question 2: Organizational Impact 
 
Question Background and Findings 
 
In order to continue advancing biomedical research in any area, including HIV/AIDS, 
funding must be secured. NIH remains the largest non-commercial funder of biomedical research 
in the US (Cech, 2005). In recent years, NIH faced budget freezes and cuts (Mandel & Vessell, 
2004) (Loscalzo, 2006). Nevertheless, the United States remains the largest funder of life science 
research. In 2003, U.S. investment in research and development from all sources (industry, 
government, academia, philanthropy) totaled $284 billion and represented 2.6 percent of the 
nation’s Gross Domestic Product (Porter, 2005). 
Biomedical research is not cheap. A large portion of it is done at university research 
centers, which rely on external funding to cover the bulk of their expenses. Most often, such 
funding is secured via various grant mechanisms awarded through a competitive application and 
review process. One of the main goals of the Emory CFAR Developmental Core is to identify 
early stage HIV/AIDS investigators and to support them by providing pilot funding necessary to 
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generate results that could be used in a successful application for an independent NIH award 
(preferably, an R01-equivalent grant). Showing that Emory CFAR is successful in this effort 
would allow it to be argued that the CFAR program is effective in bringing NIH dollars to 
Emory University. Since Emory University co-funds Emory CFAR with institutional dollars, 
demonstrating that there are financial gains to the University would allow Emory CFAR 
leadership to justify their requests for that support to continue and even be increased.  
Three types of developmental awards were studied in order to answer research question 
2: Ramp Up awards, CFAR-series pilot awards, and Administrative Supplements. Return on 
investment (ROI) was calculated for each type, and the following hypotheses were tested: 
H20: There is no relationship between Emory CFAR Developmental Core awardees 
receiving funds via a Developmental Core mechanism and the Emory fiscal portfolio as it 
pertains to NIH funding.  
H21: There is a positive relationship between Emory CFAR Developmental Core 
awardees receiving funds via a Developmental Core mechanism and the Emory fiscal portfolio as 
it pertains to NIH funding.  
H30: There is no difference in the return on investment (ROI) among the three Emory 
CFAR Developmental Core award mechanisms. 
H31: The ROI of the CFAR-series pilot grant mechanism is different from the ROI of the 
Administrative Supplement mechanism. 
H32:  The ROI of the Administrative Supplement mechanism is different from the ROI of 
the Ramp Up award mechanism. 
H33:  The ROI of CFAR-series pilot grant mechanism is different from the ROI of the 
Ramp Up award mechanism. 
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Information about funds received by Emory University as a result of Developmental Core 
grants was obtained from progress reports submitted to the NIH on an annual basis. Awardees 
are required to report to the CFAR if they were able to obtain any grants as a result, at least 
partially, of their Developmental funding received from CFAR. This means that, if early stage 
investigators generated data, presented at meetings, or acquired training on how to develop 
competitive applications, which were later funded by the NIH, with the help of the funding 
received from CFAR Developmental Core, they must report these results to the Emory CFAR. 
Emory CFAR then reports those results to the National CFAR at the NIH. Awardees typically 
know what factors contributed to the success of their applications. Those could include training, 
mentoring, and, as in the case of the CFAR, pilot funding to generate data. 
The ROI calculation was performed for each type of developmental award. The findings 
showed that Ramp Up awards had an ROI of 6,472%, CFAR-series pilot grant awards had an 
ROI of 1,266%, and Administrative Supplements had an ROI of 96%. Based on these 
calculations, the null hypotheses for this question can be rejected and the alternative hypotheses 
can be accepted. Results showed that there is a positive relationship between Emory CFAR 
Developmental Core awardees receiving funds via a Developmental Core mechanism and the 
Emory fiscal portfolio as it pertains to NIH funding, and ROI for each type of award is different.   
This research project uncovered that for years, CFAR has made an error in reporting 
funding in the Developmental Core tables as a result of relying on awardees to self-report their 
outcomes. Some awardees reported amounts for grants they were able to secure after their 
developmental awards as the total amount awarded for all years of the grant, while some reported 
the amount awarded for a single year, and some reported for the current and all previous years of 
the grant. This altered the ROI calculation when reporting the overall outcomes to the NIH. This 
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discrepancy was resolved by accessing original NIH award documents and confirming amounts 
of the grants received at least in part because of having received a developmental award for each 
year of each grant. To mitigate this going forward, Developmental Core leadership should revise 
developmental award notices to include language that clearly explains what amount to include 
when reporting back to the National CFAR. The initial NIH NOA that awardees receive typically 
includes a recommended amount of funding per year for the duration of the grant. CFAR award 
documents should include instructions to the early stage investigator for reporting outcomes and 
grants received based at least partly due to the CFAR award, and should be clear that the amount 
of the award they report they received is the sum of recommended funding for all years as listed 
in the original NIH NOA for that grant. This change will ensure consistent data will be reported 
yielding a more accurate calculation of ROI. 
Research question 3: Personal Impact 
 
Question Background and Findings 
 
One of the main goals of the Emory CFAR Developmental Core is to bolster the success 
of investigators new to the HIV/AIDS research field. Many efforts of the Core focus on career 
development of early stage investigators, which will help them become truly independent, ideally 
by obtaining an NIH R01-equivalent grant. Camplin and Steger (2000) define development as 
the targeted enhancement of an individual or a collective set of individuals to serve better the 
mission of the organization. Many sponsors of biomedical research recognize how critical it is to 
develop early stage investigators and have mechanisms in place that target those researchers that 
are trying to start and develop their careers in the fields of their interest.  
One of the concerns that exists is the “graying” of investigators. In other words, 
investigators today are older at the time they receive their R01-equivalent grant than they were in 
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the past. Investigators now receive their first independent research grant at a median age of 42 
years for those with PhD degrees, and 44 years for those with MDs (Cech, 2005). Daniels (2015) 
writes that the average age at which an investigator with a medical degree receives their first R01 
or equivalent grant has increased from less than 38 years in 1980 to more than 45 years in 2013. 
At the same time, the number of principal investigators for such grants who are 36 years old or 
younger has decreased from 18 % in 1983 to 3% in 2010. This is a concern because one can 
argue that investigators who establish themselves in biomedical research at a later age have less 
time to conduct research and make significant advances. Additionally, this delayed career start 
can be expensive, as there is less time during one’s active career to recover the investment made 
on his or her education and training ( (Stephen & Levin, 1989), (Jacob & Lefgren, 2011)).  
Emory CFAR Developmental Core provides many services, including initial pilot 
funding, to early stage investigators who are trying to develop their careers in the field of 
HIV/AIDS research. Based on observations about the aging of researchers, this project sought to 
determine whether these services and support that the Core provides help lower the average age 
at which CFAR awardees receive their first R01-equivalent award. The following hypotheses 
were tested: 
H40: There is no relationship between Emory CFAR Developmental Core Services and 
an investigator’s age at time of receipt of his or her first ever NIH R01-equivalent. 
H41: There is a relationship between Emory CFAR Developmental Core Services and an 
investigator’s age at time of receipt of his or her first ever NIH R01-equivalent. 
The entire population of CFAR awardees was available to be surveyed, and a response 
rate of 84% was achieved. Out of 41 respondents, 51% (n = 21) reported that their CFAR 
Developmental Core award helped in obtaining their first ever NIH award. The rate of awardees 
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confirming that the Developmental Core helped them secure their first ever NIH R01-equivalent 
was lower at 39% (n = 16). This can be explained by several factors.  
There are two ways in which the Developmental Core can help early stage investigators 
obtain NIH funding: by providing money to generate data on which to base an application for 
another NIH award, and by training investigators on how to compile a fundable application 
package. Applications for CFAR-series awards are subject to peer review as is an application to 
the NIH, and this provides a learning experience for investigators even if their application to 
CFAR was not funded. This question was vague enough for respondents to possibly omit some 
contributions to their success when thinking about the Developmental Core. More than likely, 
they all benefitted from their experience with the Developmental Core, as they all learned about 
the process and what interactions and actions are necessary in order to submit an application. 
Therefore, the percent of people that think that the CFAR Developmental Core helped with 
securing their first R01 may be artificially low simply due to confusion with the survey question.  
Awardees may have received other types of grants after the developmental award that 
contributed to securing that first ever NIH grant. Additionally, some investigators may have left 
the field of HIV/AIDS research as their work may have lead them to develop interest in other 
areas. Nevertheless, this result is exciting, as Developmental Core awards were helpful, at least 
in part, for nearly half of all awardees in obtaining their first ever NIH R01-equivalent award.  
One of the most intriguing questions of this project was to determine whether there is a 
relationship between CFAR Developmental Core Services and the age of early stage 
investigators when they obtain their first ever R01-equivalent grant. Data on age were obtained 
via survey and were to be compared to the average age reported by the NIH. The results showed 
that the average age of CFAR awardees at the time they received their first R01-equivalent 
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award was 43.6. However, a power calculation performed showed that a t-test could not be 
performed due to low power of data available. The sample size that was available was n = 10. 
However, for a t-test to be meaningful, a sample size of n = 20 is needed. Therefore, the null 
hypothesis cannot be rejected. It is important to state that while no clear relationship can be 
confirmed, it is possible that the average age of CFAR investigators at the time of receipt of their 
first ever R01-equivalent award could be even higher without the services provided by the 
Developmental Core.  
Finally, awardees were asked to share their opinion on what Core Services they viewed 
as most valuable. The results showed that after obtaining their developmental awards, awardees 
view other services that aim to assist in preparation of their application to the NIH as most 
useful. Those services included collaboration travel awards, data awards, opportunity awards 
designed to fill a critical need, study design consultation, pre-submission feedback, grant writing 
training, and training to present their results. As compared to services utilized in the past, these 
types of services were more desirable as awardees completed their developmental awards and 
were working on competitive NIH applications.  
The survey showed that every service is in demand. However, those that are most desired 
vary depending on where early stage investigators are in their careers. Investigators who are 
brand new to the field of HIV/AIDS research are mostly interested in pilot funding and study 
design, while investigators who completed their pilot awards are more interested in services that 
prepare them for competing for independent awards and, hopefully, future independent careers. 
Limitations 
 
Several limitations can be identified. First, due to the fact that this study was designed 
and conducted specifically for the needs of the Emory CFAR, the criteria that were chosen 
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accordingly. Metrics that matter to the Emory CFAR were selected, such as journal impact 
factor, return on investment, and age of investigators at the time of receipt of their first NIH R01 
grant. Other CFARs may focus on different development areas. Therefore, their metrics to be 
evaluated may be different. Results are exploratory and may not be replicable due to the limited 
nature of the study. No two CFARs in the country are the same, as each offers a unique set of 
services. Emory CFAR purposely bases their awards program on NIH R03 awards so that early 
stage investigators are exposed to the “NIH way” as early as possible, meaning that early stage 
investigators get a full practice in grant application process even before they submit their first 
application to the NIH. The results of this study are unique to the Emory CFAR, and this project 
was designed to be a case study, so this limitation was to be expected. These findings offer 
important insight into how awardees are adjusting to the new era of technology and the 
abundance of publication venues, (such as open access journals), by utilizing those new venues 
in order to reach broader audience; how work of the Developmental Core is influencing Emory 
University’s overall fiscal portfolio; and what services are the most desired by early stage 
investigators affiliated with this particular CFAR. Therefore, the selected approach and methods 
meet the specific needs of the Emory CFAR Developmental Core.  
The second limitation is that JIF has come under criticism for not being an appropriate 
measure of publication quality (Alberts, Brooks, & Kelner, 2008) (Notkins, 2008) and for being 
used as a measure to determine promotions, resource allocations, and even funding (Sheckman, 
2013) (Rushforth & De Rijcke, 2015). However, JIF is still being used, as it has become part of 
“the culture” (Rushforth & De Rijcke, 2015) and is readily available (Garfield, 1999). For these 
reasons, using JIF to determine whether awardees had impact on global knowledge is 
appropriate.  
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Third, a limitation that applies to all of the research questions addressed in this work is 
the fact that Emory CFAR relies on awardees to report outcomes of their developmental awards. 
Therefore, it is possible that not all publications that resulted from the awards were reported. 
Awardees may simply not realize that their Developmental Core funding and training contributed 
to the development of their publication because some time has passed since they interacted with 
the Core. Or, they could simply forget to include all appropriate publications in their report. 
While all publication information was confirmed through the Web of Science database, it is not 
possible to know if there are any other publications that awardees did not report. If there are, 
results could shift slightly. However, based on the trends seen from the publications analyzed, 
they would most likely fall on the same level as other publications as it pertains to JIF. Citations 
could yield results that are more different, meaning that it is not possible to predict how many 
times a certain article would be cited. However, if anything, unreported publications would yield 
more citations overall, not less. It is reasonable to expect that if there are any unreported 
publications, they have been cited at least once by other works, unless they are too new (i.e., 
published in 2016 or after). 
Fourth, the questions in the survey did not specify in which way the Developmental Core 
helped with obtaining investigator’s first independent grant. Was it funding that was helpful, or 
experience that provided training on application development, or both? As stated above, 
awardees may not be linking their experience with the Core award to the eventual success of 
their NIH applications. In the real world, it is not always possible for early stage investigators to 
be able to convert their first pilot award of $40,000 into a full-size R01. Often, more studies and 
data gathering are needed. It is possible that some CFAR award recipients received their NIH 
awards after conducting additional studies and developing a better application. However, the 
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Developmental award is what allowed them to start in the first place and created a “domino 
effect” that led to their success. In this type of scenario, awardees may not be thinking about that 
developmental award as the starting point that ultimately contributed to their successful NIH 
grant application. 
During the course of this study, results showed that reliance on self-reporting of grant 
data is flawed due to inconsistencies in reporting. Awardees reported amounts received from the 
NIH inconsistently, thus affecting the ROI reported to the NIH. Additionally, it is possible that 
not all external grants obtained at least in part due to a CFAR developmental award were 
reported to the CFAR. This problem was partially remedied by accessing original grant award 
documents and confirming the awarded amounts for all years. Additionally, the survey 
distributed as part of research question 3 information gathering included questions that could 
potentially identify grants that were not reported. Nonetheless, reliance on investigators to self-
report this information will never be error-proof. Consistent with the factors described above, the 
results could be artificially low if respondents did not report all their grants that were aided by 
their developmental awards. The CFAR is not in a position to verify that all awards resulting 
from CFAR Developmental Core funds were reported. Since only respondents can identify those 
awards, potential for underreporting of outcome exists.  
Fifth, since grants from agencies other than the NIH were excluded from the ROI 
calculation due to reporting requirements set by the NIH, the true dollar-for-dollar return is likely 
much higher for each of the developmental grant mechanisms. Awardees reported securing 
grants from the CDC and other sources, both federal and non-federal. Therefore, ROI 
calculations reached by this study could be higher than the study discovered. A more extensive 
study requesting awardees to report all grants they were able to obtain based on having received, 
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at least partially, Emory CFAR Developmental awards, would need to be conducted. Such a 
study would allow calculation of the true dollar-for-dollar ROI for each of the grant mechanisms 
that the CFAR Developmental Core offers. It is important to note that the focus of the study was 
to only determine ROI as it pertains to the NIH funding. While not a true limitation as far as 
answering this particular study question, it can be viewed as a limitation when it comes to 
presentation of the data to the Emory leadership when requesting institutional funding. The 
resulting ROI may appear lower than it really is because not all grants obtained with the help of 
the Developmental Core are included in the ROI calculation.  
A Sixth limitation, in attempt to answer research question 3, only total CFAR dollars 
(NIH and University) invested via the three developmental grant mechanisms were used to 
calculate ROI. This calculation fails to take into account other investments and resources, such as 
CFAR staff time, research administration staff time, and other non-financial resources that are 
necessary in order to keep the program running smoothly. Such all-inclusive analyses are 
possible, but would require an extensive study of all resources involved, which is beyond the 
scope of this project. Additionally, NIH requires ROI reporting to be based on each dollar 
invested in various developmental grant mechanisms. Funds are awarded by the NIH and the 
University to cover other expenses connected with maintenance of the Developmental Core 
programs, and hence are not limited to dollars directly funding the developmental mechanisms 
only.  
Lastly, one of the most significant barriers to answering research question 3 was the 
small sample size, which makes it impossible to answer one of the central questions of this 
project. It could not be determined whether a relationship exists between activities of the 
Developmental Core and the age at which investigators received their first ever NIH R01-
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equivalent award due to the insufficient sample size of awardees meeting specific criteria. 
However, the project did determine an appropriate sample size, so a similar test would be 
theoretically possible if data from all CFARs were obtained and analyzed.  
As can be seen from the above discussion, several limitations are common to all parts of 
this study. Reliance on self-reported information presents a concern because information may be 
incomplete. Critics may say that many of the criteria for this study are subjective. While this may 
be true, these criteria were developed in close collaboration with the leadership of the Emory 
CFAR Developmental Core in response to the reporting requirements set by the NIH. Questions 
that were asked and answered within these criteria are ones on which the Emory CFAR is 
required to report. The answers obtained through the course of this work will make information 
available that can be not only included in reports to the sponsoring agency, but can also be used 
when thinking about advancing CFAR Developmental Core services further.  
While certain limitations exist, this study provides a framework for other CFARs in 
conducting multidimensional evaluations of activities of their own Developmental Cores. Since 
each CFAR is different, specific methodological adjustments will be needed. However, this 
project provides background and examples of how similar evaluations by CFARs and other 
programs focusing on the development of early stage investigators can be structured.  
Implications of the findings and recommendations 
 
The main goal of this project was to demonstrate the impact of the Emory CFAR 
Developmental Core on the success of HIV/AIDS programs not only within Emory University 
and the Atlanta Metro Area, but also throughout the entire country and beyond. Emory CFAR 
works on improving success of efforts to fight the epidemic by investing in early stage 
investigators via several award mechanisms and various services provided by the Developmental 
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Core. By investing in these researchers, Emory CFAR is investing in the fight that can 
potentially impact the epidemic all over the world, as early stage investigators mature and work 
in different regions affected by HIV/AIDS. In order to evaluate that impact, this project 
examined the services of the Emory CFAR Developmental Core and, based on certain analyses, 
drew conclusions about their effect on the careers of early stage investigators. 
 Another goal was to determine the ROI of the CFAR’s investments on both monetary 
and non-monetary levels. Large amounts of money (both federal and non-federal) are being 
invested in the CFAR program. Evaluating the return of those investments is critical to 
demonstrate that the funds are used in ways that generate results, especially in the current climate 
in which funding amounts are at risk of being reduced. While monetary ROI is easy to 
understand, non-monetary ROI is represented by publications, citations, and other factors, such 
as collaborations formed with other researchers.  
Developing early stage investigators aligns with the goals of the NIH. As discussed 
previously, the NIH sponsors multiple career development awards that target this group of 
investigators. The Developmental Core, which utilizes both NIH and institutional funds, works 
similarly. It offers pilot funding to investigators in the beginning stages of their careers. Rangel 
and Lawrence (2004) state that previous NIH funding is the strongest positive predictor of future 
NIH support. While no formal analysis was conducted to evaluate this claim within the scope of 
this project due to myriad other factors that can influence funding success, awardees reported 
receiving 62 new NIH grants based, at least partly, on their Developmental Core award. These 
findings reinforce the statements by Rangel and Lawrence (2004) as 62 new NIH awards 
represent 85% success rate for Developmental Core awardees. While those successful 
applications may have benefitted from the CFAR awards only partly, it is possible that these 
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successes depended on the pilot funding, training, and experience provided by the initial CFAR 
award. Eighty-five percent of the early stage investigators confirming that they were able to 
obtain their first independent award as a result (at least partially) of their CFAR grant supports 
Rangel’s and Lawrence’s (2004) finding that previous NIH funding is a good predictor of future 
NIH awards. While CFAR awards are administered through Emory CFAR and do not come 
directly from the NIH, they follow the same rules and procedures and adhere to the same 
application evaluation criteria as those submitted to the NIH. This experience, in addition to the 
actual funding for a pilot project, can be invaluable to an early stage investigator trying to 
navigate the confusing world of applying to the NIH for grant funding. 
There is increased concern about the fact that researchers are receiving their first R01 
equivalent grants at an increasingly higher age (Cech, 2005; Daniels, 2015; Jacob & Lefgren, 
2011; Stephen & Levin, 1989). According to Daniels (2015), investigators’ average age at the 
time of receipt of first R01-equivalent grant was 45 years old. The results of this study were 
consistent with this figure, as it was determined that the average age at which Developmental 
Core awardees received their first R01-equivalent grant was 43.6 years old, which is close to the 
NIH average. Unfortunately, as noted above, limitations due to the sample size of this study 
make it impossible to determine if this figure is statistically significant. However, it appears to be 
in line with the overall averages. Another dimension of this question is the fact that Mason, et al 
(2013) found that K01 award recipients were, in fact, able to get their first R01-equivalent grant 
in a shorter period of time than those who did not have a K01 award or those who had other 
types of K awards. Mason’s study was one of the reasons CFAR wanted to look at whether the 
Developmental Core was contributing to lower ages at the time of receipt of first R01-equivalent 
grants by the developmental award recipients. However, the small sample size ultimately fitting 
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certain specified criteria presented a barrier for making a determination on any impact the receipt 
of a Developmental award may have. 
While the project did not uncover enough data to evaluate whether CFAR awardees 
received their first R01 earlier than those who did not have a similar award, it still presented 
groundwork that could be used to answer this question in the future. During the period examined, 
Developmental Core awardees received 13 K awards. Of them, four were K01 grants. Those 
awards can be tracked over time and outcomes can be reevaluated at a later date to see if those 
early stage investigators were able to receive their first R01 grant at a younger age than those 
who did not have a K01 award. Positive results would support Mason’s et al. (2013) findings as 
it pertains to the CFAR early stage investigators and would indicate that, while not directly, the 
Developmental Core still influenced the careers of those investigators by providing crucial 
funding early on. 
 Similarly, positive findings would align with arguments made by Chamblin and Steger 
(2000) that the reasons faculty development initiatives are needed include strengthening 
relationships among colleagues, supporting stated institutional missions, and dealing with both 
the faculty member’s and institution’s “capacity to survive”. Obtaining initial funding that later 
led to a successful K01 award application, which, in turn, led to a decreased time to obtaining the 
first R01 award, would allow the early stage investigator to not only work with colleagues and 
strengthen those relationships, it would alleviate anxiety about the need to be successful in 
obtaining grant funding. This step-by-step process (receipt of a CFAR award followed by a K01 
award and then an R01 award) would gradually teach early stage investigators how to write 
successful grant applications and deal with feedback on applications that did not get funded. 
Either way, this investment presents a valuable training tool to the investigators, which 
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ultimately should allow them to be successful in supporting the University’s mission through 
their research. 
This project did look at JIFs and citation factors in order to determine if there are returns 
as measured by publication output and the perceived quality of published works that contributed 
to the global HIV/AIDS knowledge base. Garfield (1999) and Raff et al. (2008) noted that JIFs 
often play an important role in decisions related to the early stage investigators’ careers and grant 
funding. Therefore, JIF and citation factors were deemed an important ROI dimension for the 
purposes of this project. It was discovered that awardees did publish in respected journals, as 
specified by certain criteria described in previous chapters. This information shows that 
leadership of the Emory CFAR and of the Developmental Core is advising early stage 
investigators effectively when it comes to selecting venues in which to publish. Consistently 
publishing in respected journals will position CFAR-sponsored early stage investigators better in 
the culture where JIFs are frequently used as currency or even as the basis for promotions and 
grant funding. 
Finally, and not the least important, is monetary ROI. As stated before, biomedical 
research is expensive, and universities are asked to cover increasingly larger portions of these 
costs (Daniels, 2015). For this reason, determining financial ROI was extremely important. With 
limited resources, universities will be forced to pick and choose what programs and research 
centers they will support. Emory University has been extremely supportive of the CFAR 
program and provided generous financial contributions to support its activities. The results of 
this study show that CFAR dollars invested in careers of early stage investigators via various 
developmental award mechanisms yield an extremely high return. Presenting data that shows this 
substantial ROI elevates the likelihood that the CFAR program will continue receiving support 
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from the University, as this study demonstrates that the funds are used strategically and 
effectively. CFAR leadership can rely on the results of this study to present to stakeholders the 
positive impact of the University’s investment into the CFAR program. On a more global level, 
strong ROI demonstrates to the NIH that taxpayer money is being used wisely and contributes to 
the goals of the overall CFAR by supporting promising early stage investigators who are able to 
multiply invested dollars at high rates.  
The results of this study are useful on many levels. In particular, they can be applied on a 
personal level to continue helping individual early stage investigators develop, on a CFAR 
organizational level to continue developing the program at Emory University, and on a national 
level to continue advancing the National CFAR program. Findings suggest that the CFAR 
Developmental Core is doing for early stage investigators what it was designed to do. 
Specifically, it provides resources, both monetary and non-monetary, to attract them into the 
field of HIV/AIDS research and to aid them in establishing their research independence. As 
discussed earlier, investigators are considered independent in the biomedical research when they 
obtain their first individual NIH R01-equivalent grant. R01-equivalent grants are extremely 
competitive, and resources provided by the CFAR Developmental Core are desirable by early 
stage investigators just entering the field of HIV/AIDS research. The Core should continue 
funding the various developmental award programs, as all of them showed positive financial 
ROI, and many of the awards contributed directly to obtaining R01-equivalent grants by early 
stage investigators.  
Core leadership should consider the results of the survey when it comes to providing non-
financial support to investigators, especially those who have completed their CFAR-series 
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awards and are preparing to submit competitive NIH applications. The survey clearly showed 
that investigators at different stages of their careers benefit from different types of support.  
Core awardees should continue to receive assistance when it comes to publishing their 
work. The results showed that awardees publish in well-respected HIV/AIDS journals, thus 
contributing to the global knowledge base. Additionally, publishing in respected journal ensures 
a certain image in the biomedical research community due to the culture of relying on impact 
factors of journals when evaluating researchers’ work. This culture carries consequences not 
only for an investigator’s ability to obtain grant funding, but also for the ability to progress in an 
individual’s career. Until a new measure to gauge researchers’ work is agreed upon, it is 
important for the Core to ensure that early stage investigators carefully choose the venues for 
publishing their work. As per the words of Dr. Rana Chakraborty, it is more important to publish 
in high impact factor journals in the beginning of one’s career, because, at that point, quality is 
more important than quantity. The impact factor becomes less important as a researcher’s career 
advances and they are considered experts in their fields (Chakraborty, 2016). 
On a CFAR organizational level, findings of this project are particularly useful when 
demonstrating the effectiveness of University investments into the program. As stated 
previously, CFAR is funded by the NIH as well as Emory University itself. It is important to 
demonstrate to the University that the investment is and continues to be worthwhile. Particularly, 
the University would be interested to know what ROI the program is able to yield when looking 
at dollar-for-dollar returns. This project showed that the ROI for CFAR dollars was at minimum 
close to 100% (Administrative Supplements) and as much as 6,000% (Opportunity Awards). 
These numbers can be useful to CFAR leadership when justifying the University’s investment 
into the program and when requesting additional support to develop and grow the program. 
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Additionally, publication data can be used to demonstrate that the CFAR program contributes to 
the prestige of the University, since CFAR investigators are consistently publishing in respected 
journals and awardee publications are often being cited by other researchers. Also, these results 
can be used in progress reports and competitive renewal applications. For competitive renewals 
in particular, the model of this study can be used to obtain updated data on the impact and 
effectiveness of the Developmental Core.  
This research has similar implications on the National CFAR level. As the CFAR 
program is funded by the NIH, the ability to prove its effectiveness is critical. This case study 
provides a snapshot of one CFAR, but can be used by other CFARs and even the national CFAR, 
should they desire to conduct similar evaluations. As on the organizational level, results can be 
used when arguing for additional funding for development and expansion of the program. 
Additionally, results can be used to demonstrate achievements of early stage investigator 
development in the field of HIV/AIDS research.  
Future research 
 
Multiple opportunities exist for future research based on findings of this project. First, on 
the national level, data can be obtained from all CFARs and compiled in order to evaluate the 
effectiveness of the national CFAR program and can be used in making the case for advancing 
the program. It would be interesting to see if other CFARs have similar outcomes of their 
Developmental Core initiatives. It would also be interesting to see how different CFARs 
compare to each other when it comes to awardees’ publications, ROI, desired services, and 
investigator age at the time of receipt of his or her first independent R01-equivalent grant. The 
challenge is that no two CFARs operate in the same way or provide the same services. 
Comparing one CFAR to another would not be possible, however, this project provided 
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framework methodology that can be used both by individual CFARs and by the national CFAR 
to study individual centers. The model can be adjusted by individual CFARs depending on what 
services their Developmental Cores provide, and evaluation on three levels (personal, 
organizational, and global) would still be possible.  
Second, the NIH cites the increasing age of investigators at the time they receive their 
first R01-equivalent as a negative trend. Levitt and Levitt (2017) argue that young researchers 
are crucial to basic science as they make unexpected, fundamental discoveries. Young 
investigators are needed to keep the US biomedical science field truly innovative, the authors 
maintain. Additionally, there are concerns about the “graying” of the investigators because older 
researchers have fewer productive years remaining in their careers. This means that the 
significant investment made in the careers of these researchers by the investigators themselves, 
universities, and taxpayers may not gain sufficient return. When discussing graying of the 
investigators, the fact that the average life expectancy also increased over the years has not been 
considered. There is an opportunity for a research project to be conducted that would focus on 
biomedical researchers and would evaluate their productivity while accounting for their age at 
the receipt of their first R01-equivalent grant and increased life expectancy. It would be 
interesting to see if concerns about reduced returns on investment and shorter active phases of 
research careers are valid in the climate of the changing demographic characteristics. 
Particularly, a look at how recent medical advances are allowing people to lead longer healthier 
lives affects their productivity in biomedical research field could uncover a different side to the 
debate. It is possible that established investigators are as productive and innovative as early stage 
investigators, and just as interested in continuing to develop their skills. Additionally, with large 
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parts of their lives invested in the research, they may be more productive as they possess the 
knowledge and experience that early stage investigators do not.  
Third, while excluded from this project, a study of how Developmental Cores of all 
CFARs influence the success of early stage investigators by gender would be extremely 
interesting. There is a significant amount of research that suggests that differences do exist 
(Anderson Eloy et al, 2013; Waisbren et al, 2008, Pohlhaus Reineke, et al., 2011; Pohlhaus et al, 
2011). It would be interesting to see if Developmental Cores are able to eliminate or reduce those 
differences as it relates to an individual’s ability to secure NIH R01-equivalent grants. This 
research excluded this question from the analysis due to small sample size that fit necessary 
criteria.  
Another study that would be interesting to conduct would be to examine Emory CFAR 
awardees’ success rates versus the NIH average success rate for funded grant applications.  In 
FY17 with the average NIH success rate for grant applications at only 21.2 % (National Institutes 
of Health, 2018b), securing NIH funding is highly competitive, with most applications going 
unfunded. But this research found that 85% of early stage investigators funded by the CFAR 
were successful in obtaining subsequent independent funding. What is not known is how many 
times CFAR awardees applied or whether their proposals were funded on their first attempts. 
Determining the true success rate of CFAR awardees would offer a good point of comparison 
between the general NIH applicant pool and those applicants that CFAR supported.  
Finally, in light of concerns about the graying of investigators pertaining to the CFAR 
program itself, more research is needed on whether the program helps lower investigators’ age at 
the time of receipt of their first ever R01-equivalent. This project attempted to do this, however, 
a sufficient sample size to test the difference of the means was not available. It is recommended 
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that data on age are obtained from all active CFARs using similar surveys and the sample of 
awardees’ ages be evaluated for power. If the power calculation indicates that the sample size is 
sufficient, a comparison of the means between CFAR investigators’ ages and NIH-reported ages 
of investigators at the time of receipt of their first ever R01-equivalent grants should be 
performed. This particular research project would be of great importance, since one of the central 
goals of CFAR programs is to promote the careers of early stage investigators. If research 
supports the theory that the Developmental Cores help lower investigators’ age at the time of 
receipt of their first R01-equivalent grant, CFAR would have powerful evidence supporting the 
effectiveness and importance of the program. 
With all the possible research directions, it is important that, if a survey is developed, 
questions are formulated in a way that removes any vagueness in order to ensure that the most 
accurate data are gathered. This project demonstrated how questions that leave even very little 
room for interpretation can yield results that may be incomplete. However, that should not be 
considered a failure of the project, as this type of evaluation has never been conducted before. 
Instead, the results of this project should be viewed as a foundation for development of strong 
evaluations specific to each active CFAR. 
Conclusions 
 
This project looked at the ongoing efforts to develop promising early stage investigators 
into successful researchers who can work toward addressing the HIV/AIDS epidemic. 
Developmental Core awardees are already publishing in respected journals and are consistently 
being cited by other researchers, which helps to establish themselves as experts in the field. 
Many of them were successful in obtaining various NIH grants, including R01-equivalents. 
Some have become extremely successful and have multiple ongoing grants supporting their work 
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toward ending HIV/AIDS epidemic. They are bringing significant dollar amounts to the 
University, which contributes to Emory’s world-renowned biomedical research reputation. Still, 
many studies need to be done to obtain a full picture of the impact that the CFAR program has 
on early stage investigators. This project presents a small sample of questions that can be asked 
and answered about the initiatives of similar programs. Throughout the country, similar centers 
and programs exist that focus on development of investigators in various areas of biomedical 
research, and this study can be used as a framework to conduct similar evaluations for those 
programs.  
In a time when increased financial transparency is demanded by the public, studies like 
this can present an opportunity for agencies to demonstrate exactly what taxpayers’ money is 
being used for and what areas of public health they are impacting. It is easy to connect certain 
researchers to certain discoveries and advances made in the field of HIV/AIDS research, and 
none of those discoveries would have been possible without grant funding. A clear 
demonstration of the positive impact taxpayer dollars have made on public health research could 
make the public more enthusiastic about contributing to research and to public health.  
On the administrative side, the same results could present an opportunity for CFAR 
directors to continue securing the support of the University. The CFAR grant itself is relatively 
small, but it is hugely impactful. The University’s support is critical when it comes to CFAR’s 
success, so being able to show that this support pays off is very important.  
Most importantly, these results can be used when deciding whether to establish, expand, 
or improve programs that support early stage investigators. That, in fact, is already happening. 
The new CFAR Adelante National Grants Program administered by the Emory CFAR can be 
evaluated using this model. Adelante leadership has decided to use Ramp Up awards as part of 
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their continuous commitment to the careers of early stage investigators who study the HIV/AIDS 
epidemic in Hispanic populations. The basis for that decision was the result of this project 
through its demonstration of the high ROI resulting from Ramp Up awards. 
These same results were referenced also when developing a community grants program 
sponsored by Gilead. Mechanisms similar to Ramp Up and CFAR-series awards will be used in 
that initiative, which also aims to alleviate the HIV/AIDS epidemic in the Deep South states.  
Therefore, this project is already affecting decisions being made in the field of HIV/AIDS 
research. 
Overall, this project was able to demonstrate that the Emory CFAR has a large impact on 
HIV/AIDS research on many levels. It invests in early stage investigators who later become 
successful independent researchers, thus contributing to the University by the means of bringing 
in additional grants and to the country’s and world’s public health by grooming and developing 
investigators who will continue to be successful and remain dedicated to the fight. Emory CFAR 
Developmental Core awardees publish in respected journals, contributing to the global 
HIV/AIDS knowledge base. They are successful in obtaining external independent grants, thus 
increasing the Emory University fiscal portfolio, and they are reporting that Developmental Core 
services are useful to them on a personal level.  
  As discussed above, the results of this study are already being used by other programs, 
which confirms that the Emory CFAR’s approach was recognized as valuable and effective. This 
project also demonstrates just how multidimensional the fight with this epidemic is. There are 
many stakeholders, from investigators to civilians, to universities and countries that are affected 
by the outcomes of CFAR’s work. A large portion of the fight with HIV/AIDS starts with the 
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recognition that a continuous investment is needed into similar programs in order to make 
progress against the disease.  
 Continuous support of promising researchers supports the prospect of years of continued 
advances in the fight against the HIV/AIDS epidemic, improved quality of life for people living 
with the disease, improved public health, and hopefully one day, complete eradication of 
HIV/AIDS.   
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Table A1, Impact factors for journals containing Emory CFAR Developmental Core Related 
Publications, 1998-2016 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Patient Education and Counceling 0.59
Journal of Virology 5.828 5.942 5.332 4.606
Journal of Immunology 7.14 6.486 6.068 5.646 5.362 4.922
Journal of Adolescent Health 1.415
Migration World Magazine x
Journal of Infectious Diseases 4.481 5.682 5.865
Journal of Acquired Immune Deficiency Syndroms 3.681 3.946 4.412 4.653 3.935
AIDS 5.893
Journal of STD and AIDS 1.274
Experimental Biology and Medicine 2.845
Sexually Transmitted Infections 2.616
American Journal of Public Health 3.612 4.371 3.926 4.138
American Journal of Medical Sciences 1.618
Journal of Molecular Biology 4.472
British Medical Journal 12.827
American Journal of Respiratory Cell and Molecular Biology 4.477
Pharmacotherapy 2.527
Immunology 3.276
Laboratory Investigation 4.602
Perspectives on Sexual and Reproductive Health 2.222
AIDS Research and Human Retroviruses 2.178 2.082 2.325
Current Topics in Microbiology and Immunology 4.16
PLOS Pathogens 8.978 8.057 7.562
PLOS One 4.351 4.411 4.092 3.73 3.534 3.234
AIDS Education and Prevention 1.506
Journal of Urban Health 2.205
Journal of Virological Methods 2.133
Culture, Health, and Sexuality 1.068 1.553
Child Abuse and Neglect 1.945
AIDS Research and Therapy x x
Current Infectious Disease Reports (expert reviews) x
International Journal of Health Geographics 2.341
Retrovirology 5.236 5.657
Journal of the International Association of Providers of AIDS Care x
AIDS Care 1.603
Journal of Clinical Pharmacology 2.911
Alcoholism - Clinical and Experimental Research 3.343
Journal of Medical Internet Research 4.409
Journal of Medical Ethics 1.363
Journal of Biological Chemistry 4.773
Social Science & Medicine 2.699 2.797
Science 31.027
Antiviral Therapy 3.073
African Journal of Reproductive Health x
Current Opinion in HIV and AIDS (invited articles only) 4.704
Molecular Therapy 7.041 6.425
Drug and Alcohol Dependence 3.141 3.222
The Wetern Journal of Emergency Medicine x
AIDS and Behavior 3.312 3.728
Immunological Reviews (by invitation) 12.909
Medical Anthropology Quarterly 1.382
Global Public Health 1.205 1.978 1.614
The Journal of the Association of Nurses in AIDS Care 1.274
AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV 2.095 1.902
Nicotine and Tobacco Research 3.296
Sexually Transmitted Diseases 2.842 2.358
Antimicrobial Agents and Chemotherapy 4.476
Journal of Clinical Investigation 12.575
Journal of Histochemistry and Cytochemistry 2.14
Nature Communications 11.329
Journal of Child Sexual Abuse 0.969
Journal of the International AIDS Society 6.256
Clinical Infectious Diseases 8.216
Children and Youth Services Review 1.226
Cell Host and Microbe 14.946
Current Opinion in Infectious Disease 4.242
Average Impact Factor 4.498
Lowest Impact Factor 0.590
Highest Impact Factor 31.027
IMPACT FACTORS FOR JOURNALS CONTAINING EMORY CFAR DEVELOPMENTAL CORE RELATED PUBLICATIONS, 1998-2016
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Table A2, Publications resulting from the work of Emory CFAR Developmental Core, 1998-2016 
PUBLICATIONS RESULTING FROM THE WORK OF EMORY CFAR DEVELOPMENTAL 
CORE, 1998-2016 
Citations 
Year 
Published Publication 
0 2000 
Hirsch JS.(2000). En El Norte La Mujer Manda: Gender, Generation and Geography 
in a Mexican Transnational Community. Immigration Research for a New Century 
(Ed.) New York: 369-89. 
0 2003 
Galati D, Paiardini M, Cervasi B, Albrecht H, Bocchino ML, Costantini A, Montroni 
M, Piedimonte G, Magnani M, Silvestri G. 2003. Post-translational regulation of 
nucleolin in the cell cycle disease of HIV-infected patients. J Infect Dis. 188:1483-
1491. 
0 2014 
   Berg, C. J., E. J. Nehl, X. D. Wang, Y. Y. Ding, N. He and F. Y. Wong (2014). 
"Utilization of Cessation Resources Among HIV-Positive and HIV-Negative Men 
Who Smoke and Who Have Sex With Men in Chengdu, China." Nicotine & Tobacco 
Research 16(10): 1283-1288. PMID: 24827789. PMCID: PMC4168294 
0 2015 
Winskell K1, Holmes K, Neri E, Berkowitz R, Mbakwem B, Obyerodhyambo O., 
Making sense of HIV stigma: Representations in young Africans' HIV-related 
narratives. Glob Public Health. 2015;10(8):917-29. doi: 
10.1080/17441692.2015.1045917. Epub 2015 Jul 1. 
0 2015 
Miller KS1, Winskell K2, Pruitt KL2, Saul J1., Curriculum Development Around 
Parenting Strategies to Prevent and Respond to Child Sexual Abuse in Sub-Saharan 
Africa: A Program Collaboration Between Families Matter! and Global Dialogues., J 
Child Sex Abus. 2015;24(8):839-52. doi: 10.1080/10538712.2015.1088913. 
0 2016 
Winskell K1, Sabben G2., Sexual stigma and symbolic violence experienced, enacted, 
and counteracted in young Africans' writing about same-sex attraction., Soc Sci Med. 
2016 Jul;161:143-50. doi: 10.1016/j.socscimed.2016.06.004. Epub 2016 Jun 2. 
0 2016 
Winskell K1, Sabben G1, Stephenson R2, Pruitt KL1, Allen K1, Findlay T1., From 
condemnation to normalisation: Young Africans' narratives about same-sex attraction 
and implications for communication and advocacy efforts. Glob Public Health. 2016 
Jul 13:1-15. doi: 10.1080/17441692.2016.1203969. [Epub ahead of print] 
0 2016 
Johnson EL1, Chakraborty R., HIV-1 at the placenta: immune correlates of protection 
and infection., Curr Opin Infect Dis. 2016 Jun;29(3):248-55. 
0 2016 
Rolle CP1, Bolton MD, Kelley CF., Use of a Prospective Sex Diary to Study Anal 
Lubricant and Enema Use Among High Risk Men Who Have Sex With Men-
Implications for Human Immunodeficiency Virus Prevention., Sex Transm Dis. 2016 
Aug;43(8):476-8.  
1 2012 
  Jarlais, D. C. D., H. L. F. Cooper, H. Bramson, S. Deren, A. Hatzakis and H. Hagan 
(2012). "Racial and ethnic disparities and implications for the prevention of HIV 
among persons who inject drugs." Current Opinion in Hiv and Aids 7(4): 354-361. 
PMID: 22498481  
1 2016 
 Wall, K. M., W. Kilembe, L. Haddad, B. Vwalika, S. Lakhi, N. H. Khu, I. Brill, E. 
Chomba, J. Mulenga, A. Tichacek and S. Allen (2016). "Hormonal Contraception, 
Pregnancy, Breastfeeding, and Risk of HIV Disease Progression Among Zambian 
Women." Jaids-Journal of Acquired Immune Deficiency Syndromes 71(3): 345-352. 
PMID: 26379070. PMCID: PMC4752415 
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1 2013 
Winskell K1, Brown PJ, Patterson AE, Burkot C, Mbakwem BC., Making sense of 
HIV in southeastern Nigeria: fictional narratives, cultural meanings, and 
methodologies in medical anthropology.Med Anthropol Q. 2013 Jun;27(2):193-214. 
doi: 10.1111/maq.12023. Epub 2013 Jun 26. 
1 2013 
Beres LK1, Winskell K, Neri EM, Mbakwem B, Obyerodhyambo O., Making sense of 
HIV testing: social representations in young Africans' HIV-related narratives from six 
countries., Glob Public Health. 2013;8(8):890-903. doi: 
10.1080/17441692.2013.827734. Epub 2013 Sep 5. 
1 2016 
Winskell K1, Miller KS2, Allen KA1, Obong'o CO3., Guiding and supporting 
adolescents living with HIV in sub-Saharan Africa: The development of a curriculum 
for family and community members., Child Youth Serv Rev. 2016 Feb;61:253-260. 
1 2015 
Dagnra AY1, Mlaga KD2, Adjoh K3, Kadanga E1, Disse K3, Adekambi T4., 
Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-
negative patients eligible for retreatment regimen in Togo using GeneXpert 
MTB/RIF.New Microbes New Infect. 2015 Sep 10;8:24-27. 
2 2000 
Hirsch, JS. 2000. Because he misses his normal life back home: masculinity, sexuality 
and AIDS risk behavior in a Mexican migrant community. Migration World 
Magazine. 29(4). 
2 2008 
  Ofotokun, I., E. P. Acosta, J. L. Lennox, Y. Pan, and K. A. Easley. 2008. 
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with 
human immunodeficiency virus. Pharmacotherapy 28:74-81. PMID:18154477 
2 2011 
 Khosropour, C. M. and P. S. Sullivan (2011). "Risk of disclosure of participating in 
an internet-based HIV behavioural risk study of men who have sex with men." 
Journal of Medical Ethics 37(12): 768-769. PMID: 21708832. PMCID: PMC3593712 
2 2013 
 Stephenson, R., C. D. Hall, W. Williams, K. Sato and C. Finneran (2013). "Towards 
the development of an intimate partner violence screening tool for gay and bisexual 
men." West J Emerg Med 14(4): 390-400. PMID: 23997849. PMCID: PMC3756706 
2 2014 
   Rentsch, C., Bebu, I., Guest, J. L., Rimland, D., Agan, B. K., & Marconi, V. (2014). 
“Combining Epidemiologic and Biostatistical Tools to Enhance Variable Selection in 
HIV Cohort Analyses.” PLoS ONE, 9(1), e87352. PMID: 24489902. PMCID: 
PMC3906149 
2 2016 
 Linton, S. L., H. L. F. Cooper, R. Y. Luo, C. Karnes, K. Renneker, D. F. Haley, J. 
Hunter-Jones, Z. Ross, L. Bonney and R. Rothenberg (2016). "People and places: 
Relocating to neighborhoods with better economic and social conditions is associated 
with less risky drug/alcohol network characteristics among African American adults 
in Atlanta, GA." Drug and Alcohol Dependence 160: 30-41. PMID: 26781062. 
PMCID: PMC4767629 
3 2009 
  Zhao, C., C. J. Crews, C. A. Derdeyn, and J. L. Blackwell. 2009. Lac-regulated 
system for generating adenovirus 5 vaccine vectors expressing cytolytic human 
immunodeficiency virus 1 genes. J Virol Methods 160:101-10. PMID:19409930 
3 2014 
 Finneran, C. and R. Stephenson (2014). "Social Network Composition and Sexual 
Risk-Taking Among Gay and Bisexual Men in Atlanta, GA." Aids and Behavior 
18(1): 59-68. PMID: 23904146. PMCID: 4046889 
3 2015 
Johnson EL1, Chu H1, Byrareddy SN2, Spearman P3, Chakraborty R4., Placental 
Hofbauer cells assemble and sequester HIV-1 in tetraspanin-positive compartments 
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that are accessible to broadly neutralizing antibodies., J Int AIDS Soc. 2015 Jan 
22;18:19385. doi: 10.7448/IAS.18.1.19385. eCollection 2015. 
4 2009 
   Winskell, K., and D. Enger. 2009. A new way of perceiving the pandemic: the 
findings from a participatory research process on young Africans' stories about 
HIV/AIDS. Cult Health Sex 11:453-67. PMID:19353391 
4 2013 
  Finneran, C. and R. Stephenson (2013). "Gay and Bisexual Men's Perceptions of 
Police Helpfulness in Response to Male-Male Intimate Partner Violence." West J 
Emerg Med 14(4): 354-362. PMID: 23930149. PMCID: PMC3735383 
4 2013 
  Stephenson, R., C. Rentsch, P. Sullivan, A. McAdams-Mahmoud, G. Jobson, H. 
Struthers and J. McIntyre (2013). "Attitudes Toward Couples-Based HIV Counseling 
and Testing Among MSM in Cape Town, South Africa." Aids and Behavior 17: S43-
S50. PMID: 22961498. PMCID: PMC3529975 
4 2014 
 Tangpricha, V., S. E. Judd, T. R. Ziegler, L. Hao, J. A. Alvarez, A. M. Fitzpatrick, G. 
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Table B3, Ramp Up awards outcomes 
RAMP UP AWARDS OUTCOMES 
CFAR Investigator YR Funded Funding NIH Award Number NIH Award Amount 
Daniel Kalman YR8: 2005 $2,000      
Jeffrey Lennox  YR8: 2006 $1,229      
Michael Powell YR8: 2006 $1,520      
Richard Rothenberg YR8: 2005 $2,000  R01DA019393-04S1  $59,729 
Maricia Holstad YR9: 2008 $2,000  R21NR010862  $425,938 
Wendy Armstrong YR10: 2009 $2,000      
Natasha Hochberg YR10: 2009 $2,000      
Patrick Sullivan YR10: 2009 $2,000  NIH: R34MH086331  $706,021 
Patrick Sullivan YR10: 2008 $2,000      
Bruce Wade (Spelman) YR10: 2008 $900      
Kristin Dunkle YR11: 2010 $2,000      
Annie Horn YR11: 2010 $2,000      
Anne Spaulding YR11: 2010 $2,000      
Rob Stephenson YR11: 2010 $2,000  R21 HD066306 $426,250 
Sinead Young (MSoM) YR11: 2009 $2,000      
Southeast AIDS Training 
and Education Center; 
Ira Schwartz PI (H4A 
HA 00067)  
YR12: 2010 $7,000      
Lisa Haddad YR12: 2010 $10,000   5K23HD078153  $635,175 
Allison Ross YR12: 2010 $2,000      
Julia Painter YR12: 2010 $2,000      
Rebecca Culyba YR12: 2011 $2,000      
Rana Chakraborti YR12: 2011 $2,000      
Wendy Armstrong YR13: 2012 $2,000      
Vincent Bond YR13: 2012 $2,000      
Paula Frew YR13: 2011 $2,000      
Lisa Haddad YR13: 2011 $10,667   5K23HD078153 (reported above)   
Sophia Hussen YR13: 2012 $559      
Vincent Marconi YR13: 2012 $150      
Jessica Sales YR13: 2012 $2,000      
Rob Stephenson YR13: 2012 $1,995      
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Patrick Sullivan YR13: 2011 $2,000      
Frank Wong YR13:  $1,500  5R01AI106715  $894,823 
Albert Anderson YR14: 2012 $2,000.00  1K23MH095679  $899,400 
Carla Berg YR14: 2012 $2,000.00      
Allison Eckard YR14: 2014 $2,000.00      
Marica Holstad YR14: 2013 $2,000.00      
Colleen Kelley YR14: 2012 $360.00  K23 AI108335  $887,463 
Russell Kempker YR14: 2013 $2,000.00      
Travis Sanchez YR14: 2012 $2,000.00  1R01AI112723  $3,055,493 
Aaron Siegler YR14.1: 2012 $2,000.00      
Aaron Siegler YR14.2: 2012 $500.00  1R43HD078154 $741,388 
Anne Spaulding YR14: 2012 $1,080.00  No outcome expected due to nature of award   
Rob Stephenson YR14.1: 2013 $2,000.00      
Rob Stephenson YR14.2: 2013 $2,000.00      
Colleen Kelley YR15: 2012 $2,000.00      
A.D. McNaghten YR15.1: 2013 $2,000.00      
A.D. McNaghten YR15.2: 2013 $2,000.00      
JaNelle Ricks YR15 $3,960.00      
Travis Sanchez YR15:2013 $2,000.00      
Kristin Wall YR15: 2014 $500.00      
Julie Zuniga YR15: 2014 $2,000.00      
Sophia Hussen YR16: 2014 $2,000.00      
Ameeta Kalokhe YR16: 2015 $450.00      
Igho Ofotokun YR16:  $2,000.00      
Travis Sanchez YR16 $2,000.00      
Amit Shahane YR16 $2,000.00      
Aaron Siegler YR16 $2,000.00      
Patrick Sullivan YR16.1 $2,000.00      
Patrick Sullivan YR16.2 $2,000.00      
Anders Camacho-
Gonzalez YR17 $1,500.00      
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Paula Frew YR17 $2,000.00      
Aaron Siegler YR17 $1,000.00      
Sophia Hussen YR17 $2,000.00      
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Table B4, CFAR-series awards outcomes 
 CFAR-series awards outcomes 
CFAR 
Investigator 
(Last, First) 
Date of 
CFAR-
series 
award 
(m/dd/yyyy) 
Total 
Cost 
(Direct 
+ 
Indirect) 
First Directly 
Related 
Award** (as 
PI) 
Total Cost 
of First 
Directly 
Related 
Award 
(Direct + 
Indirect) 
First Directly 
Related R01-
Equivalent 
Award 
Total Cost 
of First 
Directly 
Related 
R01-
Equivalent 
Award 
(Direct + 
Indirect) 
Blackwell, 
Jerry 8/15/2005 $20,000  R01AI069987 $1,486,500 R01AI069987 $1,486,500 
Bostik, 
Pavel 8/15/2005 $30,396  R01AI065362 $1,377,000 R01AI065362 $1,377,000 
Dunkle, 
Kristin 8/15/2005 $20,000  R03MH085599 $155,000     
Ofotokun, 
Igho 8/15/2005 $14,889  K23AI073119 $640,035     
Winskell, 
Samantha 
Kate 
8/15/2005 $20,000  R03HD054323 $153,000 R01HD085877 $1,486,056 
Kate 
Winskell Yr 8 $2,000          
Kohler, 
James & 
Lewsi, 
William 
7/24/2006 $38,000  K01DK078513 $323,500     
James 
Kohler  Yr 8: 2006 $2,000          
Ly, Hinh 7/24/2006 $35,144          
Spaulding, 
Anne 7/24/2006 $13,041  R34DA035728 $687,960     
Blackwell, 
Jerry 1/15/2007 $30,000  R21AI076080 $426,063     
Ye, Ling 1/15/2007 $30,000  R01AI077446 $1,349,719 R01AI077446 $1,349,719 
Cooper, 
Hannah & 
Bonney, 
Loida 
5/15/2008 $91,129  R01DA029513 $2,645,181 R01DA029513 $2,645,181 
Hannah 
Cooper & 
Loida 
Bonney 
Yr 10 $2,000          
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Sullivan, 
Patrick 5/15/2008 $45,900  R01MH85600 $3,153,441 R01MH85600 $3,153,441 
Ali, Sayed 11/1/2008 $9,880  *F31AI091484 $38,910     
Joshy, 
Pratibha  11/1/2008 $39,126  R01AA017627 $1,379,755 R01AA017627 $1,379,755 
Song, 
Byeongwoon  11/1/2008 $47,358          
Radziewicz, 
Henry & 
Grakoui, 
Arash 
7/1/2009 $60,000  R01DK083356 $1,525,655 R01DK083356 $1,525,655 
Johnson, 
Brent 7/1/2009 $46,500          
Eckard, 
Allison Ross 3/15/2010 $30,000  
 
K23HD069199  $630,720     
Stephenson, 
Rob  3/15/2010 $46,501  R03MH090897 $150,876 R01HD075655 $3,012,674 
Tirado-
Ramos, 
Alfredo & 
Saltz, Joel 
4/15/2010 $75,001          
Galipeau, 
Jacques & 
Silvestri, 
Guido 
4/15/2010 $93,000          
Chakraborty, 
Rana  5/1/2010 $52,020  U01AI131566 $2,264,985 U01AI131566 $2,264,985 
Marconi, 
Vincent  5/1/2010 $45,890          
Rengarajan, 
Jyothi & 
Ray, Susan 
6/15/2010 $60,000          
Frew, Paula 3/1/2011 $30,000  R03AG042831 $155,078     
Kang, Sang-
Moo 3/1/2011 $30,000  R01AI105170 $3,743,620 R01AI105170 $3,743,620 
Yue, Ling & 
Marconi, 
Vincent 
5/11/2011 $60,000          
Chahroudi, 
Ann 8/29/2011 $45,900  R56AI117851* $892,484 R01AI133706 $4,114,890 
Spaulding, 
Anne & 
Ward, Kevin 
3/1/2012 $49,019          
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Winskell, 
Samantha 
Kate 
9/1/2012 $20,000  R34MH106368 $682,590     
Wright, 
Elizabeth 6/10/2013 $31,114          
Sun, Yan 7/23/2013 $62,322          
Tukvadze, 
Nestani 8/1/2013 $30,000          
Kelley, 
Colleen 9/1/2013 $31,200  P30AI050409S $156,000     
Perkins, 
Molly 1/1/2014 $62,400  P30AI050409S $155,356     
Gavegnano, 
Christina 3/1/2014 $62,400          
Hepburn, 
Ken 6/20/2014 $61,776          
Joe 
Lipscomb 8/1/2014 $62,380  
        
Adekambi, 
Toidi 9/9/2014 $39,249          
Gary, Becky 10/10/2014 $38,352  R01NR014973 $2,510,304 1R01NR014973 $2,510,304 
Wall, Kristin 11/1/2014 $62,189  K01MH107320  $514,845     
Hussen, 
Sophia 1/7/2015 $39,988          
Haddad, Lisa 3/1/2015 $51,280          
Neigh, 
Gretchen 
(co-funded 
w/ UAG 
Aging R24) 
6/1/2015 $20,000          
Bond, Craig 8/1/2015 $42,450          
Frew, Paula 8/1/2015 $40,000          
Goswami, 
Neela 9/1/2015 $40,000          
Jenness, Sam 
& Morris, 
Martina 
(UW) 
2/1/2016 $59,102  R21MH112449 $442,103     
Bernal-
Mizrachi, 
Leon 
6/13/2016 $40,000          
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Siegler, 
Aaron & 
Little, Susan 
(UCSD) 
8/1/2016 $62,397          
Kalokhe, 
Ameeta & 
Sales, 
Jessica 
9/21/2016 $76,091          
Alonso, 
Alvaro 12/9/2016 $61,331          
Kulpa, 
Deanna 12/9/2016 $62,400          
Mocarski, 
Edward 5/1/2017 $35,000          
Auld, Sara 8/1/2017 $62,353          
Cranmer, 
Lisa 8/1/2017 $62,400          
Rubtsova, 
Anna 8/1/2017 $62,400          
Wall, Kristin 8/1/2017 $62,400          
Colasanti, 
Jonathan 8/16/2017 $15,000          
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 Table B5, Administrative Supplements outcomes 
Administrative Supplements Outcomes 
CFAR Investigator 
(Last, First) 
Date of 
Supplement 
Award 
(m/dd/yyyy) 
 Total 
Cost 
(Direct + 
Indirect)  
First 
Directly 
Related 
Award** 
 Total Cost 
of First 
Directly 
Related 
Award 
(Direct + 
Indirect)  
First 
Directly 
Related R01-
Equivalent 
Award 
Total Cost 
of First 
Directly 
Related 
R01-
Equivalent 
Award 
(Direct + 
Indirect) 
Amara, Rama 12/21/2005 $242,460         
Armstrong, Wendy 8/1/2013 $98,767         
Kalokhe, Ameeta 8/1/2013 $100,000         
Kelley, Colleen 
and Kraft, Colleen  
8/1/2014 $156,000 
R01AI128799 $2,393,299 R01AI128799 $2,393,299 
Kelley, Colleen 8/1/2015 $155,526         
Anderson, Albert 8/1/2015 $155,395         
Siegler, Aaron 8/1/2016 $312,000         
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 Research Funding  Proposal Support  Mentoring Assistance  Professional 
Development  
  
• CFAR-series Awards  • Pre-Proposal Feedback  • Mentor Connections  • Poster 
and Slide Design  
• Ramp Up Awards  • Grant Guru   • K-Club  Tutorials  
• NIH Supplements  • Grant Writing Workshops   • CLC On Call  • Oral Abstracts 
Practice  
• Science Writing  • TAM workshops  • Quantitative Research &  
• NIH Reviewer Training  Analysis 
• Qualitative Research &  
 Analysis  
  
RESEARCH FUNDING  
CFAR-series Awards: provide one year of non-renewable funding although the budget may be 
spread out over a longer project period, if needed in order to accomplish a project’s scope of work. 
CFAR-series applications are accepted twice a year (November 1, May 1). Eligibility requirements 
may be found in each mechanism’s RFA.  
CFAR-03 awards are modeled after the NIH R03 mechanism. Single or dual PI awards are 
intended to generate data that will be used to ground a future NIH application in a CFAR 
and/or NIH OAR high priority area of research.   
CFAR-K awards provide supplementary (non-salary) funding that will fill in or extend the 
research of NIH K awardees preparing to make the K to R transition.   
CFAR-C awards are intended to promote new research collaborations between a junior 
faculty member at Emory and one or more investigators at other NIH-funded CFARs.   
Ramp Up Awards: provide small amounts of financial support to address discrete, time critical 
HIV research challenges. Ramp Up applications are accepted on a rolling basis.  
Opportunity Awards (OA) enable data collection for unfunded research (e.g. for recruitment 
and / or participant incentives). They also enable expansion of, or overcame obstacles 
encountered during, currently funded NIH research.   
Data Awards (DA) support costs for data pulls and analyses stemming from use of the new 
CFAR HIV Disease Registry. The mechanism also provides support for new and early stage 
investigators who require specialized training or assistance with quantitative data from 
sources other than the HIV Disease Registry.   
Collaboration Travel Awards (CTA) make it possible for unfunded, early stage 
investigators to meet face to face with proposed collaborators at other institutions in order to 
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engage in needed training or to develop, in real time, the specific aims and approach of an 
application being prepared for submission to NIH or the Emory CFAR.   
Poster Awards (PA) are for current and former Developmental Core CFAR-series grant 
recipients who have completed a Poster Design Tutorial. These awards provide ongoing 
printing for posters describing CFAR-supported research.  
    
  
NIH Administrative Supplements (CFAR Adelante, NIH CFAR-initiated)   
CFAR Adelante is a national mechanism administered for NIH/OAR by the Emory CFAR 
that funds research to reduce HIV-related health disparities in the Hispanic / Latino 
community. CFAR Adelante projects incorporate a 4 month mentored training preparation 
period followed by a mentored research period of approximately 20 months. The next CFAR 
Adelante application submission deadline has not yet been established by NIH/OAR.   
NIH CFAR-initiated calls for administrative supplement projects in narrowly targeted, high 
priority areas are periodically issued by NIH. Because each CFAR is limited in the number of 
applications that can be submitted, the Emory CFAR Developmental and Administrative 
Cores competitively review submitted preproposals for development into full applications. An 
announcement is made through the Emory CFAR listserv each time the NIH CFAR issues a 
call for projects.  
  
PROPOSAL SUPPORT  
Pre-Proposal Feedback. Strong research starts with rigorously considered specific aims and a 
well-articulated approach. The Developmental Core arranges opportunities for junior faculty to 
present their research ideas for discussion and feedback by senior CFAR scientists and members of 
CFAR’s community advisory board. Grant Guru: Not everyone has comprehensive training in 
grant writing. To assist those who would benefit from one-on-one training, the Developmental 
Core sponsors access to a grant writing expert who works with early stage investigators on their 
NIH applications.  
Grant Writing Workshops: As a means of ensuring that the Developmental Core receives the 
strongest possible CFAR-series applications, we offer a grant writing workshop prior to each 
application submission deadline. The workshop includes strategies for preparing a successful 
application, including building a mentoring team, negotiating support from the CFAR science 
cores, creating slides and a talk outline for an optional pre-proposal feedback session with the 
CFAR CLC and Core Directors, preparing the required appendices, writing a strong specific aims 
page, and developing a scope of work in keeping with the timelimited nature of a CFAR-funded 
project.  
Science Writing: The Developmental Core offers three mechanisms for helping investigators 
strengthen their science writing skills: 1) The Core will enroll junior faculty as special standing 
students in GH592: “Successful Scientific Writing for Public Health Professionals,” a ½ semester 
(7 meeting) course; 2) will provide co-funding of any monies awarded by Emory’s Center for 
Faculty Development and Excellence (CFDE) Scholarly Writing and Publishing Fund (SWAP), 
with the award earmarked for hiring editorial support or a writing coach; and 3) will provide Ramp 
Up funding for that same purpose to faculty unable to secure a CFDE SWAP award.  
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MENTORING ASSISTANCE  
Mentor Connections: Although most faculty receive assistance in establishing career mentors by 
their departments, CFAR members frequently benefit from additional, HIV-specific mentors. The 
Developmental Core leadership helps interested faculty identify potential mentor candidates, 
checks their availability and interest, and makes introductions.  
K-Club: The CFAR co-sponsors a monthly meeting that provides an educational forum to assist 
fellows and faculty with successful NIH career development award applications. Meetings cover 
various topics pertaining to the conception, development, submission, and post-award process for 
NIH career development awards. KClub members have an excellent track record of receiving NIH 
K01, K23, and other award funding.   
CLC On Call: Investigators who are interested in conducting human subjects research that is of 
maximal relevance to the community under study benefit from consultation with members of the 
CFAR’s Community Liaison Council (CLC). Consultations are provided at the protocol design 
stage and may involve reviewing the cultural relevancy of proposed data collection plans, giving 
suggestions for optimizing study participant recruitment and retention, and/or discussing options 
for translating research findings back to the community.  
  
TAM (Training AIDS Mentors) workshops: As new investigators transition to Independent 
investigator status, they are expected to make a concurrent transition from mentee to mentor. TAM 
provides skill building training for new mentors on multiple topics including: The mentoring 
continuum: Transitioning from mentee to mentor; Building your mentorship skillset: 
Communication, aligning expectations, assessing mentee understanding; Defining your mentoring 
approach: Choosing mentees and developing mentoring agreements; and Lessons from senior 
mentors: Benefits of mentoring; tips and advice.   
NIH Reviewer Training: Pairs junior faculty with senior CFAR scientists for mentored 
participation as reviewers on Developmental Core study sections, which are operated on the NIH 
model. Training includes review of summary statement drafts, study section meeting coaching, and 
application discussion feedback.  
  
PROFESSIONAL DEVELOPMENT  
Poster and Slide Tutorials: Well-designed posters and slides add significance to scientific 
meeting presentations yet many investigators are unaware of best practices in poster and slide 
design. The  
Developmental Core provides individual poster/slide design tutorials and, for tutorial graduates, 
free printing of one poster and ongoing review of new posters and slides being prepared for 
presentation at national conferences.   
Oral abstracts practice: Prior to major HIV conferences such as CROI or the International AIDS 
Conference, the Developmental Core organizes formal sessions in which CFAR members sign up 
to practice presenting their accepted oral abstracts and receive constructive feedback on talk/slide 
content, timing, and delivery.  
Quantitative Research and Analysis: The CFAR Biostatistics and Bioinformatics Core is 
currently developing a series of analytical skill building courses. Once the training is rolled out, 
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receipt of funding for Ramp Up Data Awards will be contingent on applicants first having attended 
or “tested out” of each applicable workshop.   
Qualitative Research and Analysis: The Developmental Core will enroll interested faculty and 
postdocs in the Qualitative Research Methods and Qualitative Data Analysis workshops that are 
periodically offered through the Hubert Department of Global Health Continuing Education.  
 
Source: http://www.cfar.emory.edu/services/cores/dev/CFAR_Dev_Core_Services.pdf 
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Report #117-16  
 FY  MD-PhD MD Only PhD Only    
1980 36.1 37.7 35.7     
1981 36.2 37.3 35.6     
1982 36.3 37.7 36.0     
1983 36.5 38.2 35.9     
1984 36.9 38.8 36.4     
1985 37.0 38.2 36.6     
1986 37.5 38.0 37.3     
1987 38.0 39.5 37.6     
1988 38.2 39.1 37.9     
1989 38.8 39.2 38.7     
1990 39.0 39.7 38.7     
1991 39.2 40.0 38.8     
1992 39.2 40.7 38.9     
1993 39.9 40.7 39.5     
1994 40.0 40.5 39.8     
1995 40.1 40.9 39.7     
1996 40.1 41.1 39.8     
1997 40.3 42.0 39.9     
1998 40.4 42.0 40.0     
1999 41.2 42.9 40.7     
Table 117-16 
Average Age and Degree of NIH R01-Equivalent  
First-Time Investigators 
Fiscal Years 1980-2015 
Source:  Numbers for FY1980 -2012 are historical and from previously published sources. 
2013 data drawn from Success Rate File accessed January 2, 2014. 
2014 data drawn from Success Rate File accessed December 2, 2015. 
2015 data drawn from Success Rate File accessed March 24, 2016. 
Notes:  
* The definition of First-Time investigator has changed over time, and data reflect investigator policies that were in place during those years. 
In general, a Program Director/Principal Investigator (PD/PI) is considered a First-Time investigator if he/she has not previously competed 
successfully as PD/PI for a substantial NIH independent research award.  R01-Equivalents include activity codes R01, R23, R29, and R37, and 
beginning in 2008 included DP2 awards to First-Time NIH investigators.  Not all these activities are in use by NIH every year. 
Excludes  American Recovery Reinvestment Act (ARRA).   
Includes  NIH direct budget authority awardees only in FY 2013 and later. 
DIVISION OF PLANNING, EVALUATION AND ANALYSIS - DATA PRODUCED BY THE STATISTICAL ANALYSIS AND REPORTING BRANCH - 
 166 
 
2000 42.2 43.2 41.8     
2001 42.1 43.9 41.7     
2002 42.2 44.0 41.7    
2003 42.5 44.1 42.0    
2004 42.1 43.5 41.7    
2005 42.5 44.6 41.8     
2006 42.3 44.2 41.7     
2007 43.3 43.5 42.2     
2008 43.6 44.2 41.8     
2009 43.7 44.1 42.3     
2010  44.3 45.4 41.7     
2011  44.3 45.1 42.4     
2012 44.7 44.7 42.2     
2013 43.6 45.2 42.1     
2014 44.8 45.0 42.0     
2015 44.9 44.9 42.2    
 
Source: 
https://report.nih.gov/catalog_results.aspx?refUrl=index&sS=filter&sI=&sP=&sM=12&sA=62&
sD=10&sV=&sY=&fI=&fP=2&fM=12&fA=62&fD=10&fV=&fY=2016 
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